Development of new tools for high-throughput-synthesis and high-throughput-screening by Valeur, Eric
THE UNIVERSITY OF EDINBURGH 






Doctor of Philosophy 
School of Chemistry 
Faculty of Engineering and Sciences 
2006 
AITA 
UNIVERSITY OF EDINBURGH 
ABSTRACT 
Faculty of Engineering and Sciences 
School of Chemistry.  
Doctor of Philosophy 
The Development of New Tools for High-Throughput-Synthesis and 
High-Throughput-Screening 
by Eric Valeur 
High-throughput-synthesis has become a fundamental part of the drug-
discovery process, allowing the rapid synthesis of hundreds to potentially millions of 
compounds. There are many strategies used in high-throughput-synthesis and one 
technique, based on the use of polymer-supported reagents in solution-phase, has 
evolved considerably over the past decade. However, only a limited number of 
efficient polymer-supported coupling reagents have been reported and many of them 
offer serious drawbacks, unlike their solution-phase equivalents. The available solid-
phase supported coupling reagents fall into this category, with many available but 
few proving really reliable. A comparison between common coupling reagents 
(IIDQ, HATU, PyAOP and BOP-Ci) was therefore carried out and revealed that 
IIDQ was the reagent of choice in the absence of activation step. Polymer-supported 
IIDQ was therefore targeted. This reagent performed better than commercially 
available HATU and all supported carbodiimides. Scope and limitation studies 
proved that the reagent was a versatile tool for the synthesis of amides from 
carboxylic acids and amines, including hindered substrates, secondary amines and 
anilines. 
A new strategy for the high-throughput-screening of small-molecules was 
developed. Microarrays are a powerful method to test quickly a wide range of small 
molecules against biological targets. In parallel, fragment-based drug discovery has 
boomed in the past decade. The combination of the two principles gave birth to the 
new concept of dual fragment microarrays. The technology was developed and 
evaluated using fragments known to bind to the human FK506-binding protein. 
These fragments were synthesised in solution-phase, then linked to a PNA tag 
synthesised on solid-phase, followed by release into stock solution and hybridisation 
onto DNA microarrays. Screening the arrays of mixtures of two fragments revealed 
that the expected strongest "dual" interaction was detected as the most intense spot, 
and thus validated the concept of dual fragment microarrays. 
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PyBrop Bromotri(pyrrolidino)phosphonium hexafluorophosphate 
PyClop Chlorotri(pyrrolidino)phosphonium hexafluorophosphate 
PyClopP Chiorobispyrrolidinophenyl-phosphonium hexachioroantimonate 
PyF10P Fluorotri(pyrrolidino)phosphonium hexafluorophosphate 
PyC1U Chloro- 1,1 ,3,3-bis(tetramethylene)-formamidinium hexafluorophosphate 
PyDAOP (4-oxopyrido[3 ,2-d] [1 ,2,3]triazin-3(4H)-yloxy)tripyrrolidin- 1-ylphosphonium 
hexafluorophosphate 
PyDOP [(3,4-dihydro-4-oxo- 1 , 2 ,3-benzotriazin -3-yl)oxy]tris -(pyrrolidino)phosphonium 
hexafluorophosphate 
PyDPP Diphenyl 2-oxopyridin- 1 (2H)-ylphosphonate 
PyFOP {[6-(trifluoromethyl)benzotriazol- 1 -yl]oxy] -tris(pyrrolidino)phosphonium 
hexafluorophosphate 
PyNOP [(6-nitrobenzotriazol- 1-yl)oxy]tris-(pyrrolidino)  phosphonium hexafluorophosphate 
PyPOP (perfluorophenoxy)tripyrrolidin- 1 -ylphosphonium 
PyTOP (pyridyl-2-thio)tris(pyrrolidino)-phosphonium hexafluorophosphate 
SDPP 2,5-dioxopyrrolidin-1-yl diphenyl phosphate 
SMDOP 	4-oxobenzo[d] [1 ,2,3]triazin-3(4H)-yl methanesulfonate 
SPDOP 4-oxobenzo[d] [1 ,2,3]triazin-3(4H)-yl  benzenesulfonate 
SOMI 	5-(succinimidyloxy)- N, N-dimethyl-methaniminium hexachioroantimonate 
SOMP 5-(succinimidyloxy)-3,4-dihydro- 1-methyl 2H-pyrrolium hexachioroantimonate 
TATU 	0-(7-azabenzotriazol- l -yl)- l,l ,3,3-tetramethyluronium tetrafluoroborate 
TAPipU 1 -(I -pyrrolidinyl- 1H- 1 ,2,3-triazolo[4,5-b]pyridin-  1 -ylmethylene)pyrrolidinium 
tetrafluoroborate N-oxide 
TBFH 	N, N, N', N' -Tetramethyibromoformamidinium-hexafluorophosphate 
TBTU O-benzotriazol- l-yl-1 .1 ,3,3-tetramethyluronium tetrafluoroborate 
TCFH 	N, N, N', N' -Tetramethylchlozoformamidinium-hexafluorophosphate 
TCTU 1 H-Benzotriazolium, 1- [bis (dimethylarnino) methylene] - 
5-chioro-, tetrafluoroborate (1-), 3-oxide 
TDBTU 	2-(3 ,4-dihydro-4-oxo- 1 ,2,3-benzotriazin-3-yl)- 1,1 ,3,3-tetramethyluronium 
tetrafluoroborate 
TFMS-DEP 	Diethylphenyl(trifluoromethylsulfonyl)phosphoramidate 
TFFH Tetramethyifluoroformamidinium hexafluorophosphate 
TNTU 2-(5-norbornene-2,3-dicarboximido)- 1,1 ,3,3-tetramethyluronium tetrafluoroborate 
TOTT S-( 1-oxido-2-pyridinyl)- 1,1 ,3,3-tetramethylthiouronium tetrafluoroborate 
TODT S-( 1 -oxido-2-pyridinyl)- 1 ,3-dimethyl- 1 ,3-trimethylenethiouronium tetrafluoroborate 
TPTU 1 -((dimethylamino)(dimethyliminio)methoxy)-2-hydroxypyridinium 
tetrafluoroborate 
TSTU 2-succinimido- 1,1,3 ,3-tetramethyluronium tetrafluoroborate 
xviii 
Chapter I 
Introduction to High-Throughput-Synthesis 
1.1. Solid-Phase chemistry and library synthesis 
Since the genesis of modern organic chemistry, classical organic reactions have been 
performed in solution-phase, so-called because of the use of a solvent, which usually 
then imply a workup and purification in order to isolate the expected product and 
separate it from any unreacted starting materials, reagents or by-products. These 
steps can be particularly time consuming and even the evaporation of the reaction 
solvent can give rise to difficulties. In order to simplify purification and solubility 
issues associated with peptide synthesis, Merrifield introduced the concept of solid-
phase chemistry.' The concept was based on the immobilisation of a reactant via a 
chemical functionality present on a so-called solid support. The advantage of the 
technique relies on the simplification of the purification process to a filtration step 
and washing of the support, so that any unreacted reactant is washed away after 
reaction (Figure 1. 1). The process comes into its own when reactions are repeated 
again and again, to afford pure and complex molecules without time-consuming 
purification of the intermediates. 









Figure 1. 1: Principle of Solid-Phase Organic Synthesis 
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The method radically changed peptide synthesis, and was applied by Merrifield to 
the total synthesis of Ribonuclease A on a solid support, an enzyme of 124 amino 
acid residues. 2 The concept of solid-phase synthesis was further developed with the 
development of high throughput and automated techniques, which has facilitated the 
screenings of hundreds of thousands of compounds. This increase in the screening 
flow and the ever increasing number of therapeutic targets revealed the need to 
rapidly synthesise large collections of compounds. 
In order to make these collections possible, the concept of combinatorial chemistry 
was proposed, where compounds are systematically assembled by combining pools 
of building blocks. As an example, a range of monomers A, carrying a certain 
functionality, such as a carboxylic acid can be reacted with another range of 
monomers B, carrying another type of functionality, such as an amine. In the 
example shown below, an array of 5 x 5 = 25 amides could be obtained 
simultaneously (Figure 1. 2). 
Traditional Organic Synthethis 
A + 	B 	 0. 	A-B 
Combinatorial chemistry 
A 1 B 1 
A2 B2 
A3 + B3 Om 	A 1 -B 1 ,A 1 -B2... 
A4 B4 
A5 B5 
Figure 1. 2 : Comparison between traditional and combinatorial chemistry 
If the molecules B n  carry, another functionality such as an aromatic halogen, the n2 
compounds could be reacted with a group of 5 boronic acid C, thus forming at the 
end 125 compounds. This example illustrates how a growing number of molecules 
can be rapidly synthesised. Synthesis of each combination can be carried out either in 
separate reaction vessels (parallel synthesis) or simultaneously to generate a mixture. 
Typically libraries synthesised in parallel contain hundreds of members, often taking 
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advantage of 96- or 384- well plate formats. The synthesis of such libraries using 
traditional solution-phase techniques would require carefully chosen reaction 
conditions in order to minimise the formation of by-products. However, by taking 
advantage of the pioneering work of Merrifield, solid-phase methodology facilitates 
the removal of reagents and by-products. 
1.2. Supports for Solid-Phase Organic Synthesis (SPOS) 3 
Virtually, any inert solid material can be used as an anchor - for solid-phase organic 
synthesis, but the choice of support for a given reaction can have a dramatic effect on 
the outcome of the reaction .4  Support-types include the following categories. 
1.2.1. Hydrophobic supports 
The most common supports are hydrophobic polystyrene beads 1.3, which consist of 
polystyrene cross-linked with 1 or 2% divinylbenzene 1.2 (Scheme 1.1). The support 
swelling depends on the type of solvent. Indeed, PS beads swell significantly in 
apolar solvents while they do not swell in polar protic solvents such as alcohols and 
water. Therefore reactions involving PS beads supports are not usually carried out in 
these polar media as only 1 to 2% of the bead's reactive sites are located on the 
surface. 
ci - O 
1.3 
	
1-2% 	 Microporous 
Crosslinked 
1.1 	 1.2 	 Polystyrene 
1.4 
Merrifield resin 
Scheme 1. 1 : Synthesis of cross-linked polystyrene 
1.2.2. Hydrophilic supports 
Some supports are hydrophilic and, usually, consist of PEG chains grafted onto a 
polystyrene core. These supports (TentaGel 1.5, ArgoGel 1.6, PEGA 1.10) are 
entirely insoluble but exhibit very good swelling properties in polar solvents such as 
DMF or water, offering a suitable support for reactions based in these solvents 






n Ho ____4 —"-"o 
1.5 TentaGel 	 1.6 ArgoGel 
Figure 1. 3: General structure of TentaGel and ArgoGel resins 
However these supports usually have low loadings (0.2-0.3 minol/g for TentaGel to 
0.4-0.6 mmol/g for ArgoGel), and are often limited to specific uses.' PEGA 1.10 
resin is used for the synthesis of peptides (Figure 1. 4)6 





Figure 1. 4 Synthesis of PEGA resin 
1.2.3. Macroporous supports 
Another class of supports consist of macroscopic pores embedded in a rigid structure 
that does not allow swelling of the matrix. One of the most used supports in this class 
are 20-40% cross-linked polystyrene. 5 Macroporous supports do not normally swell, 
which make them suitable for most organic solvents. Other supports include silica-
based supports with a porous structure and controlled-pore glass (CPG). 
1.2.4. Miscellaneous supports 
Geysen developed functionalised pins for parallel synthesis in a 96-well plate 
7 format. This allowed manipulation of a large number of compounds through many 
Chapter! 	 5 
synthetic steps. Chiron extended the concept by developing so-called lanterns with 







Crown 0 OH 	 0 OH 
M
~O~OH 	OH 	 N 0 N 
1.14 	 1.15 
Scheme 1. 2: Examples of derivatisation on Crown supports 
Traditional polystyrene beads have been handled loose. However they have also been 
immobilised in a high density polyethylene matrix forming so-called resin 
66plugs".9' 10 
Other types of support have been reported, such as cellulose," cotton  12  and various 
polymeric membranes.' 3 These supports offer however low loadings (from 0.5-0.6 
mol/g for cellulose to 0.1 mmollg for cotton). Glass has also been used due to its 
chemical inertness. 14 
1.3. Polymer-assisted solution-phase synthesis 15 
1.3.1. Limitations of SPOS 
Although the solid-phase synthesis approach allows the preparation of pure 
compounds, there are several limitations with this technique. Firstly, the tethering of 
compounds to the support requires a functionality for attachment. Furthermore, in 
order to get a pure product after cleavage, the reactions have to be carried out with 
high conversion and therefore a time-consuming optimisation of the reaction 
conditions needs to be performed. Practically, the monitoring of reactions on solid-
phase is an issue as only a limited range of techniques (FTIR, Gel-phase/MAS NMR) 
are available to analyse immobilised compounds, although elegant techniques, such 
as self-indicating resins, have been develop to allow an "on-bead" monitoring.' 6 All 
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these issues have lead to the development of new solution-phase strategies while 
keeping all the benefits of solid-phase chemistry. So-called polymer-assisted 
solution-phase chemistry has other advantages over traditional solution-phase 
chemistry. The technique can be easily automatised, and toxicity and odours of 
supported species are reduced compared to the free species, while polymer-assisted 
solution-phase chemistry can be based on the use of immobilised scavengers, 
reagents or catalysts. 15 
1.3.2. Scavengers 
Scavengers are functionalised polymers which can sequester a compound from a 
reaction mixture (Figure 1. 5). This strategy was applied by Kaldor for the synthesis 
of amides using acid chlorides in excess.  17  After reaction, the excess acid chloride 
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Scheme 1. 3 : An example of the use of a supported amine to scavenge acid-chlorides 
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Scavengers of many common functionalities have been developed. Thus immobilised 
eletrophiles logically scavenge nucleophi les, while immobilised nucleophi les 
sequestrate electrophiles. Ketones and aldehydes can be scavenged using supported 
amines and hydrazines. 18 Reciprocally polymer-supported aldehydes are used to 
scavenge amines, hydrazines and keto esters, 19  while polymer-supported isocyanates 
allow selective sequestration of secondary amines in the presence of tertiary 
amines. '0 
An application of immobilised scavengers is the so-called Solid-Phase Extractors 
which are particularly advantageous in terms of time and ease of use for parallel 
synthesis and represent one of the main uses of scavengers, especially acid and base 
resins. They consist of a syringe filled with a scavenger. Purification occurs by 
eluting the solution mixture through the SPE. For example, to purify amides obtained 
from carboxylic acids and amines, the amide solution can be eluted through a syringe 
containing a mixture of acid and basic ion-exchange resin. The unreacted amine and 
carboxylic are retained on the resin and the filtrate containing the pure amide is 
collected (Figure 1. 6). It has to be noted that the use of supported-scavengers offer 
the advantages of using reagents that would normally be incompatible in solution. 
Indeed, in the example of amide synthesis explained above, the "mixed bed" of 
scavenger allows purification via removal of the acidic and basic unreacted species 
in a single step. 
40 Reaction mixture 
• Expected amide 
Unreacted amine 
• Unreacted acid 






Figure 1. 6 : Principle of purification via SPE 
Chapter / 
A broad range of Solid-Phase Extractors have been made available to organic 
chemists, including more recently thiol-based macroporous SPE for scavenging 
metal-species after cross-coupling reaction S. 
1.3.3. Catch-and-release 
Another strategy for purification consists of catch and release of the expected 
compound. After reaction, a polymer "fishes out" the targeted compound and 
impurities and unreacted species are washed away. The expected compound is then 
released using a suitable reagent (Figure 1. 7). This strategy was used by Porco to 
synthesise 1,2,3-thiadiazoles in 48-98% yield and 71-100% purity (Scheme 1. 4)•22 
Filtration 
___  
'Tether" 	 30 






+ Excess of one reactant 
+By.products 
Figure 1. 7 : Principle of catch & release strategy 
) RCHMgX, 
THF, 000  3h 
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I N' 0 	
10 min. 












Br 	 Br 
Scheme 1. 4 : An example of a catch-and-release process 
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The supported Weinreb amide 1.23 was first displaced using a Grignard reagent 
followed by hydrolysis using sulfonic acid resin to form the supported ketones 1.24. 
The desired ketones were then "caught" with a supported hydrazide via imine 
formation. The compounds were then released with thionyl chloride via cyclisation 
to form 1,2,3-thiadiazoles 1.26. 
1.3.4. Reagents 
Another strategy for polymer-assisted solution-phase synthesis involves the use of 
polymer-supported reagents. The reagent can be attached either covalently or through 
ionic interactions. Many polymer-supported reagents have been reported and 
embrace many of the areas obtainable with traditional solution-phase synthesis. 23 
The reagent can be used in large excess in order to obtain quantitative transformation 
of the reactants into the desired product. The reacted and unreacted reagent is then 
easily filtered off to yield pure products (Figure 1. 8). 
Filtration 
Immobilised 
Reactant 1 Reactant 2 reagent in 
excess 
Figure 1. 8 : Principle of polymer-supported reagents 
Polymer-supported reagents can trace their origin to 1946,24  and have seen further 
development in particular by Cainelli, 25 Leznoff, 26 Sherrington '27  and Hodge 28 in the 
1970's and 1980's. However, at that time, these reagents were considered as too 
expensive to be broadly used . 29 The need for cleaner and faster methodologies to 
synthesise collections of compounds requested by the pharmaceutical industry 
announced the huge development of immobilised reagents in the late 1990's. 
A comprehensive review has been carried out by Ley 29 and only representative 
examples, most of them commercially available, of the different classes of reagents 





Many immobilised oxidants have been developed, essentially those based on 
quaternary ammonium ion-exchange resins and Ru0 4 , C10 or HCr04 ions. 15 Thus 
oxidation of alcohols can be realised via the use of an immobilised TPAP 1.27 on 
ion-exchange resin. 30  Polymer-supported TBX 1.28 has also been used successfully to 
oxidise primary and secondary alcohols to the corresponding aldehydes and 
ketones. 31 
0 
0 	0 	 HO-....1' 0 Rh O4 Me3N(] 
1.27 	 1.28 
PS-TPAP 	 PS-IBX 
Figure 1. 9 : Polymer-supported oxidants 
Based on the Swem oxidation protocol, an immobilised sulfoxide 1.29 was used for 
the oxidation of alcohols in 91-99 % yield . 32 Advantageously, this soluble polymer 
bound sulfoxide was readily recycled after reaction with sodium periodate (Scheme 
1. 5). Other examples of immobilised oxidants include polymer-supported peracids 
which were successfully used to oxidise sulfides to sulfoxides and sulfones. 33 
OH 	 0 












Immobilised reducing agents 
The principal examples of immobilised reducing agents are ion-exchange resins 
anchoring cyanoborohydride 1.31 or borohydride 1.32 ions, and these reagents can 
be used in reductive amination reactions and reduction of ketones and aldehydes to 
alcohols.34' 35  Interestingly, polymer-supported borohydride has the additional 
advantage compared to solution-phase sodium borohydride of reducing o:,0- 
unsaturated carbonyl compounds to the corresponding a,f3-unsaturated alcohols 
without competing reduction of the double bond. 35 
	




PS-cyanoborohydride 	 PS-borohydride 
Figure 1. 10: Polymer-supported borohydrides 
Like in solution-phase synthesis, immobilised borohydrides can be doped by using 
transition metal salts. Indeed when using a catalytic amount of nickel acetate, the 
immobilised reducing agent is able to reduce moieties such as nitro, 36  azido,37 and 
aryloximes groups to the corresponding primary amines. 38 Ley took advantage of this 
possibility in his strategy for the total synthesis of (±)-epibatidine 1.35 using 
exclusively supported reagents, where the transformation of 1.33 into 1.34 proved to 
be problematic under standard hydrogenation protocols to the observed 
dechlorination (Scheme 1. 6) .39  In addition the use of the polymer-supported 
borohydride in conjunction with NiC1 2 proved to be superior to NaBH4 with NiC1 2 . 
OMs 	 QMs 
°BH4 Me3 N 
-". NiCl2 







Scheme 1. 6 An example of use of immobilised borohydride with NiC1 2 
for the reduction of a nitro group 
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Another type of immobilised reagent with reductive properties are polymer-
supported organotin reagents, especially tin hydrides. These reagents were targeted 
in order to avoid contamination of products with tin species in medicinal chemistry, 
and have been used occasionally for the reduction of alkyl halides. 40' 4 ' 
Immobilised bases 
Many organic tertiary bases have been reported and include morpholinomethyl-
polystyrene 1.36 and piperidino methyl-polystyrene 1.37.20  Other bases such as 
polymer-supported TBD 1.38 have been reported and can advantageously used for 
















MeN - R,. N 
1.41 
PS-BEMP 
Figure 1. 11 : Polymer-supported organic bases 
Globally many of the supported bases reported were obtained readily from Merrifield 
resin such as PS-DBU43 1.39 and PS-DMAP44 1.40. Even Schwesinger's 
phosphazene base has been immobilised (PS-BENT 1.41) without loss of basicity. 45 
This supported base was successfully used to mediate the alkylation of 2H-phtalazin-




0 	 Et2N ,5\J1BU 	
1.41 
ANH 0Br 	MeN N'O 
93% 
1.42 	 1.43 
0 0 T (Y 
1.44 
Scheme 1. 7 : Alkylation reaction using PS-BEMP 
Immobilised bases are not limited to organic ones, and hydroxide and 
hydrogencarbonate ion-exchange resins are frequently used , 46 although their 
applications mainly take place in scavenging acids or neutralising amines. 47 A basic 
ion-exchange resin has successfully been used to promote an intramolecular Claisen-
type condensation during the synthesis of 4-hydroxyquinolin-2(1H)-ones 1.46 
48 (Scheme 1. 8). 
OH 
CO2Me 	00H MeaN'O Ri 
C~NO 
I 	 R2 
1.45 	 1.46 
Scheme 1. 8 : Intramolecular Claisen-type condensation promoted by hydroxide ion-exchange resin 
Immobilised acids 
Only a few supported acids have been reported and these are often simply used as 
nucleophile scavengers and for catch-and-release . 49 However, a polymer-supported 
version of toluene-sulfonic acid 1.47 has been used to promote reactions requiring 




Figure 1. 12: Sulfonic acid-PS 
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Reagents for halogenation reactions 
Most of these reagents are based on ion-exchange resins. Indeed Amberlyst-26 in the 
perbromide form has been used to brominate a wide range of organic substrates. 
Saturated aldehydes and ketones are easily brominated, while a,3-unsaturated 
ketones give dibrominated products. 52  Perbromide ion-exchange resins can also be 
used to perform 1,2-addition to alkenes and alkynes. 53 
Although many reagents have been developed for bromination reactions, no direct 
reagent for chlorination has been reported, and such reactions are often carried out 
with a supported triphenylphosphine and a source of chlorine. Indeed PS-TPP and 
CC14 have been used for the chlorination of primary alcohols under mild 
conditions. 14  Similarly, PS-TPP and 12 have been used for the iodiriation of electron-
rich aromatic systems. 55 
Miscellaneous immobilised reagents 
In order to simplify the complex purification step in the Mitsunobu reaction, a 
supported diethylazodicaboxylate 1.48 was developed .56  Polymer-supported 
triphenyl-phosphine 1.49 can also be used very advantageously in Mitsunobu 
reactions as triphenylphosphine oxide that is formed during the reaction is usually 
very difficult to separate from the product. 57 
Polymer-supported coupling reagents have also been reported but these are discussed 
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Application of immobilised reagents 
Examples of complex compounds synthesised in solution-phase using polymer-
supported reagents and scavenger are numerous, and include natural products. 39 ' 47 
One of the first example of the synthesis of a fairly complex organic product using 
polymer-supported reagents used sequentially was reported in 1974 by Rebek, who 
used a polymer-supported cyclobutadiene iron complex and a polymer-supported 



















Scheme 1. 9 : First synthesis of a complex organic product using polymer-supported reagents 
One of the advantages of using immobilised reagents is the ability to use in a single 
step reagents that are mutually incompatibles. This principle was highlighted by 
Cainelli's work on the synthesis of unsaturated nitriles. 25 Using, simultaneously, 
Amberlyst 15-H 1.47 and Amberlyst-26-Phosphate 1.56, the nitriles 1.57 was 
obtained via acetal deprotection and Wittig-Homer reaction (Scheme 1. 10). 
F_\ 	 H03S-0 1.47 	
,CN 
0 II 0 x 0 
R R'  EtO, 	 R R 
1.55 	EtO CN Me3N 	 1.57 
1.56 




Using usually incompatible reagents is remarkable when unstable products are 
generated. Thus Bessodes reported a one-pot cleavage of 1,2-diols to primary 
alcohols  .59  In this work, the unstable dialdehyde generated in-situ via a supported 
periodate 1.59 was readily reduced by a supported borohydride 1.32 (Scheme 1. 11). 
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0 
1.60 
Scheme 1. 11 : One-pot cleavage of diols 
The "one-pot" use of immobilised reagents was also illustrated by Parlow who used 
three polymer-supported reagents at the same time for the synthesis of substituted 
pyrazoles 1.63 (Scheme 1. 12). 0  
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Polymer-supported catalysts use the same principle as polymer-supported reagents. 
A wide range of supported-catalysts has been reviewed by de Miguel 6 ' and a review 
emphasising the advantages of recyclable supported catalysts and reagents was 
performed by Bradley. 62  Immobilised catalysts allow high purities in reactions where. 
the catalyst is difficult to separate from the reaction mixture. Some of the first 
immobilised catalysts were reported in 1975 by Pittman, who used nickel, ruthenium 
and rhodium catalysts in particular for hydroformylation reactions. 63  Polymer-
entrapped palladium catalysts have been used advantageously in cross-coupling 
reactions, 64 while ruthenium complex bound to a resin, have efficiently mediated ring 
closure metathesis reactions. The supported catalyst is a polystyrene-immobilised 
equivalent of the second generation Grubbs Ruthenium complex 1.67 .65  Cycles of 
various sizes were synthesised in excellent yields using this catalyst (Scheme 1. 13). 
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IfN..H 1.66 	 1.70 	 100% 
Scheme 1. 13 : RCM using a polymer-supported Grubbs catalyst 
1.4. Conclusion 
A wide range of polymer-supported reagents have been reported, but if one looks 
more closely, many of them tend to be too specific or too sensitive, or even too 
difficult to synthesise. A trend in the pharmaceutical industry is for polymer-assisted 
solution-phase chemistry in order to obtain quickly, collections of few hundred 
compounds, which illustrates the need to identify and synthesise new polymer-
supported reagents in order to achieve faster high-throughput-synthesis of potentially 
biologically active molecules. 
Chapter II 
Amide-bond formation in organic chemistry 
2.1. Importance of amide-bond formation 
2.1.1. Molecules containing amide-bonds 
Peptides 
Peptides are small molecules consisting of sequences of amino-acids. They have 
many biological activities, including actions such as hormones (e.g. angiotensin 166 
2.1 and gastrin  67  2.2), first messengers in neurotransmission (vasopressin 68 2.3), local 
mediators in cardiovascular diseases (endothelin 169  2.4) and antibiotics such as 
berninamycin A7° 2.5 or fungicides such as cecropin A 2.6. 1 
	
Angiotensin I 2.1 	Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu 
Gastrin 2.2 	Pyr-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH 2 
II Vasopressin 23 	Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH 2 
Endothelin I 2.4 	Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile- 
Ile-Trp 	I I 
Berninamycin A 2.5 
02C N 
o NH 	HN 
HN 	 OXH 
o NH 	 0HHN.J 
N0 
HN- 
0:*N,:~'1 N,rA, 0 
OH 
Cecropin A 2.6 H-Lys-Trp-Lys-Leu-Phe-Lys-Lys-Ile-Glu-Lys-Val-Gly-Gln-Asn-Ile-Arg-Asp-Gly-Ile-
Ile-Lys-Ala-Gly-Pro-Ala-Val-Ala-Val-Val-Gly-Gln-Ala-Thr-Gln-Ile-Ala-Lys-NH 2 
Figure 2. 1: biologically active peptides 
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Synthesising peptides therefore holds many interests. Indeed, it allows a study of 
biochemical or biological processes, in particular for receptors. 72  It is possible to 
develop new drugs based on peptides: for example the modified natural product 
cyclosporin A is an immunosuppressive agent, and direct synthesis therefore presents 
an interest. On the other hand some natural products such as didemnins 73 2.8 are 
active but generate many side-effects, and the synthesis of analogues is desirable. 
Peptides drugs have been developed in many fields, and include Insulin and 
analogues such as Insuline Glargine (glycemic control in diabetes type 1),74  goserelin 
2.9 (breast cancer) '75  luteineizing hormone-releasing hormone 2.10 (LHRH-
analogues have applications in many cancers), 76 and antibiotics such as gramicidin 
A77 2.11 and bacitracin A 2.12.78  Very recently a new antiretroviral drug, Enfuvirtide 
2.13, became the first drug to inhibit the entry of HIV-1 into host cells. 79 Enfuvirtide 
is particularly challenging in terms of synthesis for a commercial drug as it is 




Didemmn A 	Hip-Leu-Pro-Me2Tyr-Tw-Ist 





Gramicidin A 	Formyl-Val-Gly-Ala-D-Leu-Ala-D-Val-Val-D-Val-Trp-D-Leu-Trp-D-Leu-Trp-D-Leu- 
2.11 	L-Trp-ethanolamine 
Bacitracin A 	 H1is-D-Asp-Asn-L1ys-D-Orn-Ile-D-P1he 
2.12 	 Ile-D-Leu-Leu-Cys-Ile 
Enfurvirtide 	Ac-Tyr-fle-Ser-Leu-Ile-His-Ser-Leu-lle-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-LysAsn 
2.13 	Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-N}{2 
Figure 2. 2: biologically active peptides 
Peptides have also applications as vaccines. 80, 81 They are applied to the treatment or 
prevention of allergic and autoimmune diseases 82 , infectious diseases 83 and 




to generate an immune response. Although peptides vaccines present the advantages 
of being easily synthesised via classic organic synthesis, they suffer from a lack of 
i mmunogeni city. 8° 
Other molecules containing amide-bond 
The presence of amide-bonds is not limited to peptides, and many drugs on the 
market contain the amide moiety. For example, Lipitor (Atorvastatin 2.14, 
manufactured by Pfizer), the top selling drug worldwide in 2003, blocks the 





















Figure 2. 3: examples of top drugs containing amide bond 
Other major drugs containing an amide bond include Lisinopril 2.15 and analogues 
(inhibitors of angiotensin converting enzyme), 16, 87 Valsartan 2.16 (blockade of 
angiotensin-11 receptors),  88  Diltiazem 2.17 (calcium channel blockers in the treatment 
of angina and hypertension  )'89  Zolpidern 2.18 and analogues (hypnotic, anxiolytic, 
anticonvulsant and muscle relaxant agents acting at the benzodiazepine receptor). 90 
These examples are just a small representation of the presence of amide-bonds in 




2.1.2. Basic principles of amide-bond formation 
Amides are synthesised from carboxylic acids and amines; however, the coupling 
between these two kinds of functional groups does not occur spontaneously at 
ambient temperature. At higher temperatures (e.g. >200°C) it will take place with 
elimination of water, but these conditions are often incompatible with the stability of 
the substrate. 91 At room temperature, when added together, the only reaction 
occurring is a simple acid-base reaction yielding a salt. For this reason, it is 
necessary to firstly activate the carboxylic acid thus increasing the electrophilicity of 
the carbonyl group, a process that usually takes place by using a good leaving group 
(Scheme 2. 1). 
	
0 	Activation 




Scheme.2. 1 Principle of the activation process for amide-bond formation 
Acids are usually activated as acid chlorides, (mixed) anhydrides, carbonic 
anhydrides or active esters. Many reviews on coupling reagents have been performed 
but are often incomplete. 92-98 
2.1.3. Racemisation issues when coupling amino acids 
2.1.3.1. 	Epimerisation via an oxazolone intermediate 
Epimerisation generally occurs through an oxazolone 2.19 intermediate, which can 
be formed via an internal amide once the carboxylic acid has been activated (Scheme 
2.2). 
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Scheme 2. 2: Mechanism of epimerisation via oxazolone formation 
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Enolisation of the oxazoline results in the formation of an sp 2 carbon, inducing a loss 
of stereochemistry. All this has dramatic consequences on coupling amino-acids: if 
the aminoacid is protected as an amide, or if the activated carboxylic acid is part of a 
dipeptide, then racemisation will be observed. If the amine is protected as a 
carbamate, then there is usually very little epimerisation. However, even if 
carbamates are used as protecting groups, epimerisation can be observed if the 
kinetics of the coupling reaction are poor, which provides some of the interest in 
finding efficient coupling reagents. 
2.1.3.2. Practical evaluation of the epimerisation occurring with coupling 
reagents 
Many methods have been investigated for the evaluation of epimerisation during 
both aminoacid and peptide segment coupling. For general couplings, Young's test is 
predominantly used and consists of coupling N-Benzoyl-Leucine with ethyl 
glycinate. 99 Analysis of the optical rotation of the mixture of enantiomers after 
coupling allows the determination of the extent of racemisation by comparison with 
the optical rotation of the L-isomer ({a]D = -20.8°). 
Weinstein reported a test which consisted in coupling N-Acetyl-Phenylalanine with 
alanine methyl ester and checking the extent of epimerisation by NIMR, 100 while 
Bodansky's test consisted of coupling N-Acetyl-isoLeucine and Glycine ethyl ester, 
followed by hydrolysis with HC1 and analysis with an aminoacid analyser for 
determination of racemisation (chiral HPLC).' ° ' 
Racemisation during segment-coupling is usually evaluated with Anteuni's test, via 
the coupling of Z-Gly-Phe-OH with H-Val-OMe. The extent of epimerisation can be 
determined either by HPLC or by NMR. Due to the presence of the phenyl group, the 
dipeptide is particularly subject to epimerisation and therefore Anteuni's test 
represents a very sensitive method for the detection of epimerisation. 102 
Other tests such as Anderson's (Z-Gly-Phe-OH and H-Gly-OEt, followed by 
fractional crystallisation of the racemic D/L and pure L-tripeptide),' °3 or Izumiya's 
(Z-Gly-Ala-OH and H-Leu-OBz, followed by hydrogenation and HPLC analysis), 104 
have been reported but are not widely used. The various methods, used by different 
research groups reporting new coupling reagents, make the comparison between all 




2.2. Coupling using carbodiimides 
2.2.1. Dicyclohexylcarbodiimide 
Carbodiimides were the first coupling reagents to be synthesised and 
dicyclohexylcarbodiimide (DCC, 2.20) has been used for coupling reactions since 
1955.105. 106 The mechanism for coupling carboxylic acids to amines is shown in 
Scheme 2. 3. 
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Scheme 2. 3: Coupling using DCC 
The first step involves the reaction of the carboxylic acid with DCC to form the 0-
acylurea 2.21. This intermediate can then yield different products: 
• The amide via direct coupling with the amine. (The by-product formed, 
dicyclohexylurea (DCU, 2.22), is usually insoluble in the reaction solvent 
and can be removed via filtration). 
• Formation of an N-acylurea 2.23 by-product that is unreactive 
• Formation of the anhydride of the carboxylic acid which subsequently 




As indicated earlier, formation of the oxazolone can take place after formation of the 
0-acylurea and racemisation is usually high when using DCC.' °3 
2.2.2. Use of additives 
In order to reduce the racemisation level when using carbodiimides as coupling 
reagents, Koenig and Geiger used 1-Hydroxy-1H-Benzotriazole (HOBt) 2.24 as an 
additive.' 07 ' 09 They proved that when using this acid, the yields were higher and 
racemisation levels lower. For example, when coupling Z-Gly-Phe-OH to H-Val-
OMe, the epimerisation levels dropped from 35% to only 1.5%. 
HOBt 2.24 reacts with the O-acylurea 2.21 to give the OBt active ester 2.25. HOBt 
lower the epimerisation by enhancing the reactivity of the carbonyl group and 
stabilising the attack of the amine (Scheme 2. 4). However, using HOBt can 
sometimes yield other by-products. Indeed, it catalyses the formation of diazetidine 
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Scheme 2. 4: Action of HOBt when used as an additive with DCC 
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Scheme 2. 5: Formation of diazetidine by-product when using DCC/HOBt 
In 1994, Carpino reported a similar additive, 1-Hydroxy-7-Azabenzotriazole (HOAt) 
2.27 (Figure 2. 4), which is even more efficient than HOBt 2.24 in terms of yield, 
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kinetics and racemisation levels."' For example epimerisation during coupling of 
Bz-Val-OH and H-Val-OMe using DCC 2.20 dropped from 41.9% with HOBt 2.24 
to 14.9% with HOAt 2.27, while when coupling Z-PheVal-OH to H-Ala-OMe using 







Figure 2. 4: Structure of HOAt 
Much work has been carried out on the benefit of using additives. In particular, 
Carpino studied various is of HOAt concluding that the 7-isomer was the most 
efficient.' 12 Albericio also showed that Copper(II) complexes with HOAt or HOBt 
are efficient additives in lowering the epimerisation level." 13,114 
2.2.3. Other carbodiimides 
Since the application of DCC to peptide synthesis, many carbodiimides, including 
DIC 2.28 (diisopropylcarbodiimide), have been reported and the field has been 
reviewed on many occasions. 110, 115,116 In particular, attention has focused on so-
called water-soluble carbodiimides, as the ureas formed when using DCC 2.20 or 
DIC 2.28 can sometimes be difficult to remove. Sheehan investigated several 
derivatives 2.29-2.32, and concluded that coupling was more efficient when using 
tertiary amine carbodiimides compared to quaternary derivatives. 117 Sheehan also 
reported other water-soluble carbodiimides, but no comparison with these reagents 
was given." 8 
Carpino compared DIC 2.28 to EDC 2.35 and analogues 2.33-2.34,111" 120  and also 
compared it to some unsymmetrical alkyl/aryl carbodiimides such as phenyl ethyl 
carbodiimide (PEC 2.36) and phenyl isopropyl carbodiimide (PlC 2.37). Overall, 
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Figure 2. 5: Structure of some carbodiimides 
2.3. Coupling reagents based on 1-H-benzotriazole 
2.3.1. Uronium/aminium salts 
Many coupling reagents are based on the HOBt system and uronium/aminium salts, 
but have since been surpassed by those based on HOAt because of its increased 
efficiency. 121, 122 Uronium 2.38 and aminium 2.39 isomers of these reagents have 
been structurally identified (Figure 2. 6).123  Indeed, coupling reagents based on 
uronium salts were first reported as being obtained as an 0-isomer (2.38). However, 
Carpino proved by X-ray crystallography that HATU 2.40a and HBTU 2.40b were 
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Figure 2. 7: uronium/aminium type coupling reagents 
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These reagents react with carboxylic acids to form OAtJOBt active esters, which then 
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Scheme 2. 6: Activation process using uroniumlaminium type reagents 
The uronium salts included HBTU' 24 2.40b and TBTU' 25 2.41b which had similar 
efficiency (Figure 2.7). However, after Carpino showed that the best results were 
obtained with HOAt, many coupling reagents started to be based on this additive 
such as HATU 2.40a and TATU 2.41a. It has been proven that coupling reagents 
based on HOAt, compared to HOBt, give faster, more efficient couplings with less 
epimerisation.' 26 Much work has been carried out with variation of the substituents, 
yielding HAPyU 2.42 (also named BBC by Chen ' 27) and TAPipU 2.43 with 
relatively little influence on the outcome of couplings. 128  Other modifications include 
HAPipU 2.44a,' 22 HBPipU 2.44b,' 29 HAMDU 2.45a,' 22 FIBMDU 2.45b (also named 
BOI),' 22 and HAMTU 2.46. 122  Overall the structural differences between these 
reagents did not appear to be based on rational considerations and were merely a 
screening of different substituents. These reagents 2.44-2.46 gave poor coupling 
results because the reagents were too reactive and degraded before coupling could 
take place. 
Carpino tried to modify the HOAt ring to form 5,6- Benzo 2.47 and 4,5-Benzo 2.48 
derivatives.' 0 The rational was based on the postulated fact that HOAt is more 
reactive than HOBt because the seven-ring anchimeric effect involving the nitrogen 
atom of the pyridine ring (HOAt) in the intermediate active ester 2.49 is supposed to 
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be more effective in promoting reactivity than the six-ring effect in HOBt 2.50 
(Figure 2. 8). 11 The derivatives synthesised were supposed to be more basic than the 
reagents synthesised before and therefore more reactive. The difference in 
racernisation levels were modest but 4,5-B(HATU) 2.48 decreased the reaction half-











6-ring effect in HOBt 
Figure 2. 8: Ring-effect in HOBt and HOAt 
More recently, other derivatives based on 6-chloro-HOBt were developed by 
Albericio, HCTU 2.51a and TCTU 2.51b,'31 132  and by scientists at Argonaut, 
ACTU 2.51c,  13 ' but these reagents have not been directly compared to other coupling 
reagents. Papini used HCTU 2.51a, TCTU 2.51b and HETU 2.40b in the solid-phase 
synthesis of cylcopeptides, and the 6-Cl-HOBt based reagents reacted faster and gave 
higher yields than HBTU.' 34 
Although many of these reagents couple efficiently amines to carboxylic acid, a side-
reaction can often take place with the amine reacting with the coupling reagent to 
form a guanidinium by-product 2.52 (Scheme 2. 7)•96 
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2.3.2. Phophonium salts 
Another family of coupling reagents based on HOBt/HOAt is where the 
uronium/aminium system is replaced by a phosphonium system. The first 
phosphonium salt introduced was BOP 2.52b,135' 136  but its use has been limited due 
to the carcinogenicity and respiratory toxicity associated with HvIPA generated 
when BOP is used in coupling reactions. Instead, the pyrrolidino derivative PyBOP 
2.53b was developed. 136-138  Carpino prepared AOP' 22 2.52a and PyAOP122' 139  2.53a 
and compared them to BOP 2.52b and PyBOP 2.53b. The aza-derivatives proved to 
be more reactive both for activation and coupling. Interestingly he showed that 
phosphonium salts were less stable than the corresponding aminium/uronium 
derivatives in the absence of a base. However, in the presence of a base, the 
phosphonium species were slightly more stable, and as a base is required for efficient 
coupling, the phosphonium salts appear to be more efficient. The phosphonium salts 
also have the advantage of not yielding guanidinium by-products via reaction of the 
coupling reagent with amines. In order to achieve the synthesis of thioamides, Hoeg-
Jensen et al. developed phosphonium coupling reagents based on the 6-nitro HOBt 
ring.' 40 PyNOP 2.54, PyFOP 2.55 and NOP 2.56 were used successfully for the 
formation of thioamides, with good thioamide/amide selectivity but their solubility in 
organic solvents was poor. 
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2.3.3. Immonium salts 
More recently, Li designed and synthesised new immonium type coupling 
reagents, 141,142  such as BOMII 2.57, 143-147  BDMP 2.58, 144, 146, 147 BPMIP 2.59, BMIVIIP 
2.60, and AOMP'' 146  2.61. In particular, these reagents were used to carry out the 
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Figure 2. 10: immonium type coupling reagents 
2.3.4. Other reagents 
Carpino reported DepOAt 2.62. 149  The reaction half-lives were similar to common 
reagents such as HATU but proved to be much more efficient in terms of 
epimerisation than any of the other HOAt/HOBt coupling reagents. He tested also 
named DpopOAt 2.63, as well as Dmpp0At 2.64, DtpOAt 2.65a and DtpOBt 2.65b, 
which were targeted to be more stable toward moisture in the air than the 
corresponding phosphate esters. In term of half-lives for the formation of Z-Aib-OXt, 
DpopOAt 2.63 gave similar results to DepOAt 2.62 (<2 mm.), but DtpOBt 2.65b 
gave poor comparison (65-70 mm.). A racemisation study for the coupling of Z-Phe-
Val-OH and H-Pro-NH 2 showed that Dmpp0At 2.64 (3.6% of LDL isomer) and 
DtpOAt 2.65a (2.9%) were giving less epimerisation than HATU 2.40a (5.0%), 
while DtpOBt 2.65b was worse (11.4%), but no explanation for these results was 
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Figure 2. 11: other coupling reagents based on HOXt 
A thio-analogue of HAPyU 2.42,128  HAPyTU 2.66, was tested by Kiose but proved 
to be unsuccessful as yields were lower and epimerisation higher than HAPyU 
2.42 . 150 
Another type of reagent based on sulfonates was developed by Itoh.' 5 ' These 
reagents 2.67-2.70 were designed with a HOBt and HOCt (6-chloro-HOBt) ring with 
different substituents on the sulfonate. The best results were obtained with HCSCP 
2.70, as the effects of the chlorine atoms enhanced the reactivity of the reagent. 
However, the reagents were not compared directly to each other as they were tested 
on different reactions. Compared to DCC 2.20 (without using HOBt), these reagents 
gave less side-reactions and the by-products were easily removed during aqueous 
workup. According to the authors, racemisation was lower than with DCC, but no 




2.4. Reagents generating acid halides 
2.4.1. General reagents used in organic chemistry and triazine-type reagents 
Fischer reported the first synthesis of a dipeptide (Gly-Gly) in 1901 and developed 
the acid chloride method of coupling.' 52  The general approach consists of using 
thionyl chloride or phosphorus pentachioride to generate the acid chloride which 
reacts quickly with amines to form amides. However this method is quite harsh and 
not compatible with many protecting groups. It has however been used by Carpino to 
synthesise peptides via an Fmoc strategy. 153  Triphosgene has also been reported to 
generate amino-acids acid chloride, 114,155  especially useful for hindered substrates.' 56 
Similarly, acid cyanides and azides have been used to synthesise amides. 157 
Cyanuric fluoride 2.71 can be used to synthesise acid fluorides (Scheme 2. 8),158. 159 
which couple N-methylated amino-acids very efficiently. 
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Scheme 2. 8: Use of cyanuric fluoride to generate acid fluorides 
A variety of other reagents have been reported for the formation of acid fluoride, and 
include deoxo-fluoro 2.72 and DAST 2.73 (Figure 2. 12), 160  with which amides have 
been synthesised in good yields, but many side-reactions occured with hindered 
amines. In addition, these two reagents are expensive, and purification by 
chromatography is required after reaction. 
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Part of this category of reagents is based on triazines (cyanuric fluoride, chloride and 
derivatives) and has been reviewed in details by Kaminski .' 6 ' In particular CDMT 
2.74 and DCMT 2.75 (2,4-dichloro-6-methoxy-1,3,5-triazine) have been successfully 
applied to the synthesis of anhydrides. 162 
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Cl 	 CI 
CDMT 2.74 	 DCMT 2.75 	 DMTMM 2.76 
Figure 2. 13: coupling reagents based on triazines 
DMTM1IVI 2.76 is another triazine derivative, which has the particular advantage of 
promoting amide synthesis in alcohols or aqueous media, without ester formation 
and with selectivity comparable to DCC and EDC.163' 164  Recently, a new generation 
of reagents based on DMTIvIIvI was developed by Kaminski (Scheme 2. 9)165 
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Scheme 2. 9: Exchange of counter anion on DMTMM 
Analogues using different tertiary bases have been synthesised and the derivative 
including DABCO proved to give the best synthesis yield. However a full study was 
carried out on the N-methylmorpholine derivative 2.77, because of its lower 
production cost. The reagent proved to be particularly efficient with high yields and 
low epimerisation levels. For the synthesis of the 65-74 segment of ACP, each 
coupling went faster (15 mm.) than with TBTU (45 mm.) or HATU (30 mm.) and 
gave better purities (84 %) than TBTU (69%).165 
Chapter!! 	 35 
2.4.2. Halo-uronium, halo-phosphonium and halo-sulfonium type reagents 
TFFH 2.78a,' 66 BTFFH 2.79, 166, 167 and DFIH' 66 2.80a have been used with mixed 
success to generate acid fluorides since cyanuric fluoride failed in some cases (such 
as protected histidine and arginine), while PyF1oP 2.81a did not yield any acid 
fluoride. Interestingly, 'iFFH 2.78a (100% coupling after 10 mm.) gave better results 
than the chioro- and bromo- analogues, TCFH 2.78b (86%) and TBFH 2.78c (79%), 
for the coupling of Fmoc-Val-OH to H-Ile-PEG-PS.' 66 Overall, BTFFH 2.79 gave 
the best conversions.' 67 
Reagents aimed at generating acid chlorides or bromides under milder conditions 
than thionyl chloride, for example, have been targeted. Brop 2.82a was first 
synthesised by Coste, 168 and later PyBrop 2.81b and PyClop 2.81c.'38' 169, 170 These 
reagents were more efficient that PyBOP 2.53b in coupling N-methyl amino acids. 
However, PyBroP 2.81b and PyCIoP 2.81c can give N-carboxyanhydrides when 
coupling Boc-amino acids. PyC1U 2.83, also synthesised by Coste, gave high yields 
when coupling hindered amino acids. 169 DCIH 2.80b (named CEP originally) gave 
comparable results to PyBroP and PyCIoP. 17 ' One of the drawbacks of PyBrop, 
PyClop and DCIH is the established formation of mixtures of symmetric anhydrides 
and oxazolones. Clop 2.82b was reported by Castro and shown to give low levels of 
racemisation via Young's test. 172 
An analogue of PyC1oP 2.81c, PyClopP 2.84, was reported by Li, in an attempt to 
increase reactivity by replacing a pyrolidine ring by a phenyl group. The reagent was 
reported as being efficient for hindered peptide synthesis, but no results were given 
to illustrate this fact! 141 
BOP-Cl 2.85 is a reagent that has been widely used in peptides synthesis, 173  and was 
in particular reported as being suitable for coupling hindered substrates, 174  but it has 
the major drawback of capping primary amines.' 75 
Other reagents include CDTP' 76 2.86 and CMIvIM 2.87,' but these reagents, like 
the one detailed above, usually give high racemisation during coupling. CMtvIM 2.87 
has been compared to other reagents such as FEP 2.93b, and gave poor results with 
coupling times of over 2h and racemisation over 30% with the Anteuni's test. 141 
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Figure 2. 14: Halo-uronium, halo-phosphonium and halo-sulfonium type reagents 
2.4.3. Halo-sulfonium, halo-dioxolium, and halo-dithiolium coupling reagents 
Li synthesised other types of coupling reagents, including CDMS 2.88, CBDO 2.89 
and CPDT 2.90.141  However these reagents were far too reactive and decomposed in 
solution before activation could take place! 
Figure 2. 15: halo-sulfonium, halo-dioxolium and halo-dithiolium type reagents 
Chapter II 	 37 
2.4.4. Halo-thiaziolium and halo-pyridinium type reagents 
Li designed reagents based on thiazolium and 2-halopyridinium salts. Their design 
was based on the fact that, in halouronium type coupling reagents, the carbocation is 
well stabilised via the lone electron pairs of the nitrogen atoms. Therefore, the 
carbocation shares a relatively high electron density and the uronium salt 
demonstrates a relatively low reactivity in the nucleophilic reaction involved in 
peptide synthesis. For this reason Li attempted to replace one nitrogen atom with 
other atoms without electron lone pairs or more electronegative atoms with lone 
electron pairs to enhance the reactivity of the reaction-mediated carbocations. The 
first attempt to replace one nitrogen with sulphur yielded a thiazolium. reagent, 
BEMT 2.91, with high efficiency.  177  The same type of reagent, BMTB 2.92, was 
proposed by Wischnat (Scheme 2. 1O).178  BMTB 2.92 performed better than HATU 
in coupling Boc-MeIle to MeIle-013n. However BMTB 2.92 was not compared to 
BEMT 2.91. 
S 	
a) CH3COCH3,12 	S 	 Et30BF R H2NANH2 b)NaOH 	 (Meeein 
reagent) 
	
NaNO2 	 R=NH 
NaBr, CuSO4 






R = CI 
NaSCN 
R = SCN 
CH3Br 





Scheme 2. 10: Synthesis of BEMT and BMTB 
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Figure 2. 16: Other halo-thiaziolium and halo-pyridinium type reagents 
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Scheme 2. 11: Activation mechanism for halopyndinium type coupling reagents 
Li reported 2-halopyridinium salts like BEP 2.93a, FEP 2.93b, BEPH 2.94a and 
FEPH 2.94b.' 79 Mukaiyama has used extensively 2-chioro- and 2-bromo-pyridinium 
iodides 2.95 180  to synthesise esters, lactones and amides, 180 but the conditions used 
were unsuitable for peptide synthesis, as reactions had to be performed at reflux in 
DCM due to the poor solubility of the reagents. For this reason Li used 
tetrafluoroborate and hexachioroantimonate counter anions to improve the solubility, 
and chose the fluoro-analogues for higher reactivity. A mechanism of the coupling 
reaction when using these reagents is indicated in Scheme 2. 11. The efficiency of 




BOP-CI 2.85. However these reagents might be a bit too reactive as the base used 
during the coupling had to be added very slowly to avoid the coupling reagents 
reacting too violently. 
2.5. Other coupling reagents 
2.5.1. Reagents generating carbonic anhydrides 
Another coupling reagent, EEDQ 2.96, was originally developed in 1967.181 182 
EEDQ offers several advantages over most coupling reagents, as the reaction with an 
amine cannot yield a guanidinium salt, a typical side reaction observed with uronium 
type coupling reagents. In addition, the carbonic anhydride is formed slowly but 
consumed rapidly, which avoids its accumulation and therefore minimises the 
possibility of side-reactions such as epimerisation. 182 EEDQ 2.96 has been used to 
efficiently couple hindered aromatic carboxylic acids with 
tris(hydroxymethyl)aminomethane. 183 This coupling reagent was also described in 
the synthesis of a D-lactosyl cluster nucleotide conjugate, 184  and for the formation of 
benzimidazoles' 85 and numerous other amide derivatives.' 85, 186 Analogues of EEDQ 
2.96 have also been successfully investigated such as IIDQ 2.97, and a number of 
unsymmetrical reagents.' 87 
oo 	 * 
EEDQ 2.96 	 IIDQ 2.97 
Figure 2.17: Structure of EEDQ and IJDQ 
2.5.2. Pentafluorophenol (HOPfp)-based coupling reagents 
These types of reagents are based on the traditional pentafluorophenol leaving group 
and the generation of active esters. They usually require the addition of HOAt as the 
level of racemisation is quite high: when coupling Z-Phe-Val-OH to H-Pro-NH 2 , 
33.7% of the DL isomer was observed in solution phase when using HPyOPfp 2.98a, 
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while epimerisation dropped to 1.7% when adding HOAt to the reaction mixture. 
The use of a thiophenol-analogue, HPySPfp 2.98b did not change the outcome of the 
coupling reactions. 150 Consequently these reagents are not ideal in solution-phase 
chemistry as the use of an additive means that this would have to be removed from 
the reaction mixture after coupling. 
Li described a pentafluorophenyl immonium type reagent FOMP 2.99, 144  but this 
reagent was not as efficient as the other immonium type reagents, based on 
HOBIJHOAt. 
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Figure 2. 18: coupling reagents based on pentafluorophenol 
A reagent, PFNB 2.100, was made by Pudhom, but Boc-Gly-OH reacted slowly and 
incompletely and it was necessary to add HOBt to get good conversion.' 88  In order to 
synthesise thioamides, Hoeg-Jensen synthesised PyPOP 2.101, but this reagent was 
not as efficient as PyNOP 2.54 or PyFOP 2.55. 10 Other reagents include FDPP 
2.102, which gave lower epimerisation levels than HBTU 2.40b, BOP 2.52b and 
DCC 2.20.189 
2.5.3. Reagents based on 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine 
(HODhbt) 
HODhbt was first mentioned in 1970 by Koenig who investigated over 30 N-hydroxy 
compounds as additives for peptide synthesis. 109 HOBt gave excellent results but 
HODhbt proved to be generally superior. However Koenig pointed out that HODhbt 
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is limited due to inherent side reactions, in particular the formation of a azido-





Figure 2. 19: side-product formed when using HODhbt as additive 
Knorr proposed the generation a HODhbt based coupling reagent, synthesising 
HDTU 2.104a. 125 Although HDTU 2.104a gave little epimerisation, it was noticed 
that its use is recommended only in critical cases because of the risk of side-
reactions. A similar reagent TDBTU 2.105, where the hexafluorophosphonium 
counter anion is replaced by tetrafluoroborate has also been reported with 
comparable results to HDTU 2.104a.' 25 Another disadvantage of HDTU 2.104a is its 
poor stability in DMIF compared to classic reagents such as HATU as after 5h 
HDTU 2.104a had totally decomposed compared to less than 1% for HATU. 122 
Carpino compared organophosphorus reagents to commonly used coupling 
reagents, 149  and showed that DpopODhbt 2.106 was comparable to HATU in terms 
of reaction times for the formation of the active ester of Z-Aib-OH (< 2 mm.) but 
Dep0Dhbt 2.107 (also named DEPBT by Ye190' 191)  was not as efficient (7-8 mm.). 
Another reagent, Dtp0Dhbt 2.108 gave more epimerisation (4.3% of LDL isomer) 
than Dep0Dhbt 2.107 (3.5%) but less than HATU (5.0%) when carrying out the 
coupling of Z-Phe-Val-OH and H-Pro-NH 2. The synthesis of the ACP decapeptide 
(H-Val-Gln-Ala-Ala-Ile-Asp-Tyr-Ile-Asn-Gly-NH 2) was used to show that 
Dep0Dhbt gave poor results (<1% yield) compared to HATU (85%). 
Li also based an immonium type reagents on HOBhbt, but DOIVIP 2.109 showed 
very poor results for the coupling between Z-Gly-Phe-OH and H-Val-OMe with only 
5.6% yield after 2h compared to 95% for BDMP for example. PyDOP 2.110 was 
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Figure 2. 20: Coupling reagents based on HODhbt 
More recently, Carpino developed coupling reagents based on aza-analogues of 
HODhbt,' 92 and successfully synthesised HDATU 2.104b, HDADU 2.112, HDPyU 
2.113a, HDAPyU 2.113b and PyDAOP 2.110b. As expected, derivatives of 
HODAhbt were more reactive than their HODhbt analogue. Thus, HDATU 2.104b 
gave better results than HDTU 2.104a, but was still less reactive than HATU. 
Moreover, results were more random for segment coupling as they depended on the 
system studied. However, in many cases, HDATU 2.104b proved to be better than 
HATU for the solid-phase synthesis of ACP. 
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Itoh developed sulfonate reagents based on HODhbt. 15 ' The two reagents 
synthesised, SIVIDOP 2.114 and SPDOP 2.115 were however not as efficient as the 
other sulfonate reagents that this group synthesised, such as HCSCP 2.70. 
2.5.4. Reagents based on 2-hydroxysuccinimide (HOSu) and 2-(5-norbornene-
2,3-dicarboximide) (HONE) 
Only a few reagents incorporating the hydroxysuccinimide leaving group have been 
synthesised. Knorr developed TSTU 2.116 and its succinimide analogue TNTU 
2.117, which showed high epimerisation levels whithout the use of additive. 125 
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Figure 2. 21: Coupling reagents based on HOSu and HONB 
Other examples are SOMP' 2.118 and SOMI 14 ' 2.119 developed by Li, and similar 
other immonium type reagents, like DOMP 2.109, but they gave poor results. 
Phosphate-based succinimide coupling reagents such as NDPP' 93 2.120 and SDPP 194 
2.121 have also been developed. The use of ENDPP 2.122 proved to be a better 




room temperature, but no other comparisons were reported. Similarly, SDPP was 
only reported as being a "more convenient method" to use than DCC. 
2.5.5. Phosphonium and phosphate type reagents (not based on HOAt, HOBt, - 
OPfP, -OSu, and -ODhbt 
PyTOP 2.123 was developed by Hoeg-Jensen for the formation of thioamides but the 
reagent gave poorer selectivities than PyNOP and PyFOP.' 4° 
The possibility of using using Dpp-C1 2.124 was first investigated with success by 
Jackson, 195 who claimed that racemisation studies via NMR proved that no 
epimerisation was observed with this method, 196  although this result is quite 
surprising, as racemisation is usually high when acid chloride are generated. 
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Figure 2. 22: Other phosphonium and phosphate type reagents 
Other derivatives have also been synthesised and include the azide analogue DPPA 
2.125a,'97' 198  and cyano analogue DEPC 2.126, which gave good coupling yields but 
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with many side-reactions via the cyanide.198' 199  Dpop-CI 2.125b was also tested but 
poor results were observed without the use of an additive. 149  More recently, 
Yasuhara reported TFMS-DEP 2.127 as a successful coupling reagent as Young's 
test gave only 2% racemisation in 85% yield .201 
Other reagents include FDMIP 2.128, which gave poor results (2% yield compared to 
84% yield for BEMT when coupling Z-Gly-Phe-OH to NH 2-Val-OMe), 14 ' and 
BIODPP 2.129, which gave amides in good yields but were not compared to any 
other coupling reagent 201  Finally, PyDPP 2.130 was reported as giving low 
epimerisation rates, but was not compared to other coupling reagents. 202 
2.5.6. Miscellaneous reagents 
CPMA 2.131, a reagent based on a chioroimmonium salt (Figure 2. 23), mediated the 
esterification of carboxylic acids, 203, 204 and in terms of amide bond formation, the 
reagent was efficient but only two examples were reported. 
+ CI ® X CI 
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2.131 
Figure 2. 23: structure of CPMA 
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Scheme 2. 12: Synthesis of HOTT and TOTT from 2-mercaptopyridone 
2-mercaptopyridone-1-oxide 2.132 was used as a starting material to generate a 
cheaper and new type of uronium coupling reagent HO'FI' 2.133 and TOT!' 2.134 
(Scheme 2. 12).205 206 Both reagents gave better results that CEP or PyBrop and were 
comparable to HATU, and the dipeptide Z-MeVal-Aib-OMe was obtained in 80% 




the use of TOTI resulted in only 3.7% racemisation compared to BOP (20%), 
PyBOP(15%), or HATU (20%). HOYT and TOTT have also been successfully used 
to synthesise a primary amide from carboxylic acids using ammonium chloride. 206 
Najera also synthesised two analogues of HOTT/TOYT', forming HODT 2.135 and 
TODT 2.136 (Figure 2. 24).207  These two reagents gave higher yields in SPPS, but 
were less efficient than HOTT/TOTT, giving more racemisation, which was 
explained by the fact that the DMPU derivatives are less stable than the TMU 
derivatives. 
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HOOT (Z=PF 6) 2.135 
TODT(Z=BF4) 2.136 	 2.137 
Figure 2. 24: structure of HODT and TODT 
	
Figure 2. 25: structure of TPTU 
A reagent similar to the ones based on 2-mercapto-pyridine oxide was proposed by 
Knorr but TPTU 2.137, based on 2-carbonyl-pyridine-oxide gave high racemisation 
level when used without an additive. 125 
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An original coupling reagent has been based on the rearrangement of carboxylic-
sulfonic mixed anhydrides. Substituted O-hydroxybenzenesulfonyl chlorides 2.138 
were used as condensation reagents via the mechanism detailed in Scheme 2. 13.208 
Various peptides were obtained using this method with good yields. The 
epimerisation level was only assessed through optical purity, and no comparison was 
made with any common coupling reagent. Another coupling reagent 2.139 was 
produced by activating diethylphosphate with trifluoromethanesulfonalide. 200 
Itoh investigated the possibility of using sulfonate-based coupling reagents, and 
developed 2-methanesulfonyloximino-2-cyanoacetate 2.140, which proved however 
to be outperformed by HCSCP 2.70." l 
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Figure 2. 26: Structure of other miscellaneous reagents 
Carbonyl-diimidazole (CDI 2.141) has been used to generate amide bonds, but more 
recently, Saha reported the use of an analogue (CBMIT 2.142).209  He obtained good 
yields and low racemisation but these were not evaluated on standard tests and are 
therefore difficult to compare to other results. Very recently, diphenylphosphite 
(DPP 2.143),2b0  and tetrakis(pyridine-2-yloxy)silane 2.144,211  have been used to 
synthesise amides. DPP 2.143 forms a phosphonic-carboxylic mixed anhydride, 
while tetrakis(pyridine-2-yloxy)silane yields silyl ester intermediates 2.145 (Scheme 
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Scheme 2. 14: Mechanism proposed by Tozawa when using tetrakis(pyridine-2-yloxy)silane 
2.6. Other methods of N-acylation 
2.6.1. Mixed anhydrides 
The formation of mixed anhydrides is a classic method of amide bond formation. It is 
important to note that many mixed anhydrides can be generated using some of the 
coupling reagents reported in this chapter. The mixed anhydride method was first 
reported by Vaughan, 212  who tested many acid chloride derivatives and concluded 
that the success of the amide-bond formation was governed by steric and inductive 
effects. Isovaleryl chloride proved to give the best results. However, as reported by 
many research groups, this method has a tendency to generate symmetrical 
anhydrides by reaction of a second carboxylic acid molecule on the mixed anhydride 
(Scheme 2. 15). In addition regioselectivity is a major issue, as the amine can 
potentially react on either carbonyle. These drawbacks can sometimes be minimised 
by carrying out the coupling reactions at low temperature. 







mixed 	 symetrical 
anhydride anhydride 
Scheme 2. 15: Disproportionation issue with the mixed anhydride method 
2.6.2. Chioroformates 
The use of chloroformates for amide-bond formation was first reported by 
Vaughan, 213  and was based on the mixed anhydride method. In the presence of a 
base, the reaction between a carboxylic acid and a chioroformate yields a mixed 
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carbonic anhydride, which reacts quickly with amines to form amides. Vaughan's 
study highlighted slightly better results when using s-butylchloroformate compared 
to isobuty1chloroformate. 214 The method was "reinvestigated" by Anderson , 215 who 
tested several different chioroformate, and whose conclusions suggested that 
isobutylchloroformate was the most efficient reagent. 
2.6.3. Direct preparation of active esters 
The direct formation of active esters has often attracted a lot of attention due to 
stability of many of them, which allows storage. Many example of active esters have 
therefore been reported and include -0-succinimides, 216 -OBt and derivatives, 107  p-
nitrophenol, 217 OPfP,218 HODhbt,219 an PTOC. 221 
However, in order to form these active esters, reagents such as DCC have to be used. 
Sometimes, harsher conditions such as SOC1 2 are required, making the direct active 
ester formation strategy poorly attractive. 
2.7. Polymer-supported coupling reagents 
2.7.1. Immobilised carbodiimides 
Only a few polymer-supported coupling reagents are commercially available, 
probably because coupling reagents are mainly used in peptide synthesis, which is 
usually carried out on solid phase, the coupling reagent being in solution. However 
DCC221 , DIC,222 and EDC 223 have been successfully immobilised. These reagents 
have been applied to the synthesis of hapten active esters, 224 acylsulfonamides, 225 and 
obviously amides. 226 However, these carbodiimides maintain the same drawbacks as 
their solution-phase equivalents, in particular in terms of racemisation in the absence 
of an additive. In addition the synthesis seems to be difficult to monitor and to lack 
reproducibility. Furthermore, one can wonder at the interest of PS-EDC in 
comparison to PS-DCC as EDC was originally designed and synthesised to be water 
soluble. Having the "extractable" moiety on a polystyrene support appears to' be 
pretty bizarre! In addition, the ionic part of EDC in solution-phase has proven to be 
counterproductive regarding the coupling reaction rate compared to DIC. 119 A 




2.7.2. Immobilised additives and reagents based on the HOBt ring 
Some coupling reagents in solution can in rare cases be extracted after reaction in 
relative simple ways (e.g. EDC). However, the use of an additive is often required to 
limit racemisation, and this additive has also to be separated from the reaction 
mixture. Therefore polymer-supported HOBt has been reported many times in 
different guises.228' 229  PS-HOBt has also been used as a core for synthesising 
supported reagents for the preparation of N-hydroxysuccinimide active esters. 230 
The idea of using PS-HOBt to form an immobilised HOBt-based coupling reagent 
was first exploited by Chinchilla, who synthesised a polymer-supported TBTU. 231 
The idea was also applied by Filip for the synthesis of polymer-supported 130P. 232 
These reagents present however the same drawbacks as TBTU and BOP in solution, 
while the structure of the reagent means that part of it will end up in solution after the 
coupling, clearly an undesirable occurrence for a supported reagent. 
2.7.3. Other immobilised reagents 
Triazine-based coupling reagents have been widely used in solution-phase. In 1999, 
Taddei reported a polymer-supported chlorotriazine 2.146.233  Although amides were 
synthesised in moderate to good yield using this reagent, the 'H NMR of the crude 





Figure 2. 27: Structure of polymer-supported chiorotriazine 
Chinchilla et al. developed some reagents based on polymeric succinimides such as 
P-TSTU 2.147 and P-HSTU 2.148 ,234  and ammonium salts 2.149 (Figure 2. 28 and 
Figure 2. 29). 235  The results were good for classic aminoacids but the yields were 
moderate to low when coupling hindered aminoacids. Globally these reagents did not 
really add any benefit to the range of coupling reagents available, and, like PS-BOP 
and PS-TBTU, part of the reagent ended up in solution. 
More recently, Convers reported an immobilised Mukaiyama reagent 2.150 (Figure 
236 2. 30). However, Crosignani investigated this new reagent and reported that the 
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synthesis was poorly reproducible, and thus recently developed another route (Figure 
2. 3 1).237  This reagent 2.151 appeared to work very efficiently for the synthesis of 
esters and amides including hindered substrates, secondary amines and anilines. 237, 
238 Finally, another type of supported-coupling reagent has been reported recently in 
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Figure 2. 30: Structure of immobilised 
	
Figure 2. 31: Structure of immobilised 
Mukaiyama reagent by Convers. modified Mukaiyama reagent by Crosignani 
2.7.4. Conclusion on available coupling reagents 
Li has produced a wide range of new reagents. However, most of these reagents are 
probably too reactive (the base needs to be added slowly at low temperature) and the 
use of antimonate salts is problematic in terms of toxicity. Some reagents, such as 
PyNOP or PyFOP, have solubility issues. Many of the coupling reagents reported 
have not been compared to others, making the judgement about their efficiency 
tricky. As many groups have reported "new" reagents as being wonderful and better 
than others, the organic chemist looking at the field of coupling reagent can be 
completely lost and this fact is illustrated by the title of a recent poster presented at 
an ACS national meeting: "Peptide coupling experiments: Understanding the role of 
coupling reagents and amino acid sequence" . 240  Unless new reagents are 




HATU, and traditional methods, it is likely that most new coupling reagents will 
have an application limited to the original publication by their authors. 
2.8. "In-house" comparison of some common coupling reagents 
2.8.1. The quest for a universal coupling reagent 
The huge choice of coupling reagents available provides the chemist with a lot of 
possibilities for general and more challenging amide bond formation. However, 
many of the coupling reagents reported have drawbacks or are not efficient. In 
addition, many of those reagents are targeted for peptide synthesis, which involves 
primary amines. In the area of synthesising potential drugs, the medicinal chemist 
faces the challenges of finding a method to couple efficiently, anilines, secondary 
amines and bulky substrates. However, none of the reagents reported to date can 
achieve this with good conversions. 
Overall, most of coupling reagents have the following drawbacks: 
• The structure of the reagent means that side-reactions will occur in the 
presence of nucleophiles. This is particularly the case with uronium-type 
reagents which can yield guanidinum species in the presence of amines. 
• A pre-activation step is necessary: the carboxylic acid has to be added in 
the presence of the coupling reagent before addition of the amine. This has 
particularly an impact particularly in parallel synthesis. 
• Many reagents require the use of a base in order to deprotonate first the 
carboxylic acid. However many reagents are poorly stable in the presence 
of a base. For example, only 36% of HATU remains in a solution of DMIF 
after 1 h in the presence of 1 equiv. of DIPEA. 122 
For all these reasons, the ideal coupling reagent should have the following 
characteristics: 
• no pre-activation step needed 
• all the reactants should be added at the same time 
• no particular specificity to amino-acids, the reagent should be used for 
general amide bond formation 
• no other additive, base etc. should be needed to get an efficient coupling 
• no racemisation when coupling aminoacids 
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2.8.2. Comparison of IIDQ and EEDQ 
EEDQ is an interesting, under-used coupling reagent which presents the advantage of 
being inert towards amines (no-preactivation needed) and also contains a base, which 
makes the use of a base redundant. The remaining desirable characteristic that EEDQ 
should have in order to be an "ideal" coupling reagent would be the capability to 
perform well in general amide-bond formation. A study and comparison to other 
couplings reagents was therefore targeted. Anderson demonstrated that isobutyl 
chioroformate was superior to any other chloroformate, when using this strategy of 
amide bond formation, 214,215  therefore, due to the analogy between the chloroformate 
method and the EEDQ method, this could potentially mean that IIDQ could be more 
efficient than EEDQ. As a consequence, a comparison between ITDQ and EEDQ was 
also performed. The reactivity of EEDQ and IIDQ was compared by testing them on 
three amines including an aniline (tert-butylaniline) and a secondary amine 
(morpholine) and two carboxylic acids (benzoic acid and phenylacetic acid). The 
results are presented in Table 2. 1. Yields were good including when coupling 
anilines, but conversion was only moderate when using morpholine. Those results 
proved that IIDQ was only slightly more efficient than EEDQ, and IIDQ was 
retained for a test against other common coupling reagents. 
Entry Amide Amine Acid 
IIDQ EEDQ 
Yield' 	Purity" Yield' 	Purity" 
1 2.152 tert-Bu-aniline Phenylacetic acid 96 	100 94 	100 
2 2.153 benzylamine Phenylacetic acid 91 	100 87 	100 
3 2.154 morpholine Phenylacetic acid 38 	100 32 	93 
4 	2.155 	ten-Bu-aniline Benzoic acid 88 100 85 100 
5 	2.156 	benzylamine Benzoic acid 85 100 66 100 
6 	2.157 	morpholine Benzoic acid 50 99 41 95 
Average 76 100 67 98 
'isolated yield; bpurity  determined by ELSD 
Table 2. 1: Comparison of the efficiency of EEDQ and IIDQ in terms of yield and purity over 6 
reactions 
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2.8.3. Comparison of IIDQ with HATU, PyAOP and BOP-Ci 
In order to compare the efficiency of JIDQ with three other coupling reagents during 
amide bond formation without pre-activation, four amines and three carboxylic acids 
were tested. The synthesis was carried out in CH 3CN with 1 equiv. of each 
reactant/reagent. CH 3CN was chosen as the reaction solvent because of its good 
solubility ability of carboxylic acids and its ease of evaporation in parallel synthesis. 
DMF or NMP, two of the usual solvents for amide-bond formation were not selected, 
as the evaporation of the solvent after reaction is not ideal in parallel synthesis. 
Importantly, all the reactants were added at the same time. After reaction, the 
reaction mixtures were filtrated through a SPE cartridge containing a mixed bed of 
sulfonic acid / quaternary ammonium hydroxide ion-exchange resins, in order to 
scavenge any unreacted materials. The results are reported in Table 2. 2. 
Entry Amide 	Amine 	 Acid 	
Purity' 
IIDQ PyAOP BOP-Ci HATU 
1 2.158 tert-Butyl-aniline Z-Ala-OH 100 85 3 100 
2 2.159 benzylamine Z-Ala-OH 100 97 89 100 
3 2.160 
1,2,3,4-Tetrahydro- 
Z-Ala-OH 100 99 94 100 naphthalen- 1 -ylamine 
4 2.161 morpholine Z-Ala-OH 100 95 92 100 
5 2.152 tert-Butyl-aniline 
Phenylacetic 
100 84 0 100 acid 
6 2.153 benzylamine 
Phenylacetic 
100 95 12 100 acid 
7 2.162 1 ,2,3,4-Tetrahydro- Phenylacetic 100 96 80 100 naphthalen- 1 -ylamine acid 
8 2.154 morpholine 
Phenylacetic 
87 8 2 100 acid 
9 2.155 tert-B utyl-ani line Benzoic acid 100 84 0 100 
10 2.156 benzylamine Benzoic acid 100 90 27 100 
11 2.163 
1,2,3,4-Tetrahydro- 
Benzoic acid 100 91 83 100 naphthalen- 1 -ylamine 
12 2.157 morpholine Benzoic acid 39 7 0 42 
Purity average 94 78 53 95 
a purity determined by ELSD 
Table 2. 2: comparison of IIDQ with three other coupling reagents 
The average purities clearly showed that IIDQ yielded generally highly pure 
products. It was interesting to note that quinoline was surprisingly removed after 
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filtration through the SPE. For the other coupling reagents, their products of 
decomposition remained in the reaction mixture yielding less pure products. 
However, HATU performed surprisingly well considering its usual poor stability, but 
this could be explained by the absence of tertiary base during coupling. In fact, in 
terms of purities HATU performed as well as IIDQ. 
Due to the high purities obtained when using IIDQ or HATU, the yields obtained 
when using these coupling reagents were compared (Table 2. 3). The poor purities 
obtained when using PyAOP or BOP-C1 made the investigation of the yields with 
these coupling reagents meaningless. 
Yield' 
Entry Amide Amine Acid 
IIDQ HATU 
1 2.158 tert-Butyl-aniline Z-Ala-OH 93 38 
2 2.159 benzylamine Z-Ala-OH 86 53 
3 2.160 1,2,3,4-Tetrahydro-naphthalen- 1 -ylamine Z-Ala-OH 71 37 
4 2.161 morpholine Z-Ala-OH 69 54 
5 2.152 tert-Butyl-aniline Phenylacetic acid 80 31 
6 2.153 benzylamine Phenylacetic acid 58 55 
7 2.162 1,2,3,4-Tetrahydro-naphthalen-1-ylamine Phenylacetic acid 59 37 
8 2.154 morpholine Phenylacetic acid 33 53 
9 2.155 tert-Butyl-aniline Benzoic acid 89 33 
10 2.156 benzylamine Benzoic acid 88 52 
11 2.163 1,2,3,4-Tetrahydro-naphthalen-1-ylamine Benzoic acid 67 37 
12 2.157 morpholine Benzoic acid 48 50 
Yield average 70 44 
a isolated yield 
Table 2. 3: Comparison of the yields obtained when using IIDQ and HATU 
Overall, IIDQ performed better that HATU in terms of yield. The moderate yields 
obtained with HATU could be explained by the absence of tertiary base which makes 
the activation process more difficult as the carboxylic acid does not get deprotonated. 
Most of the substrates chosen were coupled in good yield but morpholine proved to 
give lower conversion, emphasising the usual difficulty of coupling with secondary 
amines. This study showed that IDDQ could potentially be used as a coupling 
reagent for efficient, general amide-bond formation. 
Chapter III 
Preparation and evaluation of PS-IIDQ 
as a novel polymer-supported coupling reagent 
3.1. IIDQ as coupling reagent 
3.1.1. Advantages of IIDQ 
The study of coupling reagents in Chapter II showed the lack of a universal coupling 
reagent, suitable for hindered or unhindered substrates. Amongst the existing 
coupling reagents, IIDQ has been proven to be of great interest (Chapter II). IIDQ 
offers several advantages over most coupling reagents: for example, reaction with an 
amine cannot yield a guanidinium salt, a typical side reaction observed with uronium 
type coupling reagents. Another advantage of IIDQ is that there is no need to have an 
activation step: the acid, the amine, and the reagent can be introduced at the same 
time. This is different to most coupling reagent that require a pre-activation time with 
the coupling reagent and the carboxylic acid added before the introduction of the 
amine. 
3.1.2. Activation process using IIDQ and related issue 
The mechanism of activation using IIDQ is given in Scheme 3. 1.241  The reaction 
between IIDQ 3.1 and the carboxylic acid yields a carbonic anhydride 3.2 that is very 
reactive to amines. The activation process also shows that unlike many coupling 
reagents, JIDQ does not require the use of a base. 
Although IIDQ offers many advantages, it has not been widely used in amide bond 
formation. This can be easily explained by the fact that the by-product of the 
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Scheme 3. 1 Activation process using IIDQ as coupling reagent 
3.1.3. Interest of a polymer-supported IIDQ and choice of synthesis 
Immobilising IIDQ on a resin would immobilise the by-product obtained during the 
activation process, quinoline. A simple filtration would therefore yield the pure 
product and isobutanol (boiling point: 108°C) that can be removed in vacuo. 
3.2. Synthesis of the solution-phase equivalent of PS-IIDQ 
3.2.1. Synthesis of the intermediate 
The aim of synthesising the solution-phase equivalent of supported IIDQ, 6-
benzyloxy-2-isobutoxy- 1 -(isobutoxycarbonyl)- 1 ,2)-dihydroquinoline, was to 
determine the best conditions for the solid-phase synthesis of PS-IIDQ, and to ensure 




DMF, 60° C, 24h 	 I::riiIII::c'j 
47% 
3.4 	 3.5 	 3.6 
Scheme 3. 2: synthesis of 6-benzyloxyquinoline 
The first step of the synthesis consisted of coupling 6-hydroxyquinoline 3.4 with 
benzyl chloride 3.5 (Scheme 3. 2). The nitrogen atom of quinoline did not need to be 
Chapter III 	 58 
protected as Moody had reported the coupling of 6-hydroxyquinoline to 4-
nitrobenzylbromide in 77% yield, 242  while Perranti reported the synthesis of 6- 
benzyloxyquinoline in 78% yield. 243 However these conditions were not 
reproducible, and other conditions were examined (Table 3. 1). 
Entry Solvent Base (equiv.) Other conditions 	Conversion  
1 MeOH KOH (1.1) - 	 total b 
2 BuOH KOH (1.1) - 	 incomplete 
3 DMF KOH(1.1) - 	 tota l  
4 DMSO KOH (1.1) - 	 incomplete 
5 CH3CN K2CO3 (1.1) - 	 incomplete 
6 DMF K2CO3 (1.1) - 	 incomplete 
7 CH3CN K2CO3 (1.1) 1.1 equiv. KI 	incomplete 
8 DMF K2CO3 (1.1) 1.1 equiv. KI 	incomplete 
9 DMF K2CO3 (5) - 	 total b 
a determined by TLC analysis, eluant Et20IP.E. 8/2, after 24 hours; 
b 
all starting material had been consumed, but insoluble 
impurities were present 
Table 3. 1: comparison of the reaction conditions for the synthesis of 6-benzyloxyquinoline 
Conversion proved to be complete with potassium hydroxide in MeOH or in DMF 
(entries 1 and 3). As MeOH does not swell polystyrene resin, DMIF was more 
suitable. The choice of KOH for solid-phase synthesis was not ideal but potassium 
carbonate (1.1 equiv.) in DMF gave incomplete reaction (entry 6). When potassium 
carbonate was used in large excess (5 equiv., entry 9), conversion was complete. 
Therefore potassium carbonate in DMF was chosen for the attachment of 6-




3.2.2. Synthesis of 6-benzyloxy-IIDQ 
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Scheme 3. 3: Synthesis of 6-benzyloxy-IIIDQ from 6-benzyloxyquinoline 
After purification, 6-benzyloxyquinoline 3.6 was transformed into 6-benzyloxy-IIDQ 
3.7 (Scheme 3. 3). Although the synthesis of IIDQ had been reported, 2' the 
adaptation of the reaction conditions to the synthesis of 6-benzyloxy-IIDQ did not go 
to completion. According to 'H NMR data, 6-benzyloxy-IIDQ 3.7 was successfully 
synthesised using the conditions indicated in Scheme 3. 3. However it was not 
possible to isolate the product because of its apparent sensitivity which resulted in its 
conversion back to 6-benzyloxyquinoline. 
3.3. Optimisation and characterisation in solid-phase 
3.3.1. Coupling onto Merrifield resin 
Coupling of 6-hydroxyquinoline 3.4 onto Merrifield resin 3.7 succeeded using the 
same conditions as in solution as indicated on Scheme 3. 4 with 96% conversion 
according to nitrogen elemental analysis. 
HO- 	 K2CO3, KI 
CI 	 + 	






1.3 mmol/g 	 1.06-1.10 mmovg 
Scheme 3. 4: First synthesis of polymer-supported quinoline with Novabiochem Merrifield resin 
The kinetics of formation of PS-quinoline 3.8 were evaluated using nitrogen 
elemental analysis (Table 3. 2). High conversion was obtained after six hours. 
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Entry Time (h) Conversion ' (%) Loading (mmol/g) 
1 2 94 1.07 
2 4 98 1.12 
3 6 98 1.12 
4 8 96 1.09 
5 24 97 1.11 
6 48 100 1.16 
a 
determined by nitrogen elemental analysis 
Table 3. 2: kinetics of formation of PS-quinoline 
However, when using a high loading resin (Polymer Labs, 3.99 mmollg), the 
conversion using identical conditions proved to be only 66% according to nitrogen 
elemental analysis. As the percentage of the remaining chlorine was low (0.15 
mmol/g), the reduced conversion could be explained by cross-linking via the 
nitrogen of the quinoline ring, or by hydrolysis. Another explanation would be that 
Merrifield resin reacts with the decomposition products of DMF, as reported by 
Alexandratos ,245  capping some of the chlorine reactive sites. In order to solve this 
potential issue, dimethylacetamide (DMA) was used as a replacement of DMF. 
However, although this change of solvent permitted a complete conversion of 
Merrifield resin into PS-quinoline, it was necessary to carry out the reaction for 5 
days at 65°C in order to observe complete disappearance of the chlorine band seen 
via JR. 
In order to reduce the reaction time, the possibility of carrying out the reaction at 
reflux was investigated (Scheme 3. 5). After 6h, the JR spectra revealed almost 
completed conversion, while leaving the reaction mixture for a longer reaction time 
was not advantageous as insoluble compounds, which could not be identified, started 
to be formed. Nitrogen and chlorine elemental analysis of the resin after 6h revealed 
a 98% conversion with a loading of 2.74 mmollg (starting from 3.99 mmollg). 
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Scheme 3. 5: Optimised synthesis of polymer-supported quinoline 
The structure of PS-quinoline 3.8 was confirmed by Magic-Angle Spinning NMR 
and the spectrum obtained was compared to the 'H NMR spectra of 6-benzyloxy-
quinoline 3.6 (Figure 3. 1). 
-h 
±11 
PS-Qu fl 01 n e 
- __} '----.----------------.---- 
Figure 3. 1: MAS-NMR of PS-Quinoline and 'H NIMIR of 6-Benzyloxyquinoline 
3.3.2. Conversion into supported IIDQ 
The reaction of isobutyl chioroformate with the supported quinoline 3.8 in the 
presence of Hunig's base yields a highly reactive intermediate 3.9 which can be 
quenched with isobutanol to form polymer-supported IIDQ 3.10 (Scheme 3. 6). The 
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Scheme 3. 6: Synthesis of polymer-supported IIDQ 
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Figure 3. 2: JR spectra of PS-IIDQ 
Figure 3. 3 shows the 'H NMR spectra of IIDQ 3.1 in solution and the MAS-NMR 




polymer-supported IIDQ 3.10 was successfully synthesised. 1 H- 1 H COSY spectra 
confirmed the correlation between the protons H-12 (and H-16) and the proton H-13 
(and H-17 respectively). 
I 	 LcI' 
$,--I i 	ik .kJ 
3- flO 	 16 
OAO3  
Figure 3. 3: NMR spectra showing evidence of the synthesis of PS-IIDQ 
3.3.3. Optimisation of the reaction conditions 
The transformation of PS-quinoline 3.8 into PS-[IDQ 3.10 was carried out with and 
without DIPEA in DCM. In the absence of DIPEA (entry 1, Table 3. 3) the reaction 
failed proving that the presence of a base was necessary. Several other bases were 
tested, using 3 equiv. of base and 3 equiv. of isobutyichioroformate in DCM (Table 
3. 3). Conversion was evaluated by IR, via integration of the carbamate band and 
taking the integration of one of the resin backbone band at 1490 cm' as reference. 
100% was assigned to the base giving the highest integration ratio. DIPEA (entry 2) 
gave the best conversion while all the other bases performed quite poorly. 
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Entry 	 Base 	 Conversion 
1 none 0 
2 DIPEA 100 
3 TEA 10 
4 NMM 0 
5 Pyridine 0 
6 2,6-lutidine 0 
7 N-methylpiperidine 0 
8 2,6-di-Bu-4-methyl-pyridine 0 
9 DMAP 0 
10 MTBD 44 
11 2213u- 1,1 ,3,3-tetramethylguanidine 0 
Table 3. 3: Optimisation of the base for the synthesis of PS-IIDQ 
Several solvents were evaluated (Table 3. 4), but little difference was observed in the 
JR spectra in terms of conversion. Dioxane gave the best result (entry 3) but DCM 
also gave good conversion (entry 1), especially considering the error margin due to 
the determination of conversion by integration of bands in the IR spectra. Therefore 
DCM was chosen because of its good swelling properties for the resin compared to 
dioxane. 
Entry 	 Solvent 	 Base 	 Conversion 
1 DCM DIPEA 89 
2 THF DIPEA 94 
3 Dioxane DIPEA 100 
4 CH3CN DIPEA 93 
5 DMSO DJPEA 0 
6 DIPEA a DIPEA 0 
7 TEA  TEA 0 
8 DMF DIPEA 81 
a the base was used as the reaction solvent 




3.3.4. Determination of the loading 
As only carbon, hydrogen and oxygen atoms were added during the conversion of 
quinoline into ITDQ, C, H, N elemental analysis was not a suitable method for 
determination of the final loading. Therefore, the coupling between phenylacetic acid 
and benzylamine was chosen for loading determination using 1 g of resin. The 
product formed was isolated and the yield of the reaction was related to the loading. 
Using this method, a loading of 1.68 mmollg was found for the batch of PS-IIDQ 
synthesised, corresponding to a conversion of >90 % for the supported quinoline into 
the supported 1IDQ. 
3.3.5. Optimisation of the coupling conditions 
The coupling between benzylamine and phenylacetic acid was optimised with 
different solvents. DCM was the first solvent tested and this proved to work 
efficiently as shown in Table 3. 5 (entry 1). However the choice of DCM was not 
optimal, because many carboxylic acids are insoluble in it, while it is too volatile for 
parallel synthesis use. 
Entry 	 Solvent 	 Yield  
1 	 DCM 98 
2 	 DMF 32 
3 	 DMA 37 
4 	 CH3CN 91 
5 	 THF 64 
6 	 Dioxane 87 
7 	 DCE 	 94 
a isolated yield 
Table 3. 5: Optimisation of the solvent for the coupling reaction via the coupling of benzylamine 
(lequiv.) and phenylacetic acid (1 equiv.) in the presence of PS-IIDQ (3 equiv.) for 24h. 
In order to solve these problems, DMF, DMA, CH3CN, THF, dioxane and DCE were 
also evaluated, and the results presented in Table 3. 5 showed that DMF (entry 2) or 
DMA (entry 3) gave clearly worse yields/purities than DCM (entry 1). DCE (entry 7) 
gave similar results to DCM, but its choice was again not optimal in terms of 
solubility. THF (entry 5) was not efficient enough, while dioxane (entry 6) also gave 




comparable conversion to DCM but with better solubility and less volatility. 
Therefore acetonitrile was chosen as the coupling solvent, although it is known 
generally as having poor swelling properties for polystyrene supports. 246 
The quantity of coupling reagent required for an efficient coupling was also 
investigated. 1.5 equiv. of PS-IIDQ only gave 67% yield, while 2, 2.5 or 3 equiv. 
gave 80-85%. 
3.4. Comparison of PS-IIDQ with IIDQ in solution 
PS-IIDQ was tested on 3 amines and 3 carboxylic acids (Table 3. 6) in CH 3CN for 
24h at room temperature, and the yields and purities were compared to IIDQ in 
solution. Synthesis comparing PS-IIDQ and IIDQ was carried out using the 
optimised conditions and, after reaction, a quick aqueous work-up was carried out in 
order to remove any unreacted amine and carboxylic acid. 
PS-IIDQ 	 IIDQ 
Entry Amide 	Amine 	 Acid 	
Yield (%)a  Purity( %)b  Yield (%)a  Purity (%)b 
1 3.13 4-tBu-aniline Boc-Aib-OH 69 100 81 91 
2 3.14 Benzylamine Boc-Aib-OH 66 100 92 98 
3 3.15 H-PhG-OMe Boc-Aib-OH 64 100 89 98 
4 3.16 4-tBu-aniline Phenylacetic acid 60 100 83 98 
5 3.11 Benzylamine Phenylacetic acid 80 100 74 96 
6 3.17 H-PhG-OMe Phenylacetic acid 61 99 84 96 
7 3.18 4-tBu-aniline Benzoic acid 89 100 78 93 
8 3.19 Benzylamine Benzoic acid 85 100 85 96 
9 3.20 H-PhG-OMe Benzoic acid 75 99 81 94 
a Isolated yield, Purity determined by ELSD. 
Table 3. 6: Coupling using PS-IIDQ or IIDQ 
The different amides were in most cases obtained in acceptable yield and very high 
purity. The coupling with the sterically hindered building block L-PhG-OMe (entries 
3, 6 and 9) was successful even when coupling to hindered carboxylic acids such as 
Boc-Aib-OH acid. Interestingly, the coupling using an aniline succeeded in good 
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yield (entries 1, 4 and 7). Generally the results were slightly improved in terms of 
purity when using PS-HDQ. This illustrates the advantage of PS-IIDQ over the 
classic solution-phase reagent U1DQ, where an intensive work up is necessary to 
remove all the quinoline generated during coupling. 
3.5. Comparison of PS-IIDQ with commercial coupling reagents 
PS-IIDQ was compared to some commercially available coupling reagents: HATU 
and two polymer-supported carbodiimides PS-EDC and PS-DCC (Table 3. 7). The 
coupling was realised using optimised conditions and an excessive coupling time of 
24h was used in order to enable difficult substrates to react. This contrasts with many 
coupling reagents, which usually have very high reactivity but are unstable in 
solution with most of the reagent (or active HOBt ester) being degraded after an 
hour, a characteristic which is unsuitable for hindered substrates or if the coupling is 
slow. Considering this problem, PS-IIDQ offers a good balance between reactivity 
and stability. 
HATU (5 mm. pre-activation) gave lower yields than PS-IIDQ. In particular 
coupling with HATU using aminoisobutyric acid (entries 1, 2, 3) and/or anilines 
(entries 1, 4, 7) were significantly lower. This result is not surprising as HATU 
decomposes rapidly in solution. Thus, hindered substrates can couple poorly, as they 
need a longer activation time. 
Results were quite poor for the supported carbodiimides. PS-EDC gave an average 
yield of 41% while PS-DCC gave only 26%, in comparison to the average 71% yield 
obtained with PS-IIDQ. This can be explained by the usually poor quality of 
commercial supported-carbodiimides, and in-house synthesis of these supported 
reagent is usually necessary to achieve good conversions. 247  Both supported-
carbodiimides were less efficient than PS-IIDQ, making PS-IIDQ a reagent of choice 




PS.HDQ 	HATUC 	PS-EDC 	PS-DCC 
Yield' Purityb  Yield' Purityb  Yield' Purityb Yields Purityb 
o 





2 	Boc' 66 	100 	45 	93 	39 	87 	17 	94 
3.14 
64 	100 	48 	100 	24 	95 	24 	86 
3.15 
4 	 60 	100 	43 	100 	68 	100 	41 	100 
3.16 
80 	100 	69 	100 	48 	100 	25 	100 
3.11 
6 	 61 	100 	77 	92 	49 	100 	35 	100 
3.17 
o 
7 	 89 	100 	45 	100 	44 	100 	28 	100 
3.18 
8 	 85 	100 	68 	100 	48 	81 	24 	95 
3.19 
o 
N 9 	 75 	100 	54 	100 	33 	100 	24 	100 
3.20 
Average 	 72 	100 	55 	98 	41 	96 	26 	97 
'Isolated 	Purity determined h ELSE). a 5 mm. actiation time wa allowed for this eouplin reagent 
Table 3. 7: Comparison of PS-IIDQ with some commercial coupling reagents 
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3.6. Scope and limitation of PS-IIDQ 
The library reported in table 3.7 proved that Polymer-Supported IIDQ was efficient 
even when using hindered substrates. A more comprehensive study of the scope and 
limitations was carried out, by testing the same carboxylic acids used above on six 
different amines, and another two carboxylic acids on the same selection of 8 amines 
(Table 3. 9). All building blocks were commercially available, except H-Aib-OMe 
3.21, which was prepared according to the literature. 248  Coupling was realised using 
the optimised conditions and the unreacted amine and carboxylic acid were removed 
either by ion-exchange resins (Amberlyst 15 and 26) or by a quick aqueous workup 
(entries 3, 9, 15, 21, 26, 29, 34), depending on the presence of acid/basic labile 
protecting groups on the amine and/or carboxylic acid. PS-IIDQ succeeded, in almost 
all cases, to couple the amine to the acid in excellent purities. Yields were good even 
when coupling hindered substrates such as aminoisobutyric acid, to any of the 
different acids (entries 3, 9, 15, 21, 29). Similarly, H-PhG-OMe was coupled to Z-
Ala-OH and phenoxyacetic acid in high yield (entries 26 and 34). In addition 
secondary amines were successfully coupled including morpholine (entries 1, 7, 13, 
19 and 27) and Proline (entries 6, 12 and 18). However, PS-IIDQ failed to couple 4-
nitroaniline to any of the acids, which is not surprising as nitroanilines are some of 
the hardest amines to couple in view of the electron withdrawing nitro group. 
The yield was very low when coupling aminoisobutyric acid to Proline (entry 6). 
Only 3% of the expected amide product was isolated after column chromatography, 
which was needed to isolate the amide. Similarly, the amide obtained by coupling 
Proline to phenylacetic acid and benzoic acid needed purification. However the 
global library was successful as two thirds of the substrates gave the expected amides 
in yields over 67%, with a general average yield of 73% for the reactions yielding the 
expected amides. 
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Entry 	Amide 	 Amine 	 Carboxylic acid 	 Yield 
0 
H 
1 	3.22 	 0NH 	 N 	 44 
' I z 2LOH 
2 	3.23 	 Q_NH2 	 61 
0 
3 	3.24 	 O).XNH2 	 67 
4 	3.25 	 02N—Q—NH2 	 0 
5 	3.26 	 '0NH2 	 74 
0 
6 	3.27 	 Bn o ) 	 3 
HN 
OH 
7 	3.12 	 0 NH 77 
8 	3.28 	 K — NH2 	 44 
0 




11 	3.31 	 (51 NH2 	 74 
0 
12 	3.32 	 60 
HN 
13 	3.33 	 0\_2H 
°0H 	
77 
14 	3.34 	 Q_NH2 	 84 
0 
15 	335 	 Q)NH2 	 91 
16 	3.36 	 02N_Q_NH2 	 0 
17 	3.37 	 0 NH2 	 83 
0 
18 	3.38 	 34 
HN 
Table 3.8. Part!: Scope & limitations of PS-IIDQ 
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Entry Amide Amine Carboxylic acid Yield 
19 3.39 Q"J, NH 79 
Z-NH 	OH 
20 3.40 Q_NH2 71 
21 3.41 0.1tNH2 82 








26 3.46 0NH2 83 
Ph 
27 3.47 O' NH 0O)..OH 80 
28 3.48 52 
29 3.49 ,NH2 70 
30 3.50 02N---NH2 0 
31 3.51 NH2 74 
32 3.52 t.Bu-(3__NH2 83 
33 3.53 2 82 
34 354 0)NH2 82 
Ph 
Table 3. 9. Part 2: Scope & limitations of PS-IIDQ 
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3.7. Side-reactions observed when coupling proline 
The formation of a carbamate by-product can occur during the coupling reaction 
once the carbonic anhydride has been generated. The amine can in fact react at two 
electrophilic centres, either on the carbon of the carbonic anhydride itself, yielding a 
carbamate specie 3.55, or on the carbon of the carboxylic acid, yielding the expected 
amide (Scheme 3. 7). Proline was coupled to 15 carboxylic acids with various groups 
in the a and P positions (Table 3. 9). The expected amide and the carbamate by-
product 3.55 were separated by column chromatography after acidic/basic workup of 
the reaction mixtures. When the a -carbon of the acid was not sterically too hindered, 
that is to say, when it was linked to one bulky group and two hydrogen atoms, the 
major product obtained was the expected amide (entry 14). On the other hand when 
the a -carbon was much more hindered (such as two methyl groups) the carbamate 
3.55 was almost the exclusive product (entry 13) because the approach of the Proline 
to the electrophilic carbon was disfavoured. Benzoic acid since it was not so 
hindered gave intermediate results as the steric hindrance of the a -carbon does not 
disfavour the formation of the amide as much as the aminoisobutyric acid (entry 15). 
The presence of bulky groups in the a position clearly increased the quantity of by-
product (entry 5) compared to phenylacetic acid (entry 14). One of the predominant 
effects seemed to be the presence of a methyl group in the a position, which 
increased dramatically the by-product generation (entries 9 and 13), although two 




Bn 	 Bn 
3.55 
Scheme 3. 7: Side reaction observed when coupling proline using PS-IIDQ. 
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Entry Amide Carboxylic Acid 
Carbamate Amide Relative  
Yield Yield percentage 
1 3.56 
0 43 24 64/36 
0 
2 3.57 76 13 85/ 15 
3 3.58 18 74 20/80 
4 3.59 50 20 71/29 
0 
5 3.60 LJILQ 35 51 41/59 
6 3.61 CLA OH 66 22 75/25 
7 3.62 
rH 
48 37 56/44 
0 
8 3.63 57 17 77/23 
59/41 9 3.64 35 24 
0 
10 3.65 EJ)L0H 30 55 35/65 
0 




49 47 51/49 
0 
H 








34 53 39/61 
Table 3. 9: Test of acids for the side-reaction observed with H-Pro-OBn 
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However some results were quite surprising. Indeed, when removing a phenyl group 
in the 3 position (entries 1 and 2), the percentage of the carbamate increased. When 
passing from a cyclohexyl- to a cyclopentyl- the percentage changed significantly 
(entries 10 and 11). This study showed a limitation of PS-IIDQ but no real rule could 
be established for the influence of groups on the carboxylic acid. The formation of 
carbamate could presumably be reduced by using another alcohol (e.g. 2-hydroxy-3-
methyl-butane) in order to increase the steric hindrance at the carbonate position. 
3.8. Racemisation studies: Anteuni's test 
The above examples proved that PS-IIDQ worked efficiently for general amide bond 
formation. In order to apply PS-IIDQ for coupling amino-acids, the racemisation by 
epimerisation during segment coupling had to be evaluated. The classic method to 
achieve this is to carry out Anteuni's test (Scheme 3.8).' This test is particularly 
important as amide cyclisation to give the oxazolone is a real issue for dipeptides. 
Coupling between Z-Gly-L-Phe-OH 3.68 and H-L-Val-OMe 3.69 gave the expected 
tripeptide 3.70 in 65% yield without any D/L diastereoisomer detected by 1 11 NMR 
(400 MIHz). In order to make sure that the signal of the [IL and D/L isomers in the 
NMR spectra did not overlap, the D/L isomer was synthesised separately and the 
NMR spectra was compared to the [IL isomer obtained with PS-IIDQ. 
Unambiguously it confirmed the absence of epimerisation (Figure 3. 4). 
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Figure 3. 4: Evidence of the absence of epimerisation by NMR at 400 MHz. 
The signal shown corresponds to the CH group of the Phenylalanine. 
3.9. Recycling of PS-IIDQ 
The possibility of recycling/regenerating PS-IIDQ was investigated. Thus the resin 
used was washed extensively with various solvents (THF/H20 1:1, MeOH, DCM, 
Et20). Then the procedure used previously to transform PS-quinoline into PS-IIDQ 
was applied, and the loading evaluated by coupling phenylacetic acid to 
benzylamine. The same regeneration process was carried out three times with little 
variation in loading levels (Table 3. 10). 
Cycle 	Loading (mmol/g) 
1 	 ? 1.68 mmollg 
2 	 >1.7lmmoI/g 
3 	 ? 1.65 mmollg 
4 	 ? 1.64 mmollg 
Table 3. 10: Recycling of PS-IIDQ 
Interestingly, no loss of activity was observed after recycling, every evaluation of the 
loading giving results within the same range with a margin error of ± 0.1 mmol/g. 
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3.10. Conclusion 
PS-IIDQ is a high loading, efficient polymer-supported coupling reagent for general 
amide bond formation, including hindered substrates and anilines. Its use can also be 
suitable for amino-acids coupling as the epimerisation level was low. PS-IIDQ 
proved to be more efficient than other commercially available polymer-supported 
coupling reagents (PS-EDC, PS-DCC) and also better than the powerful and widely 
used HATU. Only one limitation of this new reagent was observed, but this was 
noticed only with proline. Stability, ease of recycling, convenient procedures for 
parallel amide bond formation, good yields and high purities make PS-IIDQ a 
reagent of choice for N-acylation in organic chemistry.* 
PS-IIDQ is now commercially available from Novabiochem (01-64-0469) and Polymer Laboratories 
Chapter IV 
A new approach to the screening 
of small-molecules on microarrays 
4.1. Fragment-based drug discovery 
4.1.1. Introduction 
The time usually spent in the pharmaceutical industry between the identification of 
an active compound in HTS and lead/hit optimisation represents, still, a significant 
part of the drug discovery process. 249  Attempts to reduce this time have therefore 
been investigated thoroughly. Jencks first developed the idea of fragment-based drug 
discovery by showing that drug-like molecules can be regarded as the combination of 
two or more individual binding residues. 250  Leads are usually derived from hits 
obtained via screening of large collections of compounds and the usual optimisation 
carried out allows the activity to be typically increased from the micromolar to the 
nanomolar range . 249 Big pharmaceutical companies tend to screen large libraries of 
highly functionalised compounds in order to identify a significant number of hits. 
However, although high-throughput-chemistry has provided industry with powerful 
tools to synthesise millions of compounds, no collection of compounds comes 
anywhere near the complete exploration of chemical space. As the number of 
possible drug-like molecules decreases exponentially with their size, it is more 
efficient to screen smaller molecules, i.e. fragments, with fragments being defined as 
"small, relatively simple molecules that have the ability to bind to a target and serve 
as substrates for further medicinal chemistry". 25 ' Screened fragments are small 
(typically MW 120-250), have less functionality and also weaker affinity than most 
usual HTS hits, with typical binding affinities in the millimolar to 10 micromolar 
range. 252 
In principle, fragment-based strategies can sample a larger theoretical "diversity 
space" than is practical through standard screening methods. Globally the probability 
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of finding a good ligand-target match decays exponentially as the size of the ligand 
increases due to the fact that as the complexity of the ligand increase, there are far 
more chances to obtain a mismatch rather than a match . 249  All the advantages of 
fragments are illustrated by the development of companies such as Abbott (NMR), 
Astex (HT X-ray crystallography), Triad Therapeutics (NIM1R) and Graffinity 
(surface plasmon resonance). Despite the theoretical advantages, fragment-based 
drug discovery can however be difficult in practice. 253 
4.1.2. Techniques for finding fragments 
4.1.2.1. General considerations for fragment design 
Like traditional target-oriented drug discovery, the fragment-based approach requires 
first the design of libraries of compounds. Lipinski's rules of five are traditionally 
applied to the design of libraries ,254 and more recently a new rule was added, which 
limits to a maximum of seven the number of rotable bonds . 255  However all these 
considerations are not necessary the best ways to find a good lead compound. Indeed, 
leads usually have lower molecular weight, lower lipophilicity, fewer aromatic rings 
and fewer hydrogen-bond acceptors than their clinical candidates. 256 Similarly, 
libraries of compounds with molecular weight ranging from 100 to 350 and a clogP 
ranging from 1 to 3 are usually superior for finding leads. This is easily explained by 
the fact that the lead optimisation process typically increases the molecular weight by 
80 Da and the lipophilicity by 1 log unit. Therefore when a lead already contains 
good drug-like properties in terms of oral availability, the final clinical candidate 
typically presents poorer drug-like- properties because its properties are further away 
from Lipinski's rules of five. With all these issues in mind, Jhoti elaborated adapted 
rules for fragment libraries due to their smaller size and potential for optimisation. 257 
Compounds should have a molecular weight lower than 300 Da 
The lipophilicity cLogP should be lower than 3 
The number of hydrogen bond donors and acceptors should be lower than 3 
Analyses of drugs have led to the synthesis of privileged libraries of fragments 
containing scaffolds present in drugs, 258 and Fesik in particular synthesised 
fragments that bind to proteins frequently. 259 Once the design of fragments has been 
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achieved and the libraries synthesised, 260 several techniques have been elaborated in 
order to identify active fragments. 
4.1.2.2. Functional or direct binding assays at high concentrations 
Usually fragments have relatively low binding affinities and are therefore difficult to 
detect in HTS where low concentrations are used. In order to overcome these 
difficulties, Eliman used a strategy based instead on high concentrations for the 
identification of an inhibitor of the kinase c-Src with nanomolar activity. 261 
A similar approach was used at Graffinity using surface plasma resonance and 
fragments attached to microarrays. 262 In this method, fragments are synthesised on 
solid-phase and carry a common linker for immobilisation onto the array. The result 
of the printing is an array containing 10000 fragments displayed on top of a self 
assembled monolayer (SAM). A thin layer of gold provides support for SAM 
formation and surface plasmon resonance (SPR). The use of SAM offers the 
advantage of presenting an anchor point for immobilisation of the fragment. After 
incubation with a target protein, detection of fragment-protein interactions is carried 
out by SPR. 
Both approaches have the following advantages: 
• Fewer molecules have to be synthesised 
• The technique does not rely on the knowledge of the structure of the 
biological target, or established leads 
• Functional screening is potentially more likely to provide a functionally 
relevant inhibitor rather than a molecule that binds to but does not inhibit the 
target. 
However many drawbacks can be foreseen: 
• The technique requires that two fragments bind to adjacent but non-
overlapping sites 
• The optimisation of linking fragments in the absence of any structural 
knowledge can be difficult 
• Functional screening (especially at high concentrations) is subject to a 
number of pitfalls. 
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4.1.2.3. NMR-based screening 
The principle was first developed by Fesik and consists of screening a fragment 
library against a 15N-Iabelled biological target.  259  When compounds bind, the 
resulting changes in amide chemical shifts around the binding site are detected by 
Heteronuclear Single Quantum Correlation Spectra (HSQC). If the structure is 
known and the NMR fully assigned, this allows identification where in the protein a 
compound binds. Ligands that bind to adjacent sites on the protein are then selected 
and optimised. Finally the best ligands are linked together in order to identify a 
ligand with very high affinity (Figure 4. 1). 
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Figure 4. 1: Principle of the approach from Fesik 259 
	
9 	 . With this approach,  2
5 9 	identified aminophenols amides derivatives 4.1-4.7 
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(FKBP). Another ligand 4.8, based on pipecolinic acid, a moiety which was reported 
previously as having a micromolar affinity to FKBP, was also identified as binding 
to FKBP.263' 264  After analysing the position of the binding between FKBP and the 
different fragments, Fesik linked the best ligand of the series 4.7 (based on p-
aminophenol) to 4.8. To achieve the link between these two fragments, Fesik used 
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different chain length and an impressive affinity of 19 nM was found for the 
resulting best ligand 4.9 (Figure 4. 2). 
CN~~ 0 
4.9 n=3 Kd= 19 n 
4.10 n=4 Kd=32nM 
4.11 ri=5 Kd=49nM 
4.12 n=6 Kd=228nM 
Figure 4. 2: The discovery of a high affinity ligand by Fesik 
Although the initial assays by Fesik were successful,  259  the technique presents some 
drawbacks. In particular, it requires significant quantities of pure ' 5N-labelled protein 
(usually over 200 mg). In addition, ligands need to be soluble at high concentrations 
(> 0.2 mM) and in order to obtain maximum structural information, the protein 
backbone residues need to be assigned. However the sensitivity of the method has 
recently been improved in particular by ' 3C labelling amino acids residues and by 
instrumental improvements such as cryogenic NMR probes, 265  allowing the 




4.1.2.4. Mass Spectrometry-based methods 
The possibility of using MS for fragments screening was first explored by 
Swayze. 266-268  The principle consisted in tuning the ionisation and desolvation 
processes in order to detect the binding of noncovalent weak binding fragments by 
ESMS. After linkage between the best members of different series, the resulting 
compounds proved to be more potent but still quite poor (micromolar range) • 269, 270 
An approach developed by Erlanson, called tethering, 271, 272 was based on the site-
directed modification of the targeted protein close to the active site (mutagenesis) or 
more simply using a cysteine residue, if there were any close to the pocket. This 
creates an anchoring point for fragments that contain a thiol functionality, and the 
screening of a library of hundreds of thiol fragments allows the detection of the 
fragment forming a disulfide bond with the highest affinity for the protein (Figure 4. 
2). 
s1   
R 
7SH 
F]1T 	 Target 
Figure 4. 3: Principle of the Tethering method (adapted from: www.sunesis.com ) 
Although the tethering method gives some information on the binding mode, the 
amount of information obtained by MS is relatively limited, and crystallography is 
therefore used after MS-screening, in order to get wider information about the 
binding. All this makes the technique relatively tedious, as libraries need to be 
designed in a certain way in order to incorporate a thiol moiety and MS-screening 
needs ideally to be followed by crystallography, which results in relatively high 
quantity of protein being required (0.5 to 5mg). Finally, it requires precise 
knowledge of the biological target in order to assess the presence of the cysteine 




4.1.2.5. Crystallography-based techniques 
Another technique involves the use of crystallography to identify fragments. The 
concept is based on the analysis of the electron-density map of crystals. 273  The 
changes in density are correlated with binding to a specific part of the biological 
target and the method can be used with dynamic libraries. 274 This technique was 
illustrated by the discovery of nanomolar inhibitors of Src SH2, a domain of the Src 
protein involved in signal transduction. 275 ' 276 
Fragment-based lead discovery by X-ray crystallography has been developed by 
Astex Technology in the U.K. and many companies in the U.S.A. 277 The approach 
has been made possible with the help of robotics and automatic data processing 
software. The strategy involves soaking a cocktail of fragments into preformed 
crystals of the target protein. In particular, the technique was applied to the discovery 
of novel protein kinase inhibitors using the same technique. 278 
Although crystallography is the technique giving the most binding information, it 
requires precise knowledge of the protein structure. In addition, the technique is still 
relatively low-throughput, and weak binding ligands 4o not show electron density. 
4.1.2.6. Conclusion regarding the current methods 
Most of the techniques presented show the same drawbacks. They are usually very 
time-consuming. Often the techniques require relatively high quantities of protein. In 
that respect, the Graffinity method is particular interesting as it is using tiny amounts 
of protein because fragments are attached to microarrays. This also brings the 
advantage of being suitable for high-throughput compared to most other methods. 
However, fragments needs to be linked after screening, and the possibility to have 
many fragments binding in the same portion of the protein pocket is high resulting in 
a difficult hit optimisation process. 
4.2. Small molecules microarrays: principle and applications 
4.2.1. Introduction 
The microarray concept has raised much interest in the past decade, as it allows a 
multitude of high-throughput experiments. Technologies based on micro-arrays have 




include DNA, RNA and oligonucleotides, 280 proteins,28 ' membrane proteins, 282 
peptides ,283,284  carbohydrate and tissue, 285 live cells,286 and small molecules. 287 
Since small-molecules microarrays were introduced by Schreiber in 1999, the field 
has grown significantly, and has been reviewed. 28829° Biological evaluation of small 
molecules represent a major part of the drug discovery process making the 
application of a robust screening tool essential for the identification of possible drug 
candidates. Difficulties of signal detection due to non-specific protein-binding to the 
slide surface are however a common drawback. 
4.2.2. Immobilisation of small molecules on microarrays 
4.2.2.1. 	Covalent immobilisation 
Most of the reported examples of small-molecules microarrays involved prior 
synthesis on solid-phase resins before release and immobilisation on the array 
surface. Schreiber used this strategy for his pioneering work on small-molecules 
microarrays. 287 Three known ligands of biological targets were derivatised to carry a 
thiol group and were successfully immobilised onto a maleimide-derivatised glass 
slide via a Michael addition (Figure 4. 4). The derivatised ligands were spotted onto 
the array to obtain 10800 spots in total on a single slide (3600 per ligand) with a 200-
250 pm diameter. The assays showed that the proteins were binding specifically to 
their ligand and that the intensity of fluorescent spots correlated well with the affinity 
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Figure 4. 4: Preparation of maleimide-derivatised glass slides by Schreiber 
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After validation of the concept, Schreiber's group reported many examples of small-
molecules microarrays, mainly in correlation with diversity oriented synthesis. They 
successfully activated glass slides as a chlorinated surface for the attachment of 
alcohols (Figure 4 5)291  and applied the concept one bead - one stock to dissect a 
glucose signalling pathway.  292-295  They synthesised 3780 1,3-dioxane compounds 
and an hydroxyl group was exposed after cleavage from the resin providing a 
suitable tethering point for attachment onto the chlorinated surface (Scheme 4.1.). 
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Scheme 4. 1: Generation of diversity oriented synthesis "one bead - one stock" for dissecting a 




Schreiber again used the combination of three hydroxyl-containing compounds 
libraries for immobilisation of 12396 species on chlorinated glass slides. 296 In order 
to expand the functional group compatibility, Schreiber's group developed a new 
linker for the attachment of small molecules to the array surface. The use of a 
diazabenzylidene moiety 4.16 on the derivatised glass slide allowed the linkage of 
phenol-containing compounds (Figure 4. 6).297299  Interestingly the linker does not 
react with alcohols while it captures compounds containing acidic protons such as 
phenols, carboxylic acids and sulfonamides, making this strategy a versatile tool and 
complementary to chlorinated glass slides. 
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Figure 4. . 6: Immobilisation of phenols via a diazabenzylidene linker strategy 
Waldmann developed another chemoselective method via the use of mild 
conditions. 300  Compounds are synthesised on solid-phase with a Kenner-type safety-
catch linker and released into stock solution. The compounds contain after cleavage 
an azido group which can then be used to carry out a Staudinger reaction on a 
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Figure 4. 7: Immobilisation of small-molecules on microarrays via the Staudiriger ligation strategy 
Other examples of immobilisation of small molecules have been reported. Chang 
chose a 1,3 ,5-triazine template, with a 2,2' [1 ,2-ethanedi yl-bis(oxy)]bisethanamine 
spacer in order to immobilise a triazine library onto slides activated with N-
hydroxysuccinimide esters.  301 They identified with this small-molecule microarrays 
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Figure 4. 8 : Immobilisation on hydrazide-containing molecules onto epoxide-coated slides 
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The immobilisation of hydrazide-containing substances onto epoxide-coated surfaces 
was proposed by Lee and Shin. 302  The strategy was applied to microarrays of small 
molecules, carbohydrates and peptides (Figure 4. 8). The hydrazides are incorporated 
into the small molecules while they are attached to a solid support and bind to the 
surface selectively, giving a wide functional group compatibility (alcohols, amines, 
carboxylic acids and mercapto groups did not bind to the slide under the conditions 
applied at pH 3-5, according to the selectivity tests carried out). 
4.2.2.2. Hybridisation onto DNA microarrays 
Another strategy developed by Schultz involves the indirect attachment of small 
molecules to DNA arrays. 303  Small molecules are linked and encoded through a PNA 
tag, complementary to DNA sequences on the array. 304 The compounds are linked to 
the surface via PNAIDNA hybridisation. With this technique no particular functional 
group is required after cleavage for immobilisation onto the array. However a 
particular functional group is still required for attachment to the PNA tag. 
This technique has been used to profile protein function, 305-308  and was also reported 
by Bradley at the same time (Figure 4. 9). -309 
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4.2.2.3. 	Photoactivation strategies 
Mrksich reported the synthesis of small-molecules microarrays by photoactivation of 
self-assembled alkanethiolate monolayers using photomasks. 1° The principle is 
based on n i troveratrylox ylc arbon yl -protected hydroquinone, coated onto a gold 
surface, which are first deprotected using light and then oxidised to the 
corresponding benzoquinone. The later can then react with small molecules 
containing a cyclopentadiene tag via a Diels-Alder reaction. 
small molecules 
photoreactive f group 
printing 
UV irradiation 





Figure 4. 10: Randomised immobilisation of small-molecules on microarrays (adapted from 
Kanoh3' I) 
In order to avoid the need to synthesise small-molecules with a particular functional 
group for immobilisation, Kanoh used an innovative technique. 311  Small-molecules 
are first spotted onto a surface coated with a diazirin-based photo-affinity linker. 
After UV irradiation, the small molecules react with the linker in a functional group 
independent manner, allowing therefore a randomised presentation of molecules with 
multiple facets exposed for interaction (Figure 4. 10). Immunosuppressive agents 
such as FK506, rapamycin and cyclosporin A were immobilised on an array using 
this strategy and were successfully recognised by their target protein. 
4.2.2.4. 	In situ Synthesis 
Some of the first examples of chemical synthesis carried out directly on the surface 
were reported by Fodor (light-directed photolithography), 312  and by Frank on 




conditions by spotting a solution of reagents on the membrane ("SPOT-synthesis"), 
constituting an array of spot reactors. 314  With this technique, peptides were 
successfully synthesised and tested either directly on the membrane or by releasing 
them in solution. 
Germeroth attempted to extend the strategy to other small molecules. 315 The surface 
was first derivatised at specific locations (spots) with a linker containing a terminal 
amino group. The first building block was then linked via the amine functionality, 
which was then reacted with cyanuric chloride. After substitution of the other 
chlorine atoms on the triazine ring, the 1,3,5-derivatised triazines were cleaved and 
adsorbed on to the membrane, conserving the spatially addressed format. Although 
attractive, this strategy suffers from poor purity of the final compounds synthesised 
meaning bioassays being jeopardised. 
4.2.2.5. Recent developments for improved detection 
One of the disadvantages of microarrays is the rigidity of the bound compounds due 
to their attachment to a surface. Indeed during the assays, the screening method 
varies from the in vitro / in vivo processes where ligands and protein are free to 
approach each other in a "solution-phase" manner. Gosalia decided to retain the high 
throughput concept of arrays but changed the approach. 316 Indeed, ligands are printed 
in glycerol (to avoid evaporation). The solution of enzyme to be tested is then 
sprayed onto the surface as an aerosol. The concept means that each drop constitutes 
a micro reactor where neither the biological target nor the ligand are immobilised. 
The approach is therefore closer to an in vitro assay and is potentially easier to carry 
out as ligands do not need to be designed with a particular functionality for 
attachment onto the array. 
A common issue when screening microarrays is the signal to noise ratio which can 
be quite low. In order to improve the sensitivity of the surfaces, Puskas tested six 
different surfaces involving dendrimer and triamino linker systems on acrylic and 
epoxy surfaces. 317  These surfaces successfully increased immobilisation efficiency 




4.3. The use of PNA tags for Micro-arrays 
4.3.1. Peptide Nucleic Acids (PNA): Concept and properties 
Peptide nucleic acids were first described by Nielsen, 318, 319 replacing the 
deoxyribose phosphate backbone of DNA by a poly(N-(2-aminoethyl)glycine)amide 
carrying the nucleobases via a methylenecarbonyl linker (Figure 4. 11). The DNA 
mimic obtained is of particular interest due to its remarkable properties, and has been 
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Figure 4. 11: The DNA/PNA chimera 
As all intramolecular distances and the configuration of nucleobases are similar to 
those in DNA, specific hybridisation occurs between PNA and cDNA or RNA 
sequences. In addition, the uncharged nature of PNA is responsible for the thermal 
stability of PNA-DNA duplexes compared with the DNA-DNA equivalents, and 
single-base mismatches are considerably more destabilising. Finally, PNAs are 




tool for DNA microarrays. Indeed, compounds carrying a PNA tag can be hybridised 
on DNA microarrays containing complementary DNA sequences. 3305,306,309 
4.3.2. Synthesis of PNA tags 
4.3.2.1. 	Strategies 
Several synthesis strategies have been developed for the synthesis of PNA monomers 
and oligomers. The first method involved the use of the Boc group to protect the 
primary amino group of the backbone and the use of the Z group to protect the 
exocyclic amino groups of the nucleobases:' 22 The rationale for using acid labile 
groups was based on the liability of the N-terminal nucleobase to conduct a 
rearrangement to the primary amino group of the backbone under alkaline 
conditions. 32 However Thomson successfully used the Fmoc group as an alternative 
to the Boc group without observing the rearrangement, probably because this process 
is slow. 324  More recently, Bialy developed another strategy based on Dde-protection 
which was fully orthogonal to the Fmoc group. 311, 326 This strategy allowed the direct 
synthesis of PNA-peptide conjugates. Aminoacids can be coupled to one arm of the 
supported lysine 4.17 using a Fmoc strategy, with PNA tag synthesis carried out on 
the other arm of lysine using a Dde strategy (Figure 4. 12). Alternate coupling of 
amino-acids/PNA monomers allows encoding of the combinatorial library. The use 
of Alloc-protected aminoacids and Fmoc-protected PNA monomers has also been 







Figure 4. 12: Strategy developed by Diaz-Mochon to encode aminoacid libraries 
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4.3.2.2. 	Synthesis of the backbone 
The synthesis of the backbone was optimised by Bialy. 326  The first step consisted in 
reacting ethylene diamine 4.18 with chioroacetic acid yielding 4.19 in 85% yield, 
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Scheme 4. 2 : Synthesis of the backbone 
HPLC and NMR spectra showed that some ethylene diamine dihydrochloride was 
present in the mixture. Therefore extensive purification was required because the 
impurity would react with Dde-OH 4.21 in the next step. 4.20 was purified by 
recrystallisation yielding 45 % of almost pure product. The primary amine of 4.20 
was then selectively protected with Dde-OH 4.21 (previously synthesised from 
dimedone)327 in the presence of DIPEA to yield 4.22 in moderate yield (35%). 
4.3.2.3. Synthesis of the adenine monomer 
The exocyclic amino group of adenine requires protection in order to avoid chain 
extension from this position and the introduction of the protecting group is carried 
out after alkylation. Reaction of adenine 4.23 with ethylbromoacetate in the presence 
of NaH yielded 4.24 in 67% yield and was followed by protection of the amino 
group with MMt-Cl in presence of 4-ethylmorpholine and saponification with KOH 
to afford the adenine building block 4.25 in 72% yield over two steps. Once the 
adenine building-block 4.25 was synthesised, it was coupled to the backbone 4.22 
using 1-IBTU as coupling reagent and then saponified to afford the adenine monomer 




the very high purity of the adenine derivative obtained which is an absolute 
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Scheme 4. 3: Synthesis of the adenine monomer 
4.3.2.4. Synthesis of the cytosine monomer 
In the case of cytosine, protection of the exocyclic amino group is carried out prior to 
alkylation, partly to increase the solubility of cytosine in organic solvents. Cytosine 
4.27 was first reacted with MMt-C1 in presence of 4-ethylmorpholine yielding 4.28 
in 45% yield. The low yield is easily explained by the poor solubility of cytosine in 
DCMfPyridine making the reaction difficult due to the heterogeneous conditions. 
Alkylation of 4.28 with ethyl bromoacetate and NaH followed by in situ 
saponification yielded the cytosine building block 4.29 in 68% yield. The building 
block 4.28 was then coupled to the backbone 4.22 and saponified in a similar way to 





NH2 	 MmtNH 
Mmt-CI 	
N 	
i) CICH 2CO2Et, 
N 	4- Ethyl morpholine 	- NaH, DMF, rt, 18h 
DCM/Pyridine (1:1) 	 ii) KOH, H 20, 
H 	40°C, 18h 	 H 	 MeOH, reflux 












I) HBTU, CH 3CN 
H 	 1, 1h 
j ± Dde N N M OMe 















Scheme 4. 4: Synthesis of the cytosine monomer 
4.4. High-Throughput-Screening using 
Dual Fragments Microarrays 
4.4.1. Principle of the proposed new concept to fragment-based drug discovery 
4.4.1.1. Current Method for Fragment Microarrays 
Fragment Microarrays have only been reported by Graffinity Pharmaceuticals so 
far. 262 However, a key point is the difficulty to identify weak binding, in particular 
because fragments can bind very weakly to a biological target and the interaction can 
"disappear" when the protein solution is washed away (Figure 4. 13). Therefore the 
technique does not appear to be particularly attractive at the present time and new 


















Figure 4. 13 : Classical issue when screening microarrays of fragments 
4.4.1.2. Novel approach to Fragment-Microarrays: 
Dual Fragment Microarrays 
A common step in Fragment-based drug discovery techniques is the need at some 
point to link active fragments in order to obtain a high affinity compound. The 
linkage process can be difficult, in particular in the case where no information is 
available on the binding sites of the two fragments. Indeed two active fragments can 
potentially bind to the biological target in the same area. With that issue in mind, the 
best solution is to be able to screen at least two fragments at the same time. 
Spotting two fragments on the same location of a microarray could potentially fulfil 
this requirement (Figure 4. 14). After addition of the protein solution, weak 
interactions between fragments and the target will be "amplified" by the binding at 
the same time of the other fragment to the target. This strategy would allow direct 
identification of active fragments that bind to the target with direct cooperative 
effects. The generation of lead compounds could therefore be speeded up as the 
anchoring point for the two fragments is known and optimisation of the linkage could 
be started immediately after screening the library of fragments. 
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Figure 4. 14: Principle of the proposed Dual Fragment Microarrays 
Classic screening of separate fragments can sometimes be unsuccessful for 
optimisation as the binding of one fragment can change the conformation of the 
binding pocket, making the binding of another positive fragment not as strong as 
originally screened. The proposed strategy suppresses this drawback as cooperative 
fragments are screened at the same time. 
4.4.1.3. 	Choice of biological target and fragments to validate the concept 
In order to validate the concept, assays need to be based on a well established target 
and fragments. The best example of fragment-based drug discovery is probably the 
technique developed by Fes1k. 259 The FK506-binding protein (also known as 
FKBPI2) has been used as a biological target on many occurrences, due to its role in 
immune response. Ligands of this protein and more generally of immunophilins have 
therefore attracted a lot of interest. Examples of immunosuppressive agents are 
numerous and include Rapamycin 4.38, FK506 4.39 and Cyclosporin A 4.40 (Figure 
4.). 321-33' Therefore FKBP represents an attractive target to study. 
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Figure 4. 15: Structure of some immunosuppressive agents 
In addition the fragments synthesised by Fesik have proved to validate the fragment-
based drug discovery concept. Therefore these fragments would be suitable to 
validate the new concept of Dual Fragments Microarrays. Fragments could be linked 
to various spacers in order to study at the same time the impact of the spacer 
type/length on the results that would be obtained with Dual Fragment Microarrays. 
The template "fragment-spacer" would have to be linked to the rnicroarray surface. 
The use of the PNA tag strategy developed by Diaz-Mochon appears to be attractive. 
Indeed although no complex library is initially required to validate the concept of 
dual fragment microarrays, the PNA tag could potentially be used later on to encode 
fragment libraries. 
4.4.2. Synthesis of the PNA tag 326 
The Fmoc-Rink linker was first bound to PEGA resin using PyBOP as coupling 
reagent, followed by Fmoc-deprotection. Fmoc-Lys(Dde)-OH 4.42 was then coupled 
to the resin to afford the starting point for the PNA tag synthesis 4.43 (Scheme 4. 5). 
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Scheme 4. 5: Coupling of Fmoc-Lys(Dde)-OH to the Rink-PEGA resin 
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Scheme 4. 6 : Synthesis of the PNA tag 
Leaving the Fmoc-protected arm free, the resin 4.43 was deprotected using 
conditions described by Diaz-Mochon. 325 and successive cycles of 
coupling/deprotection afforded the PNA tag 4.44 with the following chosen 
sequence: N-T-C-A-A-C-T-T-C-A-T-A-C (Scheme 4. 6). Although the use of 
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used allowing shorter reaction times (1.5h instead of 6h) and smaller quantities of 
monomer to be used (3 equiv. instead of 5.5 equiv.). These conditions are 
particularly attractive when synthesising a tag on a large scale and was therefore 
applied to the target tag. 
4.4.3. Synthesis of the fragments 
	
4.4.3.1. 	Synthesis of fragment F 1 
The synthesis of the first fragment was adapted from Taylor. 33 ' 3 1 ,4',5 1 -
trimethoxyacetophenone 4.45 was first oxidised using selenium dioxide to form the 
a-keto-acid 4.46 in 81 % yield. Separately, (S)-piperidine-1,2-dicarboxylic acid-i-
tertbutyl ester 4.46 was esterified with thionyl chlorideJMeOH in quantitative yield 
(Scheme 4. 7). The choice of 4.47 was made due to the lower cost of the material 
compared to the unprotected amine. 
OH 
Oi O 









OH SOCl2 , MeOH 
0°C then reflux 	 LiOH MeOH 	R = -CH 
Boc 	 3h 	 0 	 rt, lh —'-4.5O R= -H HC1
(Fragment F 1 ) 
4.47 	 4.48 
Scheme 4. 7: Synthesis of the first fragment 
The fragments were first coupled using DCC/DMAP, which however resulted in 
poor conversion (less than 5%). In comparison, EDC gave 40% yield but regular 
addition of the reagent was necessary to achieve this. Attempts to transform the acid 
into the acid chloride using thionyl chloride resulted in degradation of the fragment 
and were therefore unsuitable. The possibility to use PS-I[DQ was not investigated as 
the piperidine scaffold was similar to proline, which proved to yield carbamate by-





the coupling was still a moderate 48% yield (Scheme 4. 7). After coupling, the 
protected fragment 4.49 was easily saponified with lithium hydroxide in 93% yield to 
afford fragment F 1 4.50. 
4.4.3.2. Synthesis of Fragments F 2 to F5 
The other fragments reported by Fesik were based on aminophenols. 259 Coupling 
between 2-, 3- and 4-aminophenols (4.51a-c) and 4-hydroxybenzoic acid 4.52 using 
IIDQ resulted in mixtures of the expected amides 4.53a-c and the corresponding 
esters 4.54a-c (Scheme 4. 8). 
+ Q OH HO  
4.51 a-c 
 PNH2  
IIDQ,CH3CN 	0 NH 	o a 
rt 	 + 
overnight 	.-- 
OH 	 OH 
4.53a-c 	4.54a-c 
Scheme 4. 8: First strategy investigated for the synthesis of fragments F 2-F4 
Although the esters 4.54a-c could be easily cleaved, the possibility of protecting the 
phenol previous to the coupling was chosen. Indeed, this protection would insure the 
selective attachment of the fragment to the spacer through the hydroxyl group of the 
acid. Therefore 2-, 3- and 4-aminophenol 4.51a-c were protected with TBS-C1 using 
classical conditions (Scheme 4. 
OH 	 OTBS 
c 
lBS-Cl 
p imidazole, THF, rt, 18h 
NH 2 	 NH 2 
4.55a (ortho) 
4.51 a-c 	 4.55b (meta) 
4.55c (para) 
Scheme 4. 9: Protection of the phenol group 
The protected aminophenols 4.55a-c obtained failed however to couple to 4- 




reason, 4-acetoxybenzoic acid 4.56 was used as a replacement of 4-hydroxybenzoic 
acid 4.52. The coupling succeeded using IDQ in moderate yield (35%, 45% and 
49% over two steps for the ortho 4.57a, meta 4.57b and para 4.57c derivatives 
respectively) (Scheme 4. 10). 
OTBS 	 OTBS 
iIii 
c 	IIDO, CH3CN 0 N 	LiOH, MeOH 	ONH 4.56, rt lh, 	 4.58b (meta) overnight 	
I 	
4.58a (oho) 
80-92% 	 4.58c (para) NH2 
39-49% 
OAc 	 OH 
4.55a-c 	 4.57a-c 
Scheme 4. 10: Synthesis of the TBS-protected fragments F 2-F4 
Various conditions of saponification of the meta isomer 4.57b were studied and 
lithium hydroxide and potassium carbonate both gave complete conversion after lh 
and three TBS-protected fragments 4.58a-c were obtained. However, the ortho 
isomer 4.58a decomposed quickly under these conditions although only 5 mm. were 
required for complete cleavage of the ester and the product had to be purified by 
column chromatography. 
Another fragment (F5) 4.61, synthesised from aniline 4.59 and 4-acetoxybenzoic acid 
4.56 was also obtained with this method in 85% overall yield (Scheme 4. 11). 
_ 9 _ 9 
P IIDO, CH 3CN 0 N 	LiOH, MeOH 	0 N 4.56,rt 	 •lh,rt overnight  NH2 -.--- 
4.59 
I 
OAc 	 OH 
4.60 
4.61 (fragment F 5) 




4.4.4. Methodology for parallel solution-phase Mitsunobu reactions 
4.4.4.1. 	General considerations 
Many spacers could be used in the project, but diols and glycols appeared to be 
attractive to use for the phenol-based fragments (F2-F5). Indeed the Mitsunobu 
reaction provides an efficient synthetic tool for the synthesis of aryl ethers (Scheme 
4. The reaction occurs under mild, essentially neutral reaction conditions 
(0°C to room temperature), and tolerates a variety of functional groups. The pKa of 
the nucleophilic component (in this case, the phenol) has to be lower than the betaine 
intermediate pKa (about 13). Some non-polar solvents accelerate the conversion, and 
therefore TI-IF, diethylether, DCM and toluene are often preferred as solvents, 
though ethyl acetate, acetonitrile and DMIF are sometimes used. 
1 	 r 	® Ar-O°1 
I Ph3F 	® 	 Ar-OH 	I I N—NH 	I N=N 	+ PPh3 	I 	,N—N I 	 I 
Et026 	CO2Et 	 [ Et02C 	CO2Et] 	 L Et02C 	CO2Et j 
R-OH 
1 
O=PPh3 + 	/ 	 + 	,PPh3 
N=N  
	
EtO2C CO2Et 	[ 	I 	 [ R-O 	Ar-O ] 
Scheme 4. 12 : Synthesis of aryl-alkyl ethers via the Mitsunobu reaction 
However, the reagents used in this reaction are often hard to remove, although some 
newer methods have been reported . 337 For this reason the possibility of developing a 
simplified process was investigated, and fragment F 3 (meta isomer) and 1,3-
propanediol were chosen as test-substrates. 
Traditional conditions using solid-supported phosphine (Novabiochem) or 
triphenyiphosphine in solution, and DIAD were first investigated. The 
triphenylphophine oxide was difficult to separate from the reaction mixture. 




4.4.4.2. 	Alternative coupling reagents 
Other Mitsunobu coupling reagents were investigated. DEAD 4.62 and DIAD 4.63, 
which are commonly used in Mitsunobu reactions, can usually be readily removed 
from the product mixture by column-chromatography. However, this is not suitable 
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Figure 4. 16 : Mitsunobu coupling reagents 
ADDP 4.64 is a useful alternative azodicarbonyl equivalent, which can be readily 
filtered off from the reaction mixture (along with the corresponding hydrazine by- 
3 product) after dilution of the completed reaction mixture with hexanes. 38 Some other 
diazocarbonyl equivalents derived from morpholine 4.65 and N-methylpiperazine 
4.66 have also been reported but are not commercially available.  3 39  Another reagent 
was developed by Tsunoda: DHTD 4.67 can be synthesised easily but is also not 




used in order to avoid chromatographic separation. 34 ' DNAD 4.69 has been proposed 
to enable selective derivatisation by polymerisation of by-products using a 
norbornene tag. 342  After reaction, ruthenium-catalysed polymerisation of olefin-
containing compounds (ring opening metathesis) leads to insoluble by-products. 
Finally, TMAD 4.70 has been reported as being an efficient Mitsunobu reagent and 
is commercially available. 343, 	One could mention the availability of a polymer- 
345 supported DEAD 4.71 .However, this reagent is extremely expensive and has to be 
used in conjunction with a phosphine in solution. 
4.4.4.3. 	Alternative phosphines 
Removal of the by-product triphenylphosphine oxide as well as excess 
triphenylphosphine 4.72 has been the most problematic facet of Mitsunobu 
chemistry. In some cases, the by-product may be filtered from the reaction mixture, 
but often the by-products must be removed by a chromatographic separation. Tn-n-
butylphosphine 4.73 has been reported as being a useful improvement for this 
method with little or no effect on the reaction yield .346  In this case, the by-product 
tributylphosphine oxide is water soluble and may be largely removed by an aqueous 
workup. Excess tributylphosphine is volatile and is usually removed during removal 
of the reaction solvent. More generally alkylphosphines are suitable for the 
Mitsunobu reaction .347 
Other methods have been developed to increase the ease of workup of Mitsunobu 
chemistry, and a great deal of effort has been put toward the development of 
tniarylphosphines. Modification of the phosphine portion has generated reagents that 
are easily removed from the completed reaction mixture, along with the 
corresponding phosphine oxide by-products (Figure 4. 17). 0' Neil showed that 
DPPE 4.74 is a convenient replacement for tniphenylphosphine in the Mitsunobu 
reaction. 348  Due to the greater polarity of the resulting bis-tniphosphine oxide by-
product, this component is usually insoluble to the point at which it can be easily 
removed from the reaction mixture by a simple filtration prior to workup and 
purification. Other phosphine equivalents include DAP-DP 
4•75,349  Ph 2P-Py 4.76,' 
and TAP 477350  These phosphines present the advantage of containing basic 
functional ities, making the extraction through an acidic workup possible. 
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Figure 4. 17: Phosphines used in Mitsunobu reactions 
Solid-supported triphenyiphosphine 4.78 has become a standard procedure for 
Mitsunobu reactions.351 352  In particular it has been used along with DBAD for 
parallel synthesis of alkyl aryl ethers. 353,  However as explained before, DBAD is 



















Figure 4. 18: Other alternative phosphines used in the Mitsunobu reaction 
Similarly to the strategy used with the coupling reagent DBAD, Flynn used a tert-
butyl-masked, carbox y-tagged al kyldiphenyiphophine 4.79 which was deprotected 
with TFA. 355 Yoakim also used a silyl-masked phosphirie 4.80, which was unmasked 
with TBAF (Figure 4. 18). 356  Other examples of tagged-phosphine include 15- 
crown-5 tagged triphenyiphosphine 4.81, which can be scavenged via an 
ammonium-functionalised resin, and anthracene-modified phosphine 4.82, which can 
be removed via a Diels-Alder reaction with a polymer-bound maleimide. 358 
4.4.4.4. 	Conclusion on suitable reagents 
By selecting only the commercially available reagents and eliminating any reagent 
requiring strongly acidic conditions, a list of three coupling agents (DIAD 4.63, 
TMAD 4.70 and ADDP 4.64) and six phosphines (PPh3 4.72, PBu3 4.73, DPPE 4.74, 
PyPPh2 4.76, DAP-DP 4.75 and PS-PPH 2 4.78) was created. Although 
triphenyiphosphine and diisopropylazodicarboxylate are known to require 
purification, they remained in the list of reagents to screen as a comparison due to 
their well established properties as mediating well Mitsunobu reactions. 
4.4.4.5. 	Screening of coupling reagents and phosphines 
The combination of suitable and commercially available coupling reagents (DIAD, 
TMAD, ADDP) and phosphines (PPh 3 , PBu3, DPPE, PyPPh 2, DAP-DP and PS-
PPH2) was first investigated in parallel. The conditions were adapted from a reported 
synthesis of alkyl aryl ethers,  359  and in particular alkyl aryl ethers involving diols.60 
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361 An excess of diol (1.5 equiv.) to the phenol (1 equiv.) was used in order to 
prevent a double Mitsunobu reaction, and the phosphine and coupling reagents were 
used accordingly (1.5 equiv.) followed by an aqueous workup. A mixture of DCM 
and TI-IF was used and the coupling reagent was added portion-wise over 2h. After 
reaction, an aqueous workup was carried out. In the case of ADDP and TMAD, the 
hydrazine by-products formed during the reaction were filtered off prior to workup. 
Entry Coupling reagent Phosphine Purity' 
1 DIAD PPh 3 29 
2 PBu3 51 
3 Py-PPh 2 40 
4 DAP-DP 13 
5 DPPE 15 
6 PS-PPh 2 100 b 
7 TMAD PPh 3 2 
8 PBu 3 26 
9 Py-PPh 2 1 
10 DAP-DP 0 
11 DPPE 5 
12 PS-PPh 2 100 
13 ADDP PPh3 51 
14 PBu3 36 
15 Py-PPh 2 72 
16 DAP-DP 21 
17 DPPE 11 
18 PS-PPh 2 100 
determined by ELSD: DIAL) by-products were not detected by ELSD 
Table 4. 1: Screening of coupling reagents and phosphines followed by SPE purification 
The mixtures including the expected product 4.83 were analysed by LCMS with 
attention focused on the presence of phosphine oxide or coupling reagent by-product. 
Unfortunately, none of the "water-extractable" phosphines proved to be removed 
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ADDP did not leave any trace in the mixture in comparison to DIAD. Polymer-
supported triphenylphosphine (purchased from Fluka) again proved to give poor 
conversion. As removal of the "water-extractable" phosphines was surprisingly only 
partial, the combination of all phosphines and coupling reagents was investigated 
again with a new approach to the workup. After reaction, the mixtures were filtered 
through SPE extractors containing a mixed bed of acidic/basic macroporous ion 
exchange resin, and the mixtures were analysed by LCMS and ELSD (Table 4. 1). 
Polymer-supported triphenylphosphine (Polymer Lab) was tested again. 
The solid-phase extractors failed to entirely remove the phosphines oxides, making 
all the "water-extractable" phosphines unsuitable for library synthesis. However, the 
supported triphenyphosphine gave excellent results in that case. When used in 
combination with TMAD or ADDP, no coupling reagent or phosphine, were present 
















Figure 4. 19: Comparison of the product purity by HPLC (ELSD) with (a) PS-PPh 2/TMAD, 




4.4.5. Initial choice of spacers 
Six spacers were chosen initially for the validation of the Dual-Fragment 
Microarrays concept (Scheme 4. 13). All of them contained a hydroxyl group on one 
side for attachment to the fragment and either an acid or hydroxyl group on the other 
side for attachment to the PNA tag. Fragments were planned to be coupled to the 
spacers via the Mitsunobu process developed above and then linked to the resin 




	 MeO H 
13 
	
S3 	 S5 
HO OH 	
MeO OH 
S2 	 S4 
Scheme 4. 13: Spacers used for phenol-based fragments 
Before synthesising the library of spacer-fragment conjugates, the feasibility of a 
carbamate linkage to the resin was evaluated. Urethane formation (excluding 
protecting groups) has been reported on solid-phase but with the hydroxyl group 
being on the resin. 361 
The fragment-spacer conjugate synthesised (4.83) was coupled to H2N-Lys(Dde)-







1) CDI 	- 
2)TFA 
Dde NH 
4.83 	 4.43 	 Dde 
HN 
H2 N 
Scheme 4. 14 : Target reaction to study the feasibility of the carbamate linkage 
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Many conditions were tested involving the use of carbonyldiimidazole (CDI) and 4-
nitrophenyichioroformate. After reaction, the resin was washed and cleaved with 
TFAJDCM/TIS (90/5/5). The conditions tested are reported in Table 4. 2. As PEGA 
resin has a tendency to retain moisture, the resin was washed many times with dry 
THF prior to reaction. 
Entry Reagent Order of activation Solvent Base Additive Product 
1 CDI Resin first DCM DiPEA - no reaction 
2 4-NO2-0C(0)Cl Resin first DCM DiPEA - 4.85 
3 CDI Alcohol first DCM DiPEA - no reaction 
4 4-N07-0C(0)Cl Alcohol first DCM DiPEA - no reaction 
5 4-NO2-0C(0)Cl Alcohol first DCM DiPEA DMAP no reaction 
6 4-NO2-0C(0)Cl Alcohol first TI-IF DiPEA DMAP no reaction 
7 CDI Alcohol first DCM DiPEA DMAP no reaction 
Table 4. 2 : Conditions tried for carbamate-bond formation 




Figure 4. 20 : Cross-linking product formed 
None of the conditions tried afforded the expected carbamate compound. Either no 
new product was observed, or the product observed 4.85 corresponded to the 
crosslinking on the resin via the activating agent (Figure 4. 21). Other reagents could 
have been tried such as triphosgene, but this would have required extensive 
purification of each fragment-spacer conjugate after reaction, while reaction of 





4.4.6. Extension of the chain on the resin 
The amino group of the amino acid was extended with adipic acid monoester 
(Scheme 4. 15) (confirmed by MS analysis after cleavage of a few beads). A C 6 
chain was chosen because shorter chains can sometimes yield cyclic by-products 
after coupling. 
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H2N/ N O 
4.43 
Dde NH 
H3COC(0)-(CH 2 )4-CO2H, 
HATU, DiPEA, rt, 1  
HO 	 N N 10 
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H  
H2 	4.88 N 
(20/80) 	 uue 
Scheme 4. 15: Extension" of the resin with adipic acid moomethylester 
Hydrolysis of the methyl ester via lithium hydroxide in TI-IF / water was successful, 
however, under these conditions partial deprotection (about 20%) of the Dde group 
was observed. This could be easily corrected by capping the amino group with an 
acetyl group. These conditions were applied to the resin 4.44 synthesised previously 
to afford resin 4.89 (Figure 4. 21). 
H 0 Q 
Fmocf 
H 
1) 20% piperidine in DMF 
NH 	
2) adipic acid monoester, 
HN—Tag 	 HATU, DiPEA, rt, lh 
(Dde) 	
3) lithium hydroxide 







HN—Tag NH 4.89 
R 
A = -Dde or -H (mixture) 
Figure 4.21: Synthesis of resin 4.89 
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4.4.7. Coupling of spacers and fragments to the resin 
4.4.7.1. Spacers for phenol-type fragments 
Based on the spacers that were going to be used via a Mitsunobu reaction (S 1 -S6), 
three new spacers were selected (S' 1 -S'3, Figure 4. 22), with an amino group on one 
end for coupling to the resin. 
	
HO-OH 	> H2N—OH 
S i 	 S , 1 
HO. -OH E-=::* 
S2 	 S , 2 
HO -OH 	
> 
S3 	 S , 3 
Figure 4. 22: Choice of new spacers 
The three spacers were coupled to resin 4.89 using DIC/HOBt, which has been 
reported to couple amino-alcohols selectively 362 gi ving resins 4.90, 4.91 and 4.92 
(Scheme 4. 16), while this selectivity has not been investigated using IIDQ. 
HO ( i 
	 R 	 N 
0 	
1)DIC!HOBt 
2) S , 1 or S2  or s3 
HN—Tag NH 
	 HNTag' 
(Dde) 	 (Dde) 
4.89 
4.90 R= 	HOc 
4.91 R = HO ) 
4.92 R = HO ° 




4.4.7.2. 	Coupling of fragments F 2-F5 to the resin 
Fragments F2-F5 were coupled to the resin via classic Mitsunobu reaction conditions 
using PPh3 and DIAD in THFIDCM for 16h (Scheme 4. 17) (the conditions 
previously optimised for Mitsunobu reaction could not be applied to this strategy 
because the final product are immobilised and purification is not thus an issue). 4-
trifluoromethyl-phenol 4.93 (named fragment F 6) and phenol 4.94 (named fragment 
F7) and were also coupled to the resin in order to study capping effects during the 
assays. 







4.90-4.92 	 4.94  






18 supported fragment- 
spacer conjugates 
Scheme 4. 17: Coupling of fragments F 2 -F7 to the spacers via Mitsunobu reaction 
Cleavage of the resin with TFA I DCM / TES (90:5:5) allowed the release of the 




TBS group. After precipitation with ether, the 18 tagged spacer-fragments conjugates 
were obtained on a 1-3 mg scale (- 0.5 tmol).. 
4.4.7.3. Spacers for Fragment F 1 
In order to couple fragment F 1 to the resin 4.90, the spacers required an amino-group 
on both ends. However, diamines risk crosslinking. In addition during the capping 
step, the free amino-group would also be capped. For these reasons, Fmoc-
monoprotected fragments S" 1 -S"3 were selected (Figure 4. 23). 
______ 
H2N,—.NH2 	 >H2N,, 	
H 
 Fmoc 
S .. ' 
H 
I 	> Fmoc 





0 	 Fmoc 
S ,, 3 
Figure 4. 23: Spacers selected for Fragment F! 
These spacers were coupled to the resin using DCC/HOBt, and the resulting resins 
were then capped using AcOH /HATU/ DIPEA, followed by Fmoc-deprotection to 
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4.4.7.4. 	Coupling of fragment F 1 to the resin 
Fragment F 1 was easily coupled to resins 4.95, 4.96 and 4.97 with HATU/DIPEA 
(Scheme 4. 19). Rhodamine was also coupled to the same resins for detection of 
successful hybridisation. 
HOH 
Spacer 	 N 	 J.OH 
o-o 0 




Ac/Dde' 	 OMe 
4.95 -4.97 	 4.50 
HATU / DIPEA 





MeO'1OMe 	 HN—Tag NH  
OMe 	 Ac/Dde' 
3 supported fragment-spacer conjugates 
Scheme 4. 19: Coupling of fragment F 1 to the PNA tag 
Following the same cleavage conditions used for the other fragments, the 3 tagged 
spacer-F 1 conjugates and 3 tagged spacer-rhodamine conjugates were obtained on a 






4.4.8. Preparation of the microarrays 
4.4.8.1. 	Printing of the oligonucleotide sequences on aldehyde and agarose 
slides 
The complementary sequence of the PNA tag previously synthesised was purchased 
from Sigma-Genosys. This sequence was 3'-amino-modified in order to link the 
oligonucleotides to aldehyde-derivatised slides via reductive amination. In addition 
the sequence was preceded with six thymine units, to act as a spacer. The same 3'-
modified nucleotide was also purchased with an additional 5' modification with 
fluorescein in order to check successful printing on the surface. 
Two different surfaces were selected: standard aldehyde glass-slides presenting a 
planar two dimensional surface, and glass-slides covered with a layer of activated 
agarose gel forming a 3D texture. Potentially, agarose slides can immobilise more 
DNA chains due to the 3D architecture and therefore increase the fluorescence signal 
resulting in better signal to noise ratio. It was indeed successfully used for DNA and 
protein microarrays. 36 Agarose coated slides are now commercially available and 
are activated to present aldehyde functionalities for attachment of amino-derivatised 
DNA. 
Figure 4. 24 : Fluorecenee detection alter DNA printing on an aldehde slide using a FITC filter 
After printing, the slides were washed (including a reducing washing solution 
containing NaBH4) and scanned using a FITC filter (aldehyde slide, Figure 4. 24). 
The expected fluorescein-derivatised DNA pattern on the array was detected proving 
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that printing had been successful. Scanning of agarose slides interestingly showed 
higher fluorescence intensity compared to the aldehyde slides. However when 
zooming onto the pattern, the difference was more difficult to appreciate (Figure 4. 
25) 
agarose slide 	 aldehyde slide 
Figure 4. 25: Comparison of fluorescence intensity after DNA printing on an agarose (average: 8.8 
10) and an aldehyde slide (average : 5.1 10) 
4.4.8.2. Printing of the tagged fragments 
Hybridisation of PNA encoded libraries onto DNA microarrays is usually performed 
with a hybridiser which consists in passing the solution of the mixture onto the slide 
at 90°C in order to make sure that each tagged-molecules can access its 
corresponding complementary site on the array and that uncomplementary duplexes 
are separated. Direct hybridisation of a PNA-tagged molecule on to the 
complementary DNA sequence by spotting a stock solution onto the array has not 
been reported before. In order to allow some tolerance with the positioning, each 
stock solutions was spotted 5 times, making therefore a bigger drop onto the array 
and increasing the chance of superposition on the DNA spot (Figure 4. 26). 
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Successful hybridisation could be determined by comparing the printing pattern of 
rhodamine-containing tags and the image obtained by scanning the slides using a 
Cy3 filter (Figure 4. 27). 
Figure 4. 27 : Fluorescence detection after hybridisation using a Cy3 filter 
The comparison clearly showed the presence of the right patterns confirming that 
hybridisation had been successful. The elaborated procedure represents therefore a 
new way to obtain small-molecules microarrays. Indeed small-molecules can be 
synthesised in a parallel approach, linked to a PNA-tag and hybridised onto a DNA 
microarray. Although direct printing of small-molecules has been reported, this 
approach offers the advantage of controlling printing of small-molecules as shown by 
the rhodamine control. 
4.4.9. Screening of the microarrays against FKBP 
4.4.9.1. 	Methodology of the assays 
The strategy chosen was to use a protein complementary to an antibody. After 
incubation of the protein, the corresponding antibody can be added. After incubation 
of this primary antibody, a fluorescent secondary antibody can be used to detect 














Figure 4. 28 : Principle of the bioassays 
RGS-tagged FKBP 12 was kindly provided by Prof. Stuart Schreiber and Dr. Angela 
Koehler from Harvard University. This protein is recognised by Qiagen's RGS 
mouse antibody. All arrays printed previously were first incubated with RGS-
FKBP12, then incubated with Alexa 488®  anti-mouse and scanned using a FITC 
filter. The mapping of the spotted stock solutions (Figure 4. 29) was correlated with 
the intensity of fluorescence (Figure 4. 30). 
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Figure 4. 30: ('Cl) picture ()fan aldchyde slide after assay showing a hit (mixture F 1 + 1-4) 
4.4.9.2. 	Analysis of the aldehyde slides 
First Aldehvde slide 
The intensity of the spots was analysed using the FIPS software (LaVision BioTech). 
Globally the background was high. The average of the two patterns gave four hits 
(Figure 4. 31). In the case of single fragments, fragment F 1 gave the highest intensity 
when associated with spacer S3. This result was anticipated as F 1 is the ligand with 
the best affinity according to Fesik's experiment. The two other hits corresponded to 
4-trifluorometh yl -phenol associated with spacer S'2 and S'3. This result is not 
surprising as the trifluoromethyl group is known as being an excellent 
pharmacophore to many biological targets including FKBP. Results with spacer S 1 
were very similar for each fragment and the intensity of fragment F 1 was quite low. 
This could indicate that spacer S 1 is too short for efficient binding to the protein. 
Fragment F 1 
a Ns 
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H2 N - 0 - NH2 
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Figure 4. 31: Fluorescence intensities obtained on the first aldehyde slide 
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In the case of dual fragments, only one mixture was higher than the others. This was 
obtained with spacer 2 and corresponded to the mixture of fragment F 1 and fragment 
F4 . This corresponded exactly to the results from Fesik! However the difference of 
intensity between the single fragment F 1 and the mixture F 1 +F4 was not huge. In 
addition it was surprising not to observe a similar result with spacer S'3 
Second aldehyde slide 
Results were slightly different on the second aldehyde slide. Indeed fragment F2, F3 
and F5 associated with spacer S'i gave surprisingly high intensities (Figure 4. 32). 
For mixtures of fragments, an impressive result was observed as the intensity of the 
mixture F 1 + F4 associated with spacer S'2 was much higher that any other spots. 
This result corresponded once again to the affinities observed by Fesik. 
Fluorescence 	 7 	- 
intensity 	 7 Fragment F4 
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4.4.9.3. 	Analysis of the agarose slides 
Analysis did not allow many conclusions to be drawn as too many hits came up. 
Analysis (Figure 4. 33) for single fragments showed that more hits were detected 
when using spacer S'3. This tendency was also observed with mixtures of fragments. 
However, while the association of fragment F 1 and F3 proved to be the highest with 
spacers S' l and S'2, the same association showed the worse intensity that any of the 
other mixtures when associated with spacer S' 3. Across the slide, 4-
trifluoromethylphenol was detected as a hit. 
Figure 4. 33: Fluorescence intensities obtamed on the aalose lide 
4.4.9.4. 	Conclusion of the screening 
Although showing higher average intensities than the aldehyde slides, the agarose 
slides showed many spots with similar fluorescence intensities and therefore failed to 
identify any hit. 
Whatever the surface was, high background noise made the results difficult to 
interpret. However, although variations from one slide to the other were observed 
(average intensities: 4.1 10 and 5.9 10), the results obtained with aldehyde slides 
were encouraging. Indeed, on both slides the mixture of fragment F 1 with fragment 




slide showed a significant difference between the intensity of this mixture (7.2 10) 
and any other single fragment/mixture (average: 5.8 105  ). However, the difference of 
intensities for different spots in terms of percentages was quite low, which suggests 
that the results obtained need to be considered with caution. 
In order to evaluate the influence of the spacer, the average intensities over the two 
aldehydes slides were investigated (Figure 4. 34). For single fragments, the spacer 
did not seem to have a noticeable influence as the average intensities were in the 
similar range (5.01 10 5 to 5.03 105  ). However, the spacer type had a major impact on 
dual fragments. Indeed, intensities obtained with spacer S , 2 (5.21 10) were higher 
than the one obtained with spacer S , 1 (4.94 105  ) and S , 3 (4.97 10) gave lower 














Figure 4.34: Influence of the spacer on the fluorescence intensity (average intensities oer the two 
aledhyde slides) 
4.5. Conclusion 
The first results of screening of Dual Fragment Microarrays were promising and the 
tendency to detect significantly the best association expected (fragment F 1 + F4) was 
encouraging. Moreover, the results tended to show that spacer S'2 was the most 
suitable for Dual Fragment Microarrays. These primary results revealed that many 
parameters would need to be optimised. Indeed the background noise was high, 




the protein, primary and secondary antibodies would probably need to be adapted. In 
order to reduce the background, the use of a secondary antibody labelled with a 
different fluorophore would also be interesting to investigate. All this study partially 
proved that the concept of Dual Fragment Microarrays is valid but much 
optimisation is still required. 
Chapter V 
Experimental Part 
5.1. General Section 
The reagents commercially available were used without further purification. Solvents 
we're not dried or distilled except where specified. 
All solution-phase reactions were stirred magnetically, unless otherwise stated, and 
followed by HPLC or thin-layer chromatography (TLC) where appropriate, using 
aluminium-coated Silica Gel 60 (Macheray Nagel: 0.20 mm layer). TLC 
visualisation was performed using short wavelength UV light (254 nm) and/or PMA 
oxidation. 364 
NMR spectra were recorded on Bruker DPX 400 and 300, or ARX 250 
spectrometers in the solvents indicated at 298 K. Chemical shifts are reported on the 
scale in ppm and are referenced to residual non-deuterated solvent resonances. 
Signals of 'H Magic Angle Spinning-NMR spectra were assigned by comparison 
with the 1 H NIVIR spectra obtained with the solution-phase equivalent of the 
supported compound. All 13C NMR experiments were supported with DEPT. IR  
spectra were obtained on a Thermo Mattson Satellite FTIR spectrometer or Bruker 
Tensor 27 Spectrometer, with 16 scans, at a resolution of ± 4 cm - '. The FTIR 
spectrometers were fitted with a Specac single reflection diamond ATR Golden Gate, : 
and neat compounds were used for analysis. Frequencies are reported in cm' and 
only frequencies corresponding to significant functional groups are reported. 
LC-Mass spectra were recorded either on a water ZMD single quadrupole MS, with a 
2700 Autosampler and a 600 Pump, or an Agilent Technologies LC/MSD Series 
1100 Quadrupole Mass Spectrometer (QMS), both with an electrospray ion source. 
(for the Agilent). 
HPLC spectra were recorded using an Agilent 1100 Series coupled to a Polymer Lab 
100 ES Evaporative Light Scattering Detector (ELSD), with a Phenomenex Luna 
C18, 5j.im, 10cm column (column 1), a Phenomenex Gemini C18, 5tm, 10cm 
column (column 2), or a Phenomenex Luna C18, 5im, 15cm column (column 3). 
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HPLC grade water, MeOH (or CH 3CN) with 0.1 % formic acid were used as eluants, 
at a flow rate of 1 mLimin., with samples prepared to a concentration of about 30 
tg.mL1 (ZMD) or 1 mg.mL 1 (Agilent) and filtered prior to injection. The following 
methods were used: 
Method A (column 1, H20IMeOH, 12 mm.): 0 mm. (95/5), 7 mm. (5/95), 9 mm. 
(5/95), 9.05 (95/5). 
Method B (column 2, H20/MeOH, 10 mm.): 0 mm. (95/5), 7 mm. (5/95), 9 mm. 
(5/95), 9.05 (95/5). 
Method C (column 3, H20/MeOH, 15 mm.): 0 mm. (95/5), 12 mm. (5/95), 14 mm. 
(5/95), 14.05 (95/5). 
Method D (column 1, H20/CH3CN, 6 mm.): 0 mm. (95/5), 3 mm. (5/95), 4 mm. 
(5/95),4.05 (95/5). 
Melting points (Pyrex capillaries) are uncorrected. 
Specific optical rotations were recorded with Po1AAr 3001 at 589nm. 
FIRMS analyses were performed by the Mass Spectrometry Service of the University 
of Southampton, U.K. Elemental analysis were carried out by Medac Ltd, U.K. 
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5.2. Experimental for Chapter II 
5.2.1. Synthesis of the library for the comparison of IIDQ and EEDQ 
Preparation of mother solutions 
The following solutions were prepared: 
Amines: 
tert-butyl aniline: 207 iL (0.5 mmol) in 5 mL CH3CN (0.1 mmol/mL) 
benzylamine: 143 .iL (0.5 mmol) in 5 mL CH3CN (0.1 mmol/mL) 
morpholine: 114 tL (0.5 mmol) in 5 mL CH3CN (0.1 mmol/mL) 
Acids: 
phenyl acetic acid: 95 mg (0.7 mmol) in 7 mL CH3CN (0.1 mmol/mL) 
benzoic acid: 85 mg (0.7 mmol) in 7 mL CH3CN (0.1 mmol/mL) 
Coupling reagents: 
IIDO: 212 mg (0.7 mmol) in 7 mL CH3CN (0.1 mmol/mL) 
EEDO: 172 mg (0.7 mmol) in 7 mL CH3CN (0.1 mmol/mL) 
Procedure 
In each vial, a solution of an amine (1 mL, 0.1 mmol, 1 equiv.) and of a carboxylic 
acid (1 mL, 0.1 mmol, 1 equiv.) were added, followed by the addition of a solution of 
a coupling reagent (1 mL, 0.1 minol, 1 equiv.). The 12 vials were shaken at room 
temperature for 16h. The contents of the vials were then filtered through a SPE 
cartridge containing a mixed bed of TvIP acidic/basic ion-exchange resins (Polymer 
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The named compound was obtained as an off-white solid (25 mg, 96%). 
HPLC (method B): tR 7.32 mm. 
Purity (ELSD): 100% 
'H NMR (250 MHz, CDC13): 7.48 (s, 111, NH), 7.39-7.25 (m, 9H, Ar-H), 3.69 (s, 
2H, CH2), 1.28 (s, 9H, C(CH3)3 ). 
13C NMR (75 MHz, CDC13): 169.16 (C=O), 147.32 (C-Ar), 135.02 (C-Ar), 134.61 
(CH-Ar), 129.38 (CH-Ar), 129.02 (CH-Ar), 127.42 (CH-Ar), 125.63 (CH-Ar), 
119.71 (CH-Ar), 44.60 (CR 2), 34.27 (C(CH3)3), 31.27 (C(CH3 ) 3 ). 
FTIR (neat): 3285 (m), 1655 (s). 
Mp: 146-148°C (methanol) 
HRMS (ES): caic. for C 181421 N0: 268.1696 [M+H]Found: 268.1696. 
N-Benzyl-2-phenyl-acetamide365 (2.153) 
The named compound was obtained as a white solid (20 mg, 91 
HPLC (method A): tR = 7.64 mm. 
Purity (ELSD): 96% 
NMR (300 MHz, CDCI3): 7.26-7.08 (m, 10H, Ar-H), 5.71 (br s, 1H, NH), 4.32 
(d, J = 5.7 Hz, 2H, NH-CH2), 3.53 (s, 2H, CH2). 





The named compound was obtained as a colourless oil (8 mg, 38%). 
HPLC (method C): tR = 8.11 mm. 
Purity (ELSD): 100% 
1 H NMR (250 MHz, CDC13): 7.36-7.23 (m, 5H, Ar-H), 3.74 (s, 2H, Ar-CH2), 3.65-
3.46 (m, 8H, CH2). 
m/z (ESMS): 206 [M+H] (46%), 228 [M+Na] (100%) 
N-(4-tert-Butyl-phenyl)-benzamide 367 (2.155) 
Ne 
The named compound was obtained as a white solid (22 mg, 88%). 
HPLC (method A): tR = 8.88 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC1 3): 7.96 (br s, 1H, NH), 7.87-7.84 (m, 2H, OC-C-CH), 
7.59-7.35 (m, 7H, Ar-H), 1.32 (s, 9H, C(CH 3)3). 




N-Benzyl-benzamide 368 (2.156) 
oi e 
The named compound was obtained as a white solid (18 mg, 85%). 
HPLC (method A): tR = 7.52 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDCI3): 7.74-7.71 (m, 2H, OC-C-CH), 7.46-7.19 (m, 8H, Ar-
H), 6.51 (br s, 111, NH), 4.56 (d, J = 5.7 Hz, 211, CH 2). 
m/z (ESMS): 212 [M-1-H] (72%), 234 [M4-Na] (100%). 
Morpholin-4-yl-phenyl-methanone 369 (2.157) 
0 
0--~ 00 
The named compound was obtained as a white solid (9 mg, 50%). 
HPLC (method C): tR = 7.59 mm. 
Purity (ELSD): 100% 
NIVIR (300 MHz, CDC13): 7.36-7.31 (m, 5H, Ar-H), 3.85-3.32 (m, 8H, CH 2). 




- 	5.2.2. Synthesis of the library for the comparison of IIDQ, PyAOP, BOP-Ci 
and HATU 
Preparation of mother solutions 
The following solutions were prepared: 
Amines: 
tert-butyl aniline: 207 tL (1.3 mmol) in 13 mL CH 3CN (0.1 mmol/mL) 
benzylamine: 143 .tL(1.3 mn -iol) in 13 mL CH3CN (0.1 mmol/mL) 
1 ,2,3,4-Tetrahydro-naphthalen- 1 -ylamine: 137 tL (1.3 mmol) 
in 13 mL CH3CN (0.1 mmollmL) 
morpholine: 114 j.iL (1.3 mmol) in 13 mL CH3CN (0.1 mmol/mL) 
Acids: 
Z-Ala-OH: 469 mg (2.1 mmol) in 21 ml, CH3CN (0.1 mmol/mL) 
phenyl acetic acid: 285 mg (2.1 mmol) in 21 mL CH3CN (0.1 mmol/mL) 
benzoic acid: 257 mg (2.1 mrnol) in 21 mL CH3CN (0.1 mmol/mL) 
Coupling reagents: 
IIDO: 485 mg (1.6 mmol) in 16 mL CH3CN (0.1 mmol/mL) 
PyAOP: 836 mg (1.6 mmol) in 16 mL CH3CN (0.1 mmol/mL) 
BOP-Ci: 407 mg (1.6 mmol) in 16 mL CH3CN (0.1 mmol/mL) 
HATU: 608 mg (1.6 mmol) in 16 mL CH3CN (0.1 mmol/mL) 
Procedure 
In each vial, a solution of an amine (1 mL, 0.1 mmol, 1 equiv.) and of a carboxylic 
acid (1 mL, 0.1 mmol, 1 equiv.) were added, followed by the addition of a coupling 
reagent (1 mL, 0.1 mmol, 1 equiv.). The 48 vials were shaken at room temperature 
for 16h. The contents of the vials were then filtered through a SPE cartridge 
containing a mixed bed of MP acidic/basic ion-exchange resins (Polymer Lab, 











The named compound was obtained as a pale orange solid (33 mg, 93%). 
HPLC (method C): tR = 10.96 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC13): 8.37 (br s, 1H, Ar-NH), 7.43-7.28 (m, 9 H, Ar-H), 
5.61 (hr d, J = 7.5 Hz, 111, CH-NH), 5.12 (AB-d, J = 12.25 Hz, 211, 0-CH 2), 4.49-
4.38 (m, 111, CH), 1.45 (d, J = 7.2 Hz, 3H, CH3), 1.29 (s, 911, C(CH 3 )3 ). 
13  NMR (75 MHz, CDC13): 170.49 (C=0), 156.38 (C=O), 147.44 (C-Ar), 136.03 
(C-Ar), 135.00 (C-Ar), 128.58 (CH-Ar), 128.26 (CH-Ar), 128.02 (CH-Ar), 126.14 
(CH-Ar), 125.74 (CH-Ar), 119.81 (CH-Ar), 67.25 (CH 2), 51.25 (CH), 34.36 
(C(CH3)3), 31.35 (C(CH3)3), 18.29 (CH3). 
m/z (ESMS): 355 [M+H]. 
FTIR (neat): 3294 (w), 3264 (w), 1689 (s), 1661 (s). 
Mp: 85-88°C (methanol) 
HRMS (ES): caic. for C 21 1126N203: 355.2016 [M+H]Found: 355.2016. 




((S)-1-Benzylcarbamoyl-ethyl)-carbamic acid benzyl ester (2.159) 
The named compound was obtained as a white solid (27 mg, 86%). 
HPLC (method C): tR = 9.77 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 7.38-7.21 (m, 10H, Ar-H), 6.61 (br s, 111, NH), 5.46 
(br d, J = 7.2 Hz, 1H, NH), 5.03 (AB-d, J = 12.5 Hz, 211, O-CH2), 4.40 (dd, J = 2.2 
Hz, 5Hz, 2H, NH-CH2), 4.35-4.22 (m, 1H, CH), 1.39 (d, J= 7.0 Hz, 311, CH3). 
13  NMR (75 MHz, CDC13): 172.44 (C=O), 156.08 (C=O), 137.99 (C-Ar), 136.15 
(C-Ar), 128.68 (CH-Ar), 128.54 (CH-Ar), 128.20 (CH-Ar), 127.99 (CH-Ar), 127.59 
(CH-Ar), 127.47 (CH-Ar), 66.97 (OCH2), 50.62 (CH), 43.45 (NHCH2), 18.81 (CH 3). 
FTIR (neat): 3297 (w), 3279 (m), 1684 (s), 1640 (s). 
Mp: 129-131°C (methanol) 
HRMS (ES): calc. for C 18H20N203: 313.1547 [M+H]Found: 313.1547. 




[(S)-1-(1,2,3,4-Tetrahydro-naphthalen-1-ylcarbamoyl)-ethyll -carbanuc acid 
benzyl ester (2.160) 
0 
L I,-  ONH H 
0 
The named compound was obtained as a white solid (25 mg, 7 1%). 
HPLC (method C): tR = 10.55 mm. 
Purity (ELSD): 100% 
'H NMIR (300 MHz, CDC13): 7.27-6.97 (m, 10H, Ar-H), 6.37 (br s, 1H, NH), 5.40 
(br s, 1H, NH), 5.04 (m, 1H, NHCHnaphtyl), 4.91 (s, 2H, OCH2), 4.17 (m, 1 H, CH*), 
2.67 (m, 2H, Ar-CR2 naphtyl), 1.93 (m, 1H, CHnaphtyl), 1.71 (m, 3H, CHnaphtyl), 1.32 
(dd, J = 6.9 Hz, 3.3Hz, 3H, CH3). 
13C NMR (75 MHz, CDC13): 171.55 (CO), 155.90 (C=0), 137.55 (C-Ar), 136.37 
(C-Ar), 136.15 (C-Ar), 129.19 (CH-Ar), 128.52 (CH-Ar), 128.44 (CH-Ar), 128.19 
(CH-Ar), 128.04 (CH-Ar), 127.35 (CH-Ar), 127.31 (CH-Ar), 126.30 (CH-Ar), 66.95 
(OCH2), 50.72 (CH naphiyl), 47.59 (CH*), 30.14 (CR2), 29.20 (CH2), 20.03 (CH2), 
18.98 (CH3). 
FTIR (neat): 3289 (m), 1687 (s), 1639 (s). 
Mp:130-132°C (methanol) 
HRMS (ES): calc. for C 21 H24N203 : 353.1865 [M+H]Found: 353.1862 
[a1D 23 = -9.2 
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((S)- 1-Methyl-2-morpholin-4-yl-2-oxo-ethyl)-carbamic acid benzyl ester (2.161) 
JoyNH Lo 
The named compound was obtained as a white solid (20 mg, 69%). 
HPLC (method C): tR = 8.72 mm. 
Purity (ELSD): 100% 
'H N1VIR (300 MHz, CDC13): 7.34-7.29 (m, 5H, Ar-H), 5.83 (d, J = 6.9 Hz, 1H, 
NH), 5.09 (s, 2H, Ar-CH 2), 4.64 (quint., J = 6.0 Hz, 1H, CH), 3.73-3.43 (m, 8H, CH2 
morpholine), 1.32 (d, J = 6.9 Hz, 3H, CH3). 
13C NMR (75 MHz, CDC13): 170.94 (C=O), 155.56 (C=O), 136.40 (C-Ar), 128.51 
(CH-Ar), 128.11 (CH-Ar), 128.00 (CH-Ar), 66.77 (OCH 2 morpholine), 66.51 
(OCH2Ph), 46.53 (CH), 45.92 (N-CH2), 19.23 (CH3). 
FTIR (neat): 3307 (w), 3289 (w), 1711 (s), 1638 (s). 
Mp: 134-136°C (ethanol) 





2-Phenyl-N-(1,2,3,4-tetrahydro-naphthalen- 1-yl)-acetamide (2.162) 
0 Y"Y",  
The named compound was obtained as a white solid (16 mg, 59%). 
HPLC (method C): tR = 10.36 mm. 
Purity (ELSD): 100% 
1H NMR (400 MHz, CDC13): 7.33-7.04 (m, 9H, Ar-H), 5.63 (br s, 1H, NH), 5.20-
5.15 (m, 1H, NHCHnaphtyl), 3.62 (s, 2H, Ar-CH2-CO), 2.74-2.72 (m, 2H, Ar-CH2 
naphtyl), 2.07-2.00 (m, 1H, CHnaphtyl), 1.82-1.63 (m, 3H, CHnaphtyl). 
"C NMR (75 MHz, CDC13): 170.35 (C=O), 137.54 (C-Ar), 136.59 (C-Ar), 134.91 
(C-Ar), 129.33 (CH-Ar), 129.13 (CH-Ar), 129.01 '(CH-Ar), 128.21 (CH-Ar), 127.33 
(CH-Ar), 127.20 (CH-Ar), 126.22 (CH-Ar), 47.71 (CH), 44.03 (Ph-CH 2), 30.21 
(CH2), 29.18 (CH2), 20.15 (CH2). 
m/z (ESMS): 266 [M+H] (43%), 288 [M+Na] (100%). 
FTIR (neat): 3264 (m), 1631 (s). 
Mp: 124-125°C (methanol). 





N-(1,2,3,4-Tetrahydro-naphthalen- 1-yl)-benzamide (2.163) 
The named compound was obtained as a white solid (18 mg, 67%). 
HPLC (method C): tR = 10.33 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 7.71-7.68 (m, 2H, OC-C-CH), 7.43-7.03 (m, 7H, Ar-
H), 6.30 (br s, 1H), 5.32 (m, 1H, NIHCH naphtyl),  2.74 (m, 2H, Ar-CH2 naphtyl),  2.06 (m, 
1H, CHnaphtyl), 1.91-1.77 (m, 3H, CHnaphtyl). 
13C NTvER (75 MHz, CDC13): 166.70 (C=O), 137.74 (C-Ar), 136.68 (C-Ar), 134.70 
(C-Ar), 131.46 (CH-Ar), 129.27 (CH-Ar), 128.78 (CH-Ar), 128.57 (CH-Ar), 127.39 
(CH-Ar), 126.95 (CH-Ar), 126.37 (CH-Ar), 47.99 (CH), 30.22 (CR 2), 29.30 (CH2), 
20.09 (CR2). 
FTIR (neat): 3301 (m), 1632 (s). 
Mp: 122-125°C (ethanol). 
HRMS (ES): caic. for C 17R17N0: 274.1202 [M+H] Found: 274.1206. 
Chapter V 	 142 
5.3. Experimental for Chapter III 
6-benzyloxyquinoline (3.6) 
6-hydroxyquinoline (5 g, 1 equiv., 34.4 mmol) was dissolved in DMF (30 mL). 
K2CO3 (23.8 g, 5 equiv., 172 mmol) was introduced and the reaction mixture was 
stirred for 1 h. Benzyl chloride (4 mL, 1 equiv., 34.4 mmol) was added and the 
mixture was stirred at 80°C for 24 h. DMF was evaporated under reduced pressure 
yielding a dark brown solid. This solid was suspended in water (150 mL) and DCM 
(250 mL) and the insoluble impurities were filtered off. The water phase was 
extracted three times with DCM (50 mL). The combined organic phases were 
washed with brine (100 mL), dried over Na 2SO4 and evaporated in vacuo. The brown 
solid obtained was extracted with petroleum ether at 50°C. Evaporation of petroleum 
ether yielded 6-benzyloxyquinoline as a pale yellow powder (3.78 g, 47%). 
HPLC (method B): tR = 7.05 mm. 
Purity (ELSD): 98% 
'H NMR (400 MHz, CDC1 3): 8.79 (dd, 1 H, J = 4.4 Hz and 1.5 Hz, N-CH), 8.05 
(dd, 1H, J = 8.1 Hz and 1.5 Hz, N-CH-CH-CH), 8.04 (d, 1H, J = 8.8 Hz, N-C-CH), 
7.52-7.34 (m, 7H, Ar-H), 7.17 (d, 1H, J = 2.9 Hz, 0-C-CH-C), 5.20 (s, 2H, OCH 2). 
13C NMR (100 MHz, CDC13): 157.3 (0-C-Ar), 148.5 (N-CH-Ar), 144.9 (C-Ar), 
136.9 (C-Ar), 135.3 (CH-Ar), 131.4 (CH-Ar), 129.7 (CH-Ar), 129.1 (C-Ar), 128.6 
(CH-Ar), 127.9 (CH-Ar), 123.0 (CH-Ar), 121.8 (CH-Ar), 107.0 (CH-Ar), 70.7 
(OCH2). 
m/z (ElMS): 235.13 [M] (100%). 
FTIR (neat): 1618 (m), 1225 (m), 1019 (m). 
Mp: 66-68°C (ethanol). 





Polymer-Supported Quinoline (3.8) 
C  I ::::r 
oO 
N) 
Merrifield resin (25 g, Polymer Lab, 3.99 mmollg, 99.8 mmol, 1 equiv.) was swollen 
in DMA (250 mL). K2CO3, (69 g, 499 mmol, 5 equiv), 6-hydroxyquinoline (36.2 g, 
249 mmol, 2.5 equiv.) and a catalytic amount of KI were added and the reaction 
mixture was heated at reflux under mechanical agitation for 6h. The resin was 
filtered and washed successively with TITF/H20 (1:1, 3 x 250 mL), THF (3 x 250 
mL), DCM (3 x 250 mL), MeOH (3 x 250 mL), DCM (3 x 250 mL), MeOH (3 x 250 
mL), Et20 (3 x 250 mL). 
1H MAS-NMR + 1H-'H COSY (400 MHz, CDC1 3): 8.75 (N-CH), 8.05-7.96 (N-
CH-CH-CH and N-C-CH), 5.04 (OCH 2). 
FTIR (neat): 1622 (w), 1223 (m), 1016 cm' (w) 
Loading of Polymer-supported Quinoline: determined by Nitrogen Elemental 




Polymer-supported IIDQ (3.10) 
r.X::r 
PS-Quinoline (20 g, 2.74 mmollg, 54.8 mmol, 1 equiv.) was swollen in dry DCM 
(200 mL). DIPEA (27 mL, 164 mmol, 3 equiv.) was added and the mixture was 
mechanically stirred and cooled to 0°C. Isobutyl chioroformate (21.4 mL, 164 mmol, 
3 equiv.) was added dropwise to the reaction mixture. After 3 h., isobutanol (lOOmL) 
was added, the mixture allowed to warm up to room temperature and stirred 
mechanically for 16h. The resin was then filtered and washed successively with 3 
cycles of DCM, DCM/Et 20, Et20 (200 mL each). 
'H MAS-NMR (400 MHz, CDCI 3): 7.80 (N-C-CH), 6.22 (N-CH-CH), 4.80 (OCH 2-
PS), 4.00 (CO 2CH2), 3.32 (OCH2CH), 1.97 (CO 2CH2CH(CH3)2), 1.74 
(OCH2CH(CH3)2), 0.95 (CO 2CH2CH(CH3)2), 0.83 (OCH 2CH(CH3) 2). 
FTIR (neat): 1709 (s), 1265 (s), 1018 (m). 
Determination of IIDQ loading: 
Phenylacetic acid (765 mg, 5.62 mmol, 3 equiv.) and benzylamine (614. IL, 5.62 
mmol, 3 equiv.) were dissolved in DCM (5 mL). PS-IIIDQ (maximum loading 1.87 
mmol/g, 1.0 g, 1.87 mmol, 1 equiv.) was added and the reaction mixture was shaken 
at room temperature for 16 h. The resin was removed by filtration and washed with 
DCMIIVIeOH (3 cycles of 5 mL). The filtrates were combined and concentrated in 
vacuo. The residue was taken up in EtOAc (50 mL), washed with IN HCl (3 x 20 
mL), IN NaHCO 3 (3 x 20 mL), brine (1 x 20 mL), dried over MgSO 4 and 
concentrated in vacuo to give 2-phenyl-benzylacetamide as a white powder (370 mg, 
90%). The yield of the reaction was related to the loading of the resin (Loading = 
Yield x Therotical Loading = 0.88 x 1.87 = 1.68 mmol/g) 
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General Procedure for using PS-IIDQ as coupling reagent 
To a solution of amine (1 equiv.) and carboxylic acid (1 equiv.) in CH 3CN was added 
PS-IIDQ (2 equiv.). The reaction mixture was shaken at room temperature for 24h. 
The resin was then filtered off and washed with DCMIMeOH (3 cycles). The filtrates 
were concentrated in vacuo and the unreacted amine/carboxylic acid were removed 
either by an aqueous workup (EtOAc, iN HCI, iN NaHCO 3) or by using SPE 
cartridges containing a mixed bed of acidic/basic MP ion-exchange resin (Polymer 
Lab, 500 mg). 
[1-(4-tert-Butyl-phenylcarbamoyl)-1-methyl-ethyl] carbamic acid tert-butyl ester 
(3.13) 
0_'(N Ne' 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (62 mg, 69%). 
HPLC (method A): tR = 9.13 mm. 
Purity (ELSD): 100% 
'H NMR (250 MHz, CDC13): 7.47-7.30 (m, 411, Ar-H), 4.93 (br s, 1H, NH), 1.55 
(s, 6 H, C(CH3 )2), 1.44 (s, 914, Ar-C(CH 3 )3), 1.30 (s, 9H, OC(CH 3)3). 
13  NMR (62.5 MHz, CDC13): 172.55 (C=O), 155.27 (C=O), 146.93 (C-Ar), 135.54 
(C-Ar), 125.72 (CH-Ar), 119.53 (CH-Ar), 80.27 (OC(CH3)3), (57.64 (NH-C(CH 3 )2), 
34.32 (Ar-C(CH3)3), 31.35 (Ar-C(CH3)3), 28.25 (OC(CH3)3), 25.73 (C(CH 3 ) 2). 
FTIR (neat): 3315 (m), 1686 (s), 1596 (m). 
Mp: 148-151°C (methanol) 




(1-Benzylcarbamoyl- 1-methyl-ethyl)-carbamic acid tert-butyl ester (3.14) 
X0 N N 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (52 mg, 66%). 
HPLC (method B): tR = 7.47mm. 
Purity (ELSD): 99% 
'H NMR (300 MHz, CDCI3): 7.26-7.17 (m, 511, Ar-H), 6.70 (br s, 1H, NH), 4.86 
(br s, 1H), 4.37 (d, J = 5.4 Hz, 1H, CH2), 1.44 (s, 6H, C(CH 3 )2), 1.33 (s, 9H, 
C(CH3)3). 
13  NMR (75 MHz, CDC13): 174.49 (C=O), 154.73 (C=O), 138.40 (C-Ar), 128.60 
(CH-Ar), 127.65 (CH-Ar), 127.33 (CH-Ar), 80.27 (OC(CH3 )3), 56.87(C(CH3 )2), 
43.72 (CH2), 28.26 (OC(CH3 )3), 25.80(C(CH3 )2). 
FTIR (neat): 3350 (m), 3292 (m), 1682 (s),.1654 (s). 
Mp: 135-138°C (methanol) 




(R)-(2-tert-Butoxycarbonylamino-2-methyl propionylamino)-phenyl-acetic acid 
methyl ester (3.15) 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (60 mg, 64%). 
IIPLC (method A): tR = 8.02 mm. 
Purity (ELSD): 100% 
'H NMR (300 MHz, CDC13): 7.43 (br s, 1H, NH), 7.32-7.22 (m, 5H, Ar-H), 5.47 (d, 
J = 7.2 Hz, 1H, CH), 4.85 (br s, 114, NH), 3.64 (s, 3H, CH3), 1.42 (d, J = 6.0 Hz, 6H, 
C(CH3 ) 2), 1.33 (s, 9H, C(CH3 )3). 
13C NMR (75 MHz, CDC13): 173.99 (C=O), 171.30 (C=O), 154.68 (C=O), 136.61 
(C-Ar), 128.86 (CH-Ar), 128.37 (CH-Ar), 127.20 (CH-Ar), 80.32 (OC(CH3 ) 3), 56.78 
(C(CH3 )2), 56.55 (CH), 52.66 (OCH 3), 28.20 (OC(CH3) 3), 25.34 (C(CH3 )2). 
FTIR (neat): 3320 (m), 1748 (m), 1684 (s), 1657 (s). 
Mp: 104-108°C (methanol) 
HRMS (ES): caic. for C 18H26N205 : 351.1915 [M+H] Found: 351.1918. 




(S)-Phenyl-phenylacetylamino-acetic acid methyl ester (3.17) 
HI 0 
The named compound was prepared according to the general procedure of coupling 
with PS-IIIDQ and obtained as a white solid (46 mg, 61%). 
HPLC (method B): tR = 6.50 mm. 
Purity (ELSD): 100% 
'H NMR (300 MHz, CDCI3): 7.31-7.15 (m, 1OH, Ar-H), 6.41 (d, J = 6.3 Hz, 1H, 
NH), 5.48 (d, J = 7.2 Hz, 1H, CH), 3.60 (s, 3H, CH3), 3.53 (s, 2H, CH2). 
13C NMR (75 MHz, CDC13): 170.21 (C=O), 169.24 (C=O), 135.35 (C-Ar), 133.42 
(C-Ar), 128.35 (CH-Ar), 127.96 (CH-Ar), 127.90 (CH-Ar), 127.48 (CH-Ar), 126.40 
(CH-Ar), 126.10 (CH-Ar), 55.42 (CH), 51.74 (OCH 3), 42.41 (CH2). 
FTIR (neat): 3303 (m), 1740 (s), 1647 (s). 
Mp: 96-98°C (methanol) 
HRMS: caic. for C 17H17NO3 : 284.1281 [M+H] Found: 284.1283. 




(S)-Benzoylamino-phenyl-acetic acid methyl ester 370  (3.20) 
oy 
JH Q 
The named compound was prepared according to the general procedure of coupling 
with PS-JIDQ and obtained as a white solid (54 mg, 75%). 
HPLC (method C): tR = 9.38 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC13): 7.85-7.80 (m, 2H, OC-C-CH), 7.55-7.30 (m, 8H, Ar-
H), 7.19 (br d, J= 6.3 Hz, 111, NH), 5.78 (d, J= 7.2 Hz, 1H, CH), 3.77 (s, 3H, CH 3 ). 
mlz (ESMS): 270 [M+H] (27%),292 [M+Na] (100%). 
Amino-isobutyric acid methyl ester hydrochloride 371  (3.21) 
H2N 0- 
.HCI 
To a solution of Aminoisobutyric acid (5 g, 48.5 mmol, 1 equiv.) in MeOH (50 mL) 
was added dropwise at 0°C thionyl chloride (5.5 mL, 242 mmol, 5 equiv.). After 
completion of the addition, the solution was allowed to warm up to room temperature 
and stirred for 5h. The volatiles were then evaporated in vacuo. The residue was 
taken up in MeOH and crystallised upon addition of Et 20. The solid was filtered off, 
washed with Et20 and dried in vacuo to afford the named compound as white 
crystals (6.46g. 87%). 
NI1VER (300 MHz, CDC13): 8.70 (br s, 1H, N112), 3.76 (s, 3H, CH3), 1.63 (s, 6H, 
C(CH3 ) 2) 




(1,1-Dimethyl-2-morpholin-4-yl-2-oxo-ethyl)-carbamic acid benzyl ester (3.22) 
H O 
0 00 
The named compound was prepared according to the general procedure of coupling 
with PS-IIIDQ and obtained as a white solid (40 mg, 44%). 
HPLC (method B): tR = 7.91 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC13): 7.36-7.30 (m, 5H, Ar-H), 5.49 (br s, 1H, NH), 5.06 (s, 
2H, Ar-CH2), 3.64-3.42 (m, 8H, CH2 morpholine), 1.52 (s, 6H, C(CH3 )2). 
13C NMR (62.5 MHz, CDCI3): 171.17 (C=O), 154.18 (C=O), 136.20 (C-Ar), 128.47 
(CH-Ar), 128.35 (CH-Ar), 128.27 (CH-Ar), 66.53 (CH20CH2 , Ar-CH2-0), 56.76 
(C(CH3 )2), 45.59 (N-CH), 25.98 (C(CH 3 )2) 
FTIR (neat): 3306 (w), 3265 (m), 1714 (s), 1605 (s) 
Mp: 135-141°C (methanol) 
HR1VIS (ES): caic. for C 15H22N204: 307.1652 [M-i-H] Found: 307.1650. 
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[1-(Cyclohexylmethyl-carbamoyl)-1-methyl-ethyl]-carbamic acid benzyl ester 
(3.23) 
OLO7çILwXD 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (5 8mg ,61 
HPLC (method C): tR = 10.32 mm. 
Purity (ELSD): 100% 
'H N1\'IR (400 MHz, CDC13): 7.27 (m, 511, Ar-H), 6.03 (s, 114, NH), 5.26 (s, 1H, 
NH), 5.01 (s, 2H, Ar-CH2), 3.64 (m, 1H, CH), 1.74-0.99 (m, 10H, CH2 cHex), 1.43 
(s, 6H C(CH3)2). 
' 3C NMR (100 MHz, CDCI3): 172.64 (C=O), 154.47 (C=O), 135.74 (C-Ar), 127.93 
(CH-Ar), 127.58 (CH-Ar), 127.52 (CH-Ar), 66.08 (OCH 2), 56.28 (C(CH3)2), 47.65 
(CH), 32.19 (CH2), 24.94 (C(CH3)2), 24.46 (CH2), 24.08 (CH2). 
m/z (ESMS): 319 [M+H] (30%),341 [M+Na] (100%). 
FTIR (neat): 3341 (w), 3296 (m), 1699 (s), 1649 (s). 
Mp: 121-122°C (methanol). 






acid methyl ester 372  (3.25) 
H 
OyNNO 
0 	 0 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (67 mg, 67%). 
HPLC (method C): tR = 9.35 mm. 
Purity (ELSD): 100% 
'H NMR (300 MHz, CDCI 3): 7.27-7.23 (m, 5H, Ar-H), 6.83 (br s, 1H, NH), 5.26 
(br s, 1H, NH), 5.03 (s, 2H, CH2), 3.64 (s, 3H, OCH3), 1.44 (s, 12H, C(CH 3 ) 2). 
m/z (ESMS): 337 [M+H]+ (20%), 359 [M+Na] (100%). 
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[1-Methyl- 1-(1,2,3,4-tetrahydro-naphthalen- 1-ylcarbamoyl)-ethyll-carbamic 
acid benzyl ester (3.26) 
OLaf 0 
The named compound was prepared according to the general procedure of coupling 
with PS-II1DQ and obtained as a white solid (81 mg, 74%). 
HPLC (method C): tR = 10.63 mm. 
Purity (ELSD): 100% 
'H NMR (300 MHz, CDC13): 7.32-7.08 (m, 9H, Ar-H), 6.40 (br d, J = 7.8 Hz, 1H, 
NH-CH), 5.34 (br s, 1H, NH), 5.14-5.09 (m, 1H, NHCH naphlyl), 5.07 (s, 2H, 
OCH2), 2.84-2.68 (m, 2H, Ar-CH 2  naphtyl),  2.02-1.99 (m, 111, CHnaphtyl), 1.804.69 (m, 
311, CHnaphtyl), 1.55 (s, 6H, C(CH02). 
13  NMR (75 MHz, CDC13): 173.48 (C=O), 154.90 (C=O), 137.65 (C-Ar), 136.67 
(C-Ar), 136.19 (C-Ar), 129.14 (CH-Ar), 128.55 (CH-Ar), 128.20 (CH-Ar), 128.13 
(CH-Ar), 127.22 (CH-Ar), 126.28 (CH-Ar), 66.76 (OCH 2), 56.67 (C(CH3)2), 47:71 
(CH), 30.04 (CH 2), 29.28 (CH2), 25.57 (C(C113)2), 20.08 (CH2). 
FTIR (neat): 3351 (w), 3286 (m), 1694 (s), 1645 (s). 
Mp: 119-121°C (ethanol). 
HRMS (ES): caic. for C 22H26N203 : 376.2016 [M+H] Found: 376.2018. 
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(S)- 1(2Benzy1oxycarbony1amino-2-methy1-propiony1)-pyrro1idine-2-CarbOXYIiC 
acid benzyl ester (3•27)t 
O ON Q 
N 
o 	LI 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and separated from the carbamate by-product by column 
chromatography (Hexane/EtOAc 6:4) and was obtained as a colourless oil (4 mg, 
3%). 
HPLC (method B): tR = 6.32 mm. 
Purity (ELSD): 100 % 
FTIR (neat): 3277 (m), 1739 (s), 1702 (s), 1621 (s). 
HRMS (ES): caic. for C 21 H30N205: 391.2228 [M+H]Found: 391.2231 
In the case of amides derived from proline, the presence of rotamers 373 made the NMR spectra 






0 Yo Lo 
The named compound was prepared according to the general procedure of coupling 
with PS-ITDQ and obtained as a white solid (29 mg, 44%). 
HPLC (method C): tR = 9.96 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 7.27-7.16 (m, 5H, Ar-H), 5.22 (hr s, 11-1, NH), 3.73-
3.63 (m, 1H, CH), 3.46 (s, 2H, Ar-CH2), 1.79-0.88 (m, 1OH, CH2 cHex). 
13C NMR (75 MHz, CDC13): 169.98 (C=O), 135.21 (C-Ar), 129.34 (CH-Ar), 
128.94 (CH-Ar), 127.22 (CH-Ar), 48.16 (Ph-CH 2), 44.01 (CH), 32.89 (CH 2), 25.46 
(CH2), 24.68 (CH2). 
FTIR (neat): 3267 (m), 1665 (s). 
Mp: 125-127°C (methanol) 
HRMS (ES): calc. for C 14H19N0: 218.1540 [M+H] Found: 218.1540. 
2-methyl-2-phenylacetylamino-propionic acid methyl ester 374  (3.29) 
YO 
The named compound was prepared according to the general procedure of coupling 
with PS-IIIDQ and obtained as a white solid (51 mg, 73%). 
HPLC (method C): tR = 8.66 mm. 
Purity (ELSD): 100% 
NPVIR (300 MHz, CDC13): 7.31-7.19 (m, 5H, Ar-H), 5.93 (hr s, 1H, NH), 3.64 (s, 
311, OCH3), 3.47 (s, 2H, CH2), 1.42 (6H, C(CH3 )2). 
m/z (ESMS): 236 [M+H] (33%),258 [M+Na] (!00%). 
Chapter V 	 156 
(S)-1-Phenylacetyl-pyrrolidine-2-carboxylic acid benzyl ester (3.32) 
011A OiN 
L 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and separated from the carbamate by-product by column 
chromatography (Hexane/EtOAc 6:4) and was obtained as a colourless oil (52 mg, 
60%). 
HPLC (method A): tR = 8.19 mm. 
Purity (ELSD): 100% 
FTIR (neat): 1740 (s), 1642 (s). 
HRMS (ES): caic. for C 20H21 NO3 : 324.1594 [M+H] Found: 324.1592. 
N-Cyclohexylmethyl-benzamide375 (3.34) 
0 OA"O  
H 
The named compound was prepared according to the general procedure of coupling 
with PS-IIIDQ and obtained as a white solid (51 mg, 84%). 
HPLC (method C): tR = 9.77 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 7.77-7.75 (m, 211, OC-C-CH), 7.5 1-7.39 (m, 3H, OC-
C-CH-CH-CH), 6.09 (br s, 1H, NH), 4.05-3.92 (m, 1H, NHCH), 2.06-2.01 (m, 2H, 
CHnaphtyl), 1.80-1.59 (m, 311, CHnaphtyl), 1.51-1.34 (m, 2H, CHnaph tyl), 1.32-1.14 (m, 
311, CHnaphtyl). 




2-Benzoylamino-2-methyl-propionic acid methyl ester (3.35) 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (60 mg, 91%). 
HPLC (method C): tR = 8.35 mm. 
Purity (ELSD): 100% 
'H NMR (400 MHz, CDCI3): 7.70 (d, J = 6.8 Hz, 2H, OC-C-CH), 7.42-7.33 (m, 
3H, OC-C-CH-CH-CH), 6.74 (hr s, 1H, NH), 3.71 (s, 3H, OCH 3), 1.46 (s, 6H, 
C(CH3)2). 
'3C NMR (100 MHz, CDCI3): 176.81 (C=O), 168.12 (C=O), 136.05 (C-Ar), 133.05 
(CH-Ar), 130.04 (CH-Ar), 128.46 (CH-Ar), 58.44 (C(CH 3 )2), 54.26 (OCH3), 26.26 
(C(CH3)2). 
FTIR (neat): 3223 (m), 1732 (s), 1627 (s). 
Mp: 116-119°C (ethanol). 
HRMS (ES): caic. for C 12H15NO3: 244.0944 [M+Na]' Found: 244.0943. 
(S)-1-Benzoyl-pyrrolidine-2-carboxylic acid benzyl ester (3.38) 
)LJ 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and separated from the carbamate by-product by column 
chromatography (Hexane/lEtOAc 6:4) and was obtained as a colourless oil (26 mg, 
34%). 
HPLC (method A): tR = 7.88 mm. 
Purity (ELSD): 100% 
FTIR (neat): 1740 (s), 1629 (s). 









The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (69 mg, 71 
HPLC (method C): tR = 10.20 mm. 
Purity (ELSD): 100% 
111 NMR (300 MHz, CDCI3): 7.26 (m, 5H, Ar-H), 5.96 (br s, 1H, NH), 5.39 (br s, 
1H, NH), 5.03 (s, 2H, Ar-CH2), 4.10 (m, 1H, CH*),  3.64 (m, 1H, CH cHex), 1.86-
0.97 (m, 10H, CH2 cHex), 1.26 (d, J= 7.2 Hz,3H, CH3 ). 
13  NMR (75 MHz, CDC13): 171.23 (C=O), 155.97 (C=O), 136.25 (C-Ar), 128.53 
(CH-Ar), 128.18 (CH-Ar), 128.01 (CH-Ar), 66.95 (OCH2), 50.65 (CH*),  48.26 (CH 
cHex), 32.88 (CH2), 25.47 (CH2), 24.73 (CH 2), 18.79 (CH 3). 
FTIR (neat): 3277 (m), 1688 (s), 1642 (s). 
Mp: 153-156°C (methanol) 
HRMS (ES): caic. for C 17H24N203 : 327.1679 [M+H] Found: 327.1677. 









The named compound was prepared according to the general procedure of coupling 
with PS-1TDQ and obtained as a white solid (79 mg, 82%). 
HPLC (method C): tR = 9.24 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 7.30-7.21 (m, 5H, Ar-H), 6.65 (br s, 1H, NH), 5.37 
(hr s, 1H, NH), 5.04 (s, 2H, CH2), 4.17-4.13 (m, 1H, CH), 3.64 (s, 3H, OCH 3), 1.44 
(d, J= 2.7 Hz, 6H, C(CH3 )2), 1.29 (d, J= 6.9 Hz, 3H, CH-CH3). 








0 NH HI 0 
The named compound was prepared according to the general procedure of coupling 
with PS-ITDQ and obtained as a white solid (92 mg, 83%). 
HPLC (method C): tR = 9.76 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 7.24 (m, 10H, Ar-H), 7.11 (br s, 1H, NH), 5.46 (d, J= 
7.2 Hz, 1H, CH-Ph), 5.32 (br s, 1H, NH), 4.99 (s, 2H, Ar-CH2), 4.27 (m, 1H, CH-
CH3), 3.63 (s, 3H, OCH3), 1.31 (d, J= 6.9 Hz, 3H, CH-CH3). 
13  N1VIR (75 MHz, CDC13): 171.69 (C=0), 171.05 (C=O), 155.93 (C=0), 136.17 
(C-Ar), 136.11 (C-Ar), 128.99 (CH-Ar), 128.60 (CH-Ar), 128.53 (CH-Ar), 128.17 
(CH-Ar), 128.06 (CH-Ar), 127.21 (CH-Ar), 67.03 (OCH2), 56.49 (CH-Ph), 52.82 
(OCH3), 50.35 (CHCH3), 18.61 (CH3). 
m/z (ESMS): 371 (M+H). 
FTIR (neat): 3301 (m), 1734 (s), 1692 (s), 1650 (s). 
Mp: 121-123'C (methanol). 
HR1VIS (ES): caic. for C20H22N205: 371.1602 [M+H] Found: 371.1601. 




1-Morpholin-4-yl-2-phenoxy-ethanone 377 (3.47) 
Cr 0  
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (53 mg, 80%). 
HPLC (method C): tR = 8.21 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 7.20 (m, 2H, O-C-CH-CH), 6.89 (m, 3H, O-C-CH-
CH-CH), 4.62 (s, 2H, Ar-O-CH 2), 3.57 (m, 8H, CH2 morpholine). 
m/z (ESMS): 222 [M+H] (23%),244 [M+Na] (100%). 
N-Cyclohexylmethyl-2-phenoxy-acetamide (3.48) 
Cr H 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (36 mg, 52%). 
HPLC (method C): tR = 10.36 mm. 
Purity (ELSD): 100% 
'H NVIR (300 MHz, CDC13): 7.26-7.22 (m, 2H, O-C-CH-CH), 6.95 (t, J = 7.5 Hz, 
111, O-C-CH-CH-CH), 6.85 (d, J = 7.8 Hz, 211, O-C-CH), 6.35 (br s, 1H, NH), 4.40 
(s, 2H, Ar-O-CH20.80 (m, 11-1, CH), 1.88-1.04 (4m, 10H, CH 2 cHex). 
13C N1VIIR (75 MHz, CDC13): 167.20 (C=O), 157.26 (C-Ar), 129.77 (CH-Ar), 
122.10 (CH-Ar), 114.74 (CH-Ar), 67.47 (OCR 2), 47.83 (CH), 32.98 (CH2), 25.45 
(CH2), 24.77 (CH2). 
FTIR (neat): 3335 (m), 1647 (s). 
Mp: 75-78°C (methanol) 
HRMS (ES): calc. for C 14H19NO2: 256.1308 [M+Na] 1 Found: 256.1305. 
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2-Methyl-2-(2-phenoxy-acetylainino)-propionic acid methyl ester (3.49) 
Cr 01-AN 
The named compound was prepared according to the general procedure of coupling 
with PS-IIIDQ and obtained as a white solid (53 mg, 70%). 
HPLC (method C): tR = 9.14 mm. 
Purity (ELSD): 100% 
1H N1VIR (300 MHz, CDC13): 7.25 (t, J = 7.5 Hz, 2H, O-C-CH-CI-1), 7.08 (br s, 1.H, 
NH), 6.95 (t, J = 7.5 Hz, 1H, O-C-CH-CH-CH), 6.87 (d, J = 7.8 Hz, 2H, O-C-CH), 
4.37 (s, 2H, CH2), 3.69 (s, 3H, OCH3), 1.53 (s, 6H, C(CH3)2). 
13C NMR (75 MHz, CDC13): 174.70 (C=O), 167.52 (C=O), 157.23 (C-Ar), 129.74 
(CH-Ar), 122.14 (CH-Ar), 114.81 (CH-Ar), 67.53 (OCH2), 56.43 (C(CH3 )2), 52.73 
(OCH3), 24.71 (C(CH3 )2). 
m/z (ESMS): 252 [M+H] (22%),274 [M+Na] (100%). 
FTIR (neat): 3209 (w), 1738 (s), 1649 (s). 
Mp: 61-62°C (methanol). 





2-Phenoxy-N-(1,2,3,4-tetrahydro-naphthalen- 1-yl)-acetamide (3.51) 
Cro HU 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (62 mg, 74%). 
HPLC (method C): tR = 10.76 mm. 
Purity (ELSD): 100% 
1H NMR (400 MHz, CDC13): 7.31 (t, J = 8.8 Hz, 2H, O-C-CH-CI-1), 7.22-7.10 (m, 4 
H, Ar-Hnaphtyl), 7.02 (t, J = 7.2 Hz, 1H, O-C-CH-CH-CH), 6.90 (d, J = 8.0 Hz, 2H, 0-
C-CH), 6.79 (d, J = 7.6 Hz, 1H, NH), 5.32-5.28 (m, 1H, NHCIT/), 4.57 (AB-d, J = 
14.8 Hz, 2H, OCH2), 2.87-2.74 (m, 2H, Ar-CH2 naph,1), 2.14-2.09 (m, 1H, CHnaphty l), 
1.87-1.77 (m, 3H, CH naphtyl). 
13C NMR (75 MHz, CDC13): 167.67 (C=0), 157.17 (C-Ar), 137.64 (C-Ar), 136.21 
(C-Ar), 129.77 (CH-Ar), 129.23 (CH-Ar), 128.42 (CH-Ar), 127.39 (CH-Ar), 126.33 
(CH-Ar), 122.14 (CH-Ar), 114.72 (CH-Ar), 67.43 (OCH 2), 47.25 (CH), 30.28 (CH2), 
29.11 (CH2), 20.15 (CH2). 
m/z (ESMS): 304 [M+Na] (100%) 
FTIR (neat): 3309 (m), 1649 (s). 
Mp: 79-82°C (ethanol). 








The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (70 mg, 83%). 
HPLC (method C): tR = 11.09 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 8.16 (br s, 1H, NH), 7.43-7.39 (m, 2H, HN-C-CH), 
7.30-7.23 (m, 2H, HN-C-CH-CH, 2H, O-C-CH-CH) , 6.99-6.89 (m, 3H, O-C-CH-
CH-CH), 4.51 (s, 2H, CH 2), 1.23 (s, 9H, C(CH 3)3). 
13C NMR (75 MHz, CDCI3): 166.23 (C=O), 157.10 (C-Ar), 147.93 (C-Ar), 134.21 
(C-Ar), 129.91 (CH-Ar), 125.92 (CH-Ar), 122.44 (CH-Ar), 120.02 (CH-Ar), 114.89 
(CH-Ar), 67.69 (OCH2), 34.43 (C(CH3 )3), 31.36 (C(CH3 )3). 
mlz (ESMS): 306 [M+Na](47%), 589 [2M+Na] (100%). 
FTIR (neat): 3264 (w), 1657 (s). 
Mp: 80-82°C (methanol). 






C  0 N HJ 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ and obtained as a white solid (59 mg, 82%). 
HPLC (method C): tR = 9.85 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDC13): 7.26-7.18 (m, 7H, Ar-H), 6.94 (t, J = 7.5 Hz, 1H, 0-
C-CH-CH-CH), 6.82 (d, J = 7.5 Hz, 2H, 0-C-CH), 4.46 (d, J = 5.7 Hz, 211, NIH-
CH2), 4.46 (s, 2H, OCH2). 
m/z (ESMS): 242 [M+H]' (22%),264 [M+Na] (100%). 
(S)-(2-Phenoxy-acetylamino)-phenyl-acetic acid methyl ester 
379  (3.54) 
0  
Cr N H 
The named compound was prepared according to the general procedure of coupling 
with PS-IIIDQ and obtained as a white solid (73 mg, 82%). 
HPLC (method C): tR = 9.94 mm. 
Purity (ELSD): 99% 
1H NIMR (300 lVfflz, CDC1 3): 7.58 (d, J = 6.6 Hz, 1H, NH), 7.37-7.29 (m, 7H, Ar-
H), 7.06-7.01 (m, 1H, O-C-CH-CH-CH), 6.97-6.92 (m, 2H, 0-C-CH), 5.67 (d, J = 
7.5 Hz, 1H, CH) 4.53 (AB-d, J = 15 Hz, 2H, CH2), 3.74 (s, 3H, CH 3 ). 
mlz (ESMS): 300 [M-i-H] (19%),322 {M+Na] (100%). 
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(S)-Pyrrolidine-1,2-dicarboxylic acid 2-benzyl ester 1-isobutyl ester (3.55) 
x~ 0 
Isobutyichioroformate (54 j.tL, 0.41 mmol, 1 equiv.) was added to a mixture of 
praline benzyl ester hydrochloride (100 mg, 0.41 mmol, 1 equiv.) and DIPEA (137 
tL, 0.82 mmol, 2 equiv.) in DCM (10 mL). The mixture was stirred at room 
temperature for 2h. and concentrated in vacuo. The residue was taken up in EtOAc 
(50 mL) and washed with IN NaHCO3 (3 x 25 mL), IN HCl (3 x 25 mL), brine (1 x 
25 mL), dried over MgSO4, filtered, and concentrated in vacuo to give the named 
compound as a pale yellow oil (109 mg, 85%). 
HPLC (method A): tR = 9.02 mm. 
Purity (ELSD): 100% 
1H NMR (400 MHz, 373K, d6-DMSO): 7.38-7.33 (m, 5H, Ar-H), 5.15 (s, 2H, Ar-
CH2), 4.34 (dd, J = 3.5 Hz and 8.5 Hz, 1H, CH*),  3.78 (d, J = 6.4 Hz, 2H, 
OCH2CH), 3.44 (m, 2H, N-CH2), 2.26 (m, 1H, CH(CH3)2), 1.94-1.84 (m, 4H, 
CH*CH2CH2), 0.87 (d, J = 6.75 Hz, 6H, CH(CH3)2). 
13  NMR (100 MHz, 373K, d6-DMSO): 172.01 (C=O), 154.00 (C=O), 135.9 C-
Ar), 128.23 (CH-Ar), 127.84 (CH-Ar), 127.56 (CH-Ar), 70.60 (Ph-CH2), 65.85 
(OCH2CH) , 58.75 (CH*), 46.28 (CH2), 29.80 (CH2), 27.44 (CH(CH3)2), 23.28 
(CH2), 18.56 (CH(CH3)2). 
FTIR (neat): 1745 (m), 1702 (s). 
HRMS (ES): caic. for C 17H23N04: 306.1700 [M+H] Found: 306.1699. 




(S)-1-(3,3-Diphenyl-propionyl)-pyrrolidine-2-carboxylic acid benzyl ester (3.56) 
2 o 2 0115~ ;ON0 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as pale yellow oil (48 mg, 43%). 
HPLC (method A): tR = 9.44 mm. 
Purity (ELSD): 94% 
FTIR (neat): 1740 (s), 1645 (s). 
HRMS (ES): calc. for C 27H27NO3 : 414.1907 [M+H] Found: 414.1905. 
(S)-1-(3-Phenyl-propionyl)-pyrrolidine-2-carboxylic acid benzyl ester  380  (3.57) 
0 O'__0 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (69 mg, 76%). 
HPLC (method A): tR = 8.72 mm. 
Purity (ELSD): 100% 
FTIR (neat): 3222 (w), 1739 (s), 1642 (s). 




(S)-1-(3,3,3-Triphenyl-propionyl)-pyrrolidine-2-carboxylic acid benzyl ester 
(3.58) 
1 O ON)  
a 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (24 mg, 18%). 
HPLC (method B): tR = 8.22 mm. 
Purity (ELSD): 100% 
FTIR (neat): 3218 (w), 1738 (s), 1643 (s). 
HRMS (ES): caic. for C 33H31 NO3 : 490.2377 [M+H] Found: 490.2385. 
(S)-1-Diphenylacetyl-pyrrolidine-2-carboxylic acid benzyl ester (3.59) 
0 
0 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (54 mg, 50 %). 
HPLC (method A): tR = 9.19 mm. 
Purity (ELSD): 100% 
FTIR (neat): 1740 (s), 1645 (s). 





benzyl ester (3.60) 
cLcy oQ 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (44 mg, 43%). 
HPLC (method A): tR = 9.31 mm. 
Purity (ELSD): 96%. 
FTIR (neat): 1740 (s), 1637 (s). 
HRMS: caic. for C 22H22NO3C1: 384.1361 [M+H] Found: 284.1362. 
(S)- 1-(2-Cyclohexyl-acetyl)-pyrrolidine-2-carboxylic acid benzyl ester (3.61) 
01'j 0~_
O,~__O 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (58 mg, 66%). 
IIPLC (method A): tR = 9.26 mm. 
Purity (ELSD): 100% 
FTIR (neat): 1742 (s), 1642 (s). 




(S)-1-(2-Adamantan- 1-yI-acetyl)-pyrrolidine-2-carboxylic acid benzyl ester 
(3.62) 
o 
0 0 j 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether/ EtOAc 6:4), and obtained as a pale yellow oil (49 mg, 48%). 
HPLC (method A): tR = 10.10 mm. 
Purity (ELSD): 100%. 
FTIR (neat): 1742 (s), 1638 (s). 
HRMS: calc. for C 24H31 NO3 : 382.2382 [M+H] Found: 382.2383. 
(S)-1-(3-Phenyl-butyryl)-pyrrolidine-2-carboxylic acid benzyl ester (3.63) 
( J 
The named compound was prepared according to the general procedure of coupling 
with PS-IJDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (54 mg, 57%). 
HPLC (method B): tR = 7.14 mm. 
Purity (ELSD): 100% 
FTIR (neat): 1742 (s), 1644 (s). 




(S)-1-(2-Phenyl-propionyl)-pyrrolidine-2-carboxylic acid benzyl ester (3.64) 
0 N Z _~i Lj 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (32 mg, 35%). 
HPLC (method B): tp. = 7.11 mm. 
Purity (ELSD): 99% 
FTIR (neat): 1742 (s), 1644 (s). 
HRMS (ES): calc. for C 21 H23NO3 : 338.1751 [M+H] Found: 338.1748. 
(S)-1-Cyclohexanecarbonyl-pyrrolidine-2-carboxylic acid benzyl ester  381  (3.65) 
0 CD-11 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (25 mg, 30%). 
HPLC (method A): tR = 8.80 mm. 
Purity (ELSD): 100% 
FTIR (neat): 1741 (s), 1639 (s). 
HRMS (ES): calc. for C 19H25NO3: 316.1907 [M+H] Found: 316.1910. 
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(S)- 1-Cyclopentanecarbonyl-pyrrolidine-2-carboxylic acid benzyl ester (3.66) 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (44 mg, 55%). 
HPLC (method A): tR = 8.42 mm. 
Purity (ELSD): 100% 
FTIR (neat): 1741 (s), 1639 (s). 
HRMS (ES): caic. for C 18H23NO3: 302.1751 [M+H] Found: 302.1746. 
Boc-Pro-Pro-OBn 373 (3.67) 
o el LJ 
The named compound was prepared according to the general procedure of coupling 
with PS-IIDQ, separated from the carbamate by-product by column chromatography 
(Petroleum ether! EtOAc 6:4), and obtained as a pale yellow oil (53 mg, 49%). 
HPLC (method A): tR = 8.46 mm. 
Purity (ELSD): 100% 
FTIR (neat): 3222 (w), 1741 (m), 1693 (s), 1656 (s). 
HRMS (ES): calc. for C 22H30N205 : 403.2228 [M+H] Found: 403.2229. 
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Z-Gly-L-Phe-Val-OMe 372 (3.70) 
b 
To a solution of H-Val-OMe hydrochloride (29 mg, 0.175 mmol, 1 equiv.), DIPEA 
(29 pL, 0.175 mmol, 1 equiv.) and Z-Gly-Phe-OH (60 mg, 0.175 mmol, 1 equiv.) in 
CH3CN (5 mL) was added PS-IIDQ (250 mg, 0.350 mmol, 2 equiv.). The reaction 
mixture was shaken at room temperature for 24h. The resin was then filtered off and 
washed with DCMJMeOH (3 cycles of 5 mL). The filtrates were concentrated in 
vacuo and the unreacted amine/carboxylic acid were by using a SPE cartridge 
containing a mixed bed of acidic/basic MP ion-exchange resin (Polymer Lab, 500 
mg). The named compound was obtained as a pale yellow oil (82 mg, 65%). 
HPLC (method A): tR = 7.12 mm. 
Purity (ELSD): 100% 
1H NMR (300 MHz, CDCI3): 7.33-7.15 (m, 10 H, Ar-H), 6.82 (br s, 1 H, NH), 6.46 
(br s, 1H, NH), 5.48 (br s, 1H, NH), 5.09 (s, 2H, Ph-CH 2-0), 4.74-4.69 (m, 1H, 
CH*phe), 4.40 (dd, J = 8.4 Hz and 5.2 Hz, 1H, CH* vai), 3.83 (m, 2H, NH-CH2), 3.67 
(s, 3H, OCH3), 3.03 (d, J = 4.4 Hz, 2 H, CHCH2Ph), 2.10-2.02 (m, 1H, CH(CH 3)2), 
0.83 (d, J= 6.8 Hz, 3 H, CH3), 0.80 (d, J = 6.8 Hz, 3H, CH3). 





H tN ~y g' 
N 	N 	0111 
The named compound was prepared according in analogy to compound 3.70 and 
obtained as a pale yellow oil (78 mg, 63%). 
HPLC (method A): tR = 7.01 mm. 
Purity (ELSD): 100% 
N1VER (300 MHz, CDC13): 7.32-7.15 (m, 10 H), 6.66 (br s, 1 H, NIH), 6.31 (br s, 
1H, NH), 5.37 (br s, 1H, NH), 5.08 (s, 2H, Ph-CH2-0), 4.70-4.65 (m, 1H, CH*phe), 
4.38 (dd, J = 8.4 Hz and 5.2 Hz, 1H, CH* vai), 3.83 (m, 2H, NH-CH2), 3.66 (s, 3H, 
OCH3), 3.08-2.98 (m, 2 H, CHCH2-Ph), 2.09-2.01 (m, 1H, CH(CH3)2), 0.82 (d, J = 
6.8 Hz, 3 H, CH3), 0.79 (d, J = 6.8 Hz, 3H, CH3). 




5.4. Experimental for Chapter IV 




Chioroacetic acid (90.0 g, 952 mmol, 1 equiv.) was added portionwise at 0°C to 
ethylene diamine (636 mL, 9.52 mol, 10 equiv.). After completion of the addition, 
the reaction mixture was stirred at room temperature for 48h. Ethylene diamine was 
evaporated in vacuo, and DMSO was added to the residue occurring precipitation of 
a white solid. Out of the 85g of the solid obtained, 80 g (0.52 mol, 1 equiv.) was 
suspended in MeOH (1.5 Q. The mixture was cooled to 0°C and thionyl chloride 
(188 mL, 2.58 mol, 5 equiv.) was added dropwise. The mixture was then stirred at 
room temperature for 18h. The solid was filtered off and recrystallised from MeOH 
to afford the named compound as white crystals (74g, 38% over two steps). 
IIPLC (method C): tR = 1.44 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, d6-DMSO): 8.55 (br s, 3H, NH), 4.06 (s, 2H, CH2CO), 3.74 (s, 
3H, Cl3), 3.30-3.20 (m, 4H, CH2-CH2) 







To a solution of dimedone (23 g, 164 mmol, 1 equiv.) in DMF (350 ML) was added 
acetic acid (9.52 mL, 164 mmol, 1 equiv.), DCC (34 g, 164 mmol, 1 equiv.) and 
DMAP (20 g, 164 mmol, 1 equiv.). The reaction mixture was stirred at room 
temperature for 48h. The solution was filtered (elimination of DCU) and 
concentrated in vacuo. The residue was taken up in EtOAc and washed with IN 
KHSO4 (3 x 100 mL), brine (1 x 100 mL), dried over MgSO 4 and concentrated in 
vacuo. The residue was taken up in EtOAc, filtered (elimination of DCU) and 
concentrated in vacuo to afford the named compound as an orange oil (29.9 g, 84%). 
HPLC (method B): tR = 7.13 mm. 
Purity (UV, 254 nm): 91% 
1H NMR (250 MHz, CDC13): 2.59 (s, 3H, CH3), 2.52 (s, 2H, CH2), 2.34 (s, 2H, 
CH2), 1.06 (s, 6H, C(CH3) 2). 








To a stirred solution of 4.20 (10 g, 48.7 mmol, 1 equiv.) and DiPEA (16.1 mL, 97.5 
mmol, 2 equiv.) in DCMJMeOH (1:1, 200 mL) was added portionwise Dde-OH 
(8.88 g, 48.7 mmol, 1 equiv.). The reaction mixture was stirred at room temperature 
for 18h. After evaporation of the solvent in vacuo, the crude was taken up in EtOAc 
(150 mL), and extracted with 1M KHSO4 (3 x 100 mL). The aqueous extracts were 
combined and brought to pH 9 with NaHCO3 and extracted with EtOAc (3 x 100 
mL). The organic phase were combined, washed with brine (1 x 100 mL), dried over 
MgSO4 and concentrated in vacuo to give the named compound as a dark orange oil 
(4.5 g, 31%). 
HPLC (method B): tR = 1.43 mm. 
Purity (ELSD): 100% 
NIVIR (250 MHz, CDC13): 13.48 (br s, 1H, NH-Dde), 171 (s, 3H, UGH3), 3.43-
3.47 (m, 4H, NH(CH2)2), 2.92 (t, J = 6.0 Hz, 2 H, NHCH2CO), 2.54 (s, 3H, CCH3), 
2.33 (s, 4H, CH2-Dde), 1.87 (br s, 1H, NH), 0.99 (s, 6H, C(CH 3)2). 









To a suspension of adenine (25 g, 185 mmol, 1 equiv.) in DMF was added NaH 
(60% dispersion in mineral oil, 8.88 g, 222 mmol, 1.2 equiv.), and the resulting 
mixture was stirred at room temperature for lh. The reaction mixture was then 
cooled to 0°C and methyl-2-bromoacetate (41 mL, 370 mL, 2 equiv.) was added 
dropwise. The mixture was stirred at room temperature for 18h and the solvent was 
removed in vacuo. Water was added to the residue, which resulted in crystallisation 
of a solid. The solid was filtered off and recrystallised from EtOH to give the named 
compound as white crystals (16.85 g, 41%). 
HPLC (method C): tR = 4.99 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, d6-DMSO): 8.14 (s, 1H, CH), 8.12 (s, 1H, CH), 7.32 (s, 211, 
NH2), 5.09 (s, 2H, C112), 3.70 (s, 3H, OCH3 ). 
nz/z (ESMS): 222 [M+H] (100%) 
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To a stirred suspension of 4.24 (5 g, 22.6 mmol, 1 equiv.) in DCIvI/ Pyridine (1:1, 
200 mL) was added N-ethylmorpholine (2.87 mL, 22.6 mmol, 1 equiv.) and 4-
monomethoxytrityl-chioride (10.5 g, 33.9 mmol, 1.5 equiv.). The mixture was heated 
to 40°C and stirred for 18h. After evaporation of the solvents in vacuo, the residue 
was taken up in EtOAc (150 mL), washed with IN aq. KHSO4 (3 x 50 mL), 1M aq. 
NaHCO3 (3 x 50 mL), brine (1 x 50 mL), and dried over MgSO 4. The solvent was 
removed in vacuo and the residue was purified by chromatography (EtOAc) to give a 
buff coloured solid. 
The previous solid was suspended in IN aqueous NaOH (100 mL) and the mixture 
was stirred at reflux for 2h. The solution was then cooled to 0°C. IN aq. KHSO4 (120 
mL) was added and the mixture was stirred at 0°C for 30 mm. The resulting 
precipitate was collected by filtration and washed with water. The brown solid 
obtained was taken up in DCM and the insoluble particles were filtered off. Et 20 was 
added to the solution and the resulting precipitate was collected, affording the named 
compound as a buff coloured solid (9.21 g, 87% over 2 steps). 
HPLC (method B): tR = 8.52 mm. 
Purity (ELSD): 98% 
1H NMR (250 MHz, d6-DMSO): 8.20 (s, 1H, CHpur), 7.91 (s, 1H, CHpur), 7.34-7.20 
(m, 12H, CHMmt), 6.85 (d, J = 9.0 Hz, 2H, CHMmt), 4.96 (s, 2H, CH 2), 3.71 (s, 3H, 
OCH3 ). 
m/z (ESMS): 466 [M+H] (100%) 
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To a solution of 4.25 (3 g, 6.44 mmol, 1 equiv.) in CH3CN (50 mL) was added 
HBTU (2.93g, 7.73 mmol, 1.2 equiv.) and DIPEA (1.06 mL, 6.44 mmol, 1 equiv.). 
The mixture was stirred for 3 mm. and added to a solution of 4.22 (1.91g, 6.44 
mmol, 1 equiv.) in CH 3CN (50 mL). The resulting solution was stirred at room 
temperature for 45 mm. and the solvent was removed in vacuo. The residue was 
taken up in EtOAc (150 mL), washed with 1M KHSO4 (3 x 50 mL), 1M NaHCO3 (3 
x 50 mL), brine (1 x 50 mL), dried over MgSO4 and concentrated in vacuo to give a 
buff coloured solid. The previous solid was suspended in a 2:1 mixture of MeOH and 
2N Cs2CO3 (30 mL) and stirred for 1.5 h. The mixture was evaporated to dryness and 
taken up in water (150 mL), washed with DCM (2 x 50 mL), acidified with 1M aq. 
KHSO4 and extracted with DCM (3 x 100 mL). The organic phases were combined, 
washed with brine (1 x 100 mL), dried over Na2SO4 and concentrated in vacuo. The 
residue was dissolved in a minimum amount of EtOAc and precipitated with 
hexanes. The named compound was obtained as a pale yellow solid (3.2 g, 68% over 
2 steps). 
HPLC (method B): tR = 8.66 mm. 
Purity (ELSD): 98% 
'H NMR (250 MHz, CDC13) two rotamers: 13.25 and 13.16 (s, 1H, Dde-NH), 8.09 
and 8.08 (s, 1H, CHpur), 7.87 (s, 1H, CHPUr), 7.31-7.18 (m, 12H, CHMmt), 6.85 (d, J 




3.77 (m, 2H, CH2N), 3.71 (s, 3H, OCH3), 3.53 (m, 2H, CH2N), 2.56 and 2.46 (s, 3H, 
CCH3), 2.29 and 2.26 (s, 4H, CH2-Dde), 0.93 (s, 6H, CH 3-Dde). 
m/z (ESMS): 728 [M-H] (100%) 
(4-Amino-2-oxo-2H-pyrimidin-1-yl)-acetic acid ethyl ester 385  (4.28) 
HN 
To a stirred suspension of cytosine (5g, 45 mmol, 1 equiv.) in DCMI Pyridine (1:1, 
200 mL) was added N-ethylmorpholine (5.75 mL, 45 mmol, 1 equiv.) and 4-
monomethoxytrityl-chloride (20.8 g, 67.5 mmol, 1.5 equiv.). The mixture was heated 
to 40C and stirred for 24h. The mixture was cooled down to room temperature and 
water (200 mL) was added. The precipitate formed was filtered off, washed with 
water, THF and dried in vacuo. The named compound was obtained as a white solid 
(11.2 g, 65%). 
HPLC (method D): tR = 3.19 mm. 
Purity (ELSD): 95% 
m/z (ESMS): 273 [Mmt] (100%), 767 [2M+H] (20%) 
(The named compound is insoluble in common deuterated solvents and therefore 
cannot be analysed by NMR as reported in the literature for a Z-protected 
cytosine 384). 
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To a suspension of 4.28 (5.0 g, 13 mmol, 1 equiv.) in DMF (50 mL) was added NaH 
(60% in mineral oil, 520 mg, 13 mmol, 1 equiv.) and the resulting mixture was 
stirred at room temperature for lh. The reaction mixture was then cooled to 0°C and 
ethyl-2-bromoacetate (1.73 mL, 15.6 mmol, 1.2 equiv.) was added dropwise. The 
mixture was stirred at room temperature for 18h and the solvent was removed in 
vacuo. The resulting gum was precipitated with water and collected by filtration. The 
solid was washed with water and a small portion of CH 3CN, and dried in vacuo. 
The previous solid was suspended in 2N aqueous NaOH (50 mL) and the reaction 
mixture was stirred at reflux for 2h. After cooling to room temperature, the solution 
was acidified with 2N aqueous HC1 (70 mL) and the resulting precipitate was 
collected by filtration. The solid was washed with water and dried in vacuo to afford 
the named compound as a white solid (3.93 g, 66% over 2 steps). 
HPLC (method B): tR = 7.81 mm. 
Purity (ELSD): 98% 
NMR (250 MHz, d6-DMSO): 8.36 (br s, 114, NH), 7.45 (d, J = 6.75 Hz, 1H, 
CHc), 7.25-7.15 (m, 12H, CHM mt), 6.87-6.82 (m, 2H, CHM mt), 6.18 (d, J= 6.75 Hz, 
1H, CHc), 4.23 (s, 2H, CH2), 3.72 (s, 3H, CH3). 




N-{2- [N'4-(4-Methoxytrityl)-cytosin- 1-yl}-acetyl}-N-{2- [1 -(4,4-dimethyl-2,6- 
dioxo-cyclohexyliden)-ethyl -aminol -ethyl}-glycine382  (4.30) 
Qx° 
HN 




The named compound was synthesised from 4.29 (3.0 g, 6.79 mmol) in analogy to 
4.26 and obtained as a buff coloured solid (2.9 g, 61% over two steps). 
HPLC (method B): tR = 8.26 mm. 
Purity (ELSD): 100% 
'H NMR (250 lVllIz, CDC13) two rotamers: 13.16 and 13.14 (s, 1H, NH-Dde), 8.34 
(s, 1H, NH-Mmt), 7.51-7.23 (m, 10H, CHM mt, 1H, Mc), 7.17 (d, J = 8.5 Hz, 2H, 
CHMmt), 6.84 (d, J = 8.0 Hz, 2H, CHMmt), 6.18 (d, J = 5.25 Hz, 1 H, CHc ), 4.50 and 
4.36 (s, 2H, CH2CO2), 4.26 and 3.99 (s, 2H, CH2CO), 3.73 (s, 3H, OCH 3), 3.78-3.63 
(m, 4H, CH2-CH2), 2.50 and 2.47 (s, 3H, CCH 3), 2.28 (s, 4H, CH2-Dde), 1.00 and 
0.94 (s, 6H, CH3 -Dde). 
m/z (ESMS): 704 [M-H] (100%) 
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PEGA-Rink resin (4.41) 
Fmoc 
The Fmoc-Rink linker (1.14 g, 2.11 mmol, 5 equiv.), PyBOP (800 mg, 2.11 mmol, 5 
equiv.) and DiPEA (697 tL, 4.22 mmol, 10 equiv.) were premixed in DMF (10 mL) 
and added to PEGA resin (Polymer Lab, 0.4 mmol/g, 7.1 g wet) and the mixture was 
shaken for 3h at room temperature. Completion of the reaction was confirmed by 
ninhydrin test. The resin was filtered, washed with DMF (3 x 20 mL), DCM (3 x 20 
mL), MeOH (3 x 20 mL), DCM (3 x 20 mL) and MeOH (3 x 20 mL). 
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Fmoc-Lys(Dde)-0H 386 (4.42) 
0 
Fmoc JAOH 
Dde '  
To a suspension of Fmoc-Lysine (16.2 g, 43.9 mmol, 1 equiv.) in ethanol (250 mL), 
was added Dde-OH 4.21 (18.0 g, 98.8 mmol, 2 equiv.) and TFA (630 j.tL, 8.48 
mmol, 0.2 equiv.). The mixture was refluxed for 72h and concentrated in vacuo. The 
residue was taken up in EtOAc (350 mL), washed with iN aq. KHSO 4 (3 x 100 mL), 
brine (1 x 100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The 
resulting oil was triturated in Hexane to afford a yellowish solid, which recrystallised 
from DCM I Hexane to yield the named compound as an off-white solid (9.54 g, 
82%). 
HPLC (method C): tR = 11.12 mm. 
Purity (ELSD): 99% 
1H NMR (250 MHz, CDCI3): 13.32 (br s, 1H, NCH),  8.03 (hr s, 1H, CO2H), 7.74 (d, 
J = 7.5 Hz, 2H, CHFmoc), 7.58 (t, J = 6.5 Hz, 2H, CHFmoc), 7.37 (t, J = 7.0 Hz, 2H, 
CHFmoc), 7.28 (d, J = 7.25 Hz, 2H, CHFmOC), 5.84 (d, J = 8.25 Hz, 1H, NaH),  4.50-
4.47 (m, 1H, CH), 4.35 (d, J = 7.25 Hz, 2H, CH2 Fmoc), 4.19 (t, J = 7.0 Hz, 1H, CH-
Fmoc), 3.39 (m, 2H, C''H2 Lys), 2.53 (s, 3H, CH3 Dde), 2.35 (s, 4H, CH2 Dde), 1.99-
1.89 (m, 2H, CUH2  Lys), 1.87-1.63 (m, 2H, C&H 2  Lys), 1.61-1.45 (m, 2H, CH2 Lys), 
1.00 (s, 6H, C(CH3)2 Dde). 




Fmoc-Lys(Dde)-Rink-PEGA 382 (4.43) 
0 
Fmo '1 J1 
DdeA' 
H 
Fmoc-(Dde)LysOH 4.42 (1.13 g, 2.11 mmol, 5 equiv.), PyBOP (800 mg, 2.11 mmol, 
5 equiv.) and DiPEA (697 tL, 4.22 mmol, 10 equiv.) were premixed in DMIF (10 
mL) and added to Rink-PEGA resin 4.41 (previously deprotected with 20% 
piperidine in DMF) and the mixture was shaken for 5h at room temperature. 
Completion of the reaction was confirmed by ninhydrin test. The resin was filtered, 
washed with DMF (3 x 20 mL), DCM (3 x 20 mL), MeOH (3 x 20 mL), DCM (3 x 




PNA tag synthesis (4.44) 
General procedure for the deprotection of the Dde group 
The resin (3.5 g wet, 0.2 mmol) was pre-swollen in DMF (5 mL). A 20% solution of 
imidazole/hydroxylamine (1:0.75 equiv) in NMP/DIvIF (5:1, 10 mL) was added to 
the resin and the resulting mixture was shaken for lh at room temperature. The resin 
was then filtered and washed with DMF (3 x 10 mL), DCM (3 x 10 mL) and MeOH 
(3 x 10 mL). 
General procedure for coupling PNA monomers 
The PNA monomer (Adenine: 438 mg, Cytosine: 424 mg or Thymine: 269 mg, 0.6 
mmol, 3 equiv.) was premixed with HATU (228 mg, 0.6 mmol, 3 equiv.) and DIPEA 
(99 tL, 0.6 mmol, 3 equiv.) in DMF (2 mL). This solution was added to the 
deprotected resin (pre-swollen in 5 mL DMF) and shaken for 1.5 h at room 
temperature. Ninhydrin confirmed complete conversion and the resin was filtered 
and washed with DMF (3 x 10 mL), DCM (3 x 10 mL) and MeOH (3 x 10 mL). 
PNA tag characterisation 
A small sample of resin was cleaved using TFAJDCMJTIS (90:5:5) for 1.5 h. 




Oxo-(3,4,5-trimethoxy-phenyl)-acetic acid 387  (4.46) 
Me 
To a solution of 3',4',5'-trimethoxyacetophenone (5.0 g, 23.8 mmol, 1 equiv.) in 
pyridine (50 mL) was added selenium dioxide (9.9 g, 89.2 mmol, 3.75 equiv.). The 
mixture was stirred at 110°C for 16h and the solvent was removed in vacuo. The 
residue was taken up in 5% NaOH (100 mL), filtered through celite, and extracted 
with Et20 (2 x 50 mL). The aqueous phase was then acidified with conc. HC1 and the 
resulting precipitate was collected by filtration. The solid was redissolved in EtOAc 
(150 mL), washed with brine (1 x 50 mL), dried with Na2SO4 and concentrated in 
vacuo to afford the named compound as pale yellow crystals (4.62 g, 81%). 
HPLC (method C): tR = 7.20 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, d-DMSO): 7.21 (s, 2H, Ar-H), 3.86 (s, 6H, OCH3 meta), 3.80 
(s, 3H, OCR3 para) 




Piperidine-2-carboxylic acid methyl ester hydrochloride 388  (4.48) 
(N 	011-1 
.HCI 
To a solution of N-Boc piperidine-2-carboxylic acid (5.0 g, 21.8 mmol, 1 equiv.) in 
MeOH (150 mL) was added at 0°C thionyl chloride (15.9 mL, 218 mmol, 10 equiv.). 
After addition, the mixture was refluxed for 3h and the solvent was removed in 
vacuo. The residue was taken up in a minimum amount of MeOH and precipitated 
with Et20. The solid obtained was collected by filtration and washed with Et20. The 
named compound was obtained as white crystals (3.87 g, 98 %). 
HPLC (method C): tR = 1.92 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC13): 4.05 (dd, J= 3.5 Hz, 11.5 Hz, 1H, CH*),  3.83 (s, 3H, 
OCH3), 3.53-3.45 (m, 1H, 	3.11-3.00 (m, 1H, 	2.32-2.26 (m, 1H, 
1.92-1.57 (m, 5H, CH 1 ). 
m/z (ESMS): 144 [M+H] (100%) 
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To a 2 mm. premixed solution of 4.46 (1.34 g, 5.57 mmol, 1 equiv.), HBTU (2.32g, 
6.12 mmol, 1.1 equiv.) and DiPEA (1.84 mL, 11.1 mmol, 2 equiv.) in CH3CN (50 
mL), was added 4.48 (1.0 g, 5.57 mmol, 1 equiv.). The mixture was stirred for 3h at 
room temperature and the solvent was removed in vacuo. The residue was taken up 
in EtOAc (100 mL), washed with IN HCl (3 x 50mL), IN NaHCO3 (3 x 50mL), 
brine (1 x 50mL), dried over M92SO4 and concentrated in vacuo to afford the named 
compound as a pale brown solid (977 mg, 2.67 mmol, 1 equiv.). To a solution of the 
previous brown solid in MeOH (20 mL) was added LiOH (168 mg, 4.01 mmol, 1.5 
equiv.) and the mixture was stirred at room temperature for lh. The solvent was 
evaporated in vacuo and the residue was taken up in water (50 mL), washed with 
DCM (2 x 25 mL), and acidified with conc. HC1. The resulting precipitate was 
collected by filtration and washed with water. The solid was dissolved in EtOAc (50 
mL), washed with brine (1 x 25 mL), dried over Na2SO4, filtered and concentrated in 
vacuo to afford the named compound as an off-white solid (874 mg, 44% over two 
steps). 
HPLC (method B): tR = 7.10 mm. 
Purity (ELSD): 100% 	 - 
'H NMR (250 MHz, CDC13) two rotamers: 9.17 (hr s, 1H, OH), 7.33 and 7.30 (s, 
2H, Ar-H), 5.49 (m, CH*), 3.97 and 3.96 (s, 311, OCH3 para), 3.93 and 3.92 (s, 6H, 
OCH3 meta), 3.66 and 3.55 (d, J = 13.25 Hz, 1H, CHp1 ), 3.26 and 3.03 (dt, J = 3.0 





13C NMR (62.5 MHz, CDCI3): 190.47 (C=O), 175.53 (C=O), 167.82 (C=O), 153.50 
(C-Ar), 144.03 (C-Ar), 127.95 (C-Ar), 106.81 (CH-Ar), 61.00 (OCH 3 para), 56.28 
(OCH3 meta), 51.45 (CH*), 44.42 (CH2), 26.07 (CH2), 24.68 (CH2), 21.13 (CH2). 
Mp: 172-175°C (methanol) 
FTIR (neat): 1734 (s), 1678 (s), 1127 (s). 
HRMS (ES): caic. for C 17H21 N07 : 374.1210 [M+Na] Found: 374.1218. 
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Ac0' e H OTBS 
The procedure followed for the protection step was reported by Swenton. 389 
To a solution of 2-aminophenol (5.0 g, 45.8 mmol, 1 equiv.) and imidazole (4.68 g, 
68.7 mmol, 1.5 equiv.) in THF (100 mL) was added TBS-Cl (8.97 g, 59.5 mmol, 1.3 
equiv.) under vigorous agitation. A heavy white precipitate was formed quickly. 
After 30 mm., the mixture was poured into water (250 mL) and extracted with Et 20 
(2 x 100 mL). The organic phase were combined, washed with water (2 x 50 mL), 
brine (1 x 50 mL), dried over MgSO 4 and concentrated in vacuo to afford an orange 
oil. The previous oil (9.22 g, 41.3 mmol, 1 equiv.) was dissolved in CH 3CN (150 
mL). 4-acetoxybenzoic acid (7.43 g, 41.3 mmol, 1 equiv.) and IIDQ (12.52 g, 41.3 
mmol, 1 equiv.) were added and the mixture was stirred at room temperature for 18h 
and the solvent was removed in vacuo. The residue was taken up in EtOAc (200 
mL), washed with iN HC1 (3 x 100 mL), iN NaHCO 3 (3 x 100 mL), brine (1 x 100 
mL), dried over MgSO 4 and concentrated in vacuo. The residue was redissolved in 
DCM and solid impurities filtered off. Evaporation of DCM under reduced pressure 
afforded the named compound as a white solid (6.18 g, 35% over two steps). 
HPLC (method B): tR = 8.74 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC13): 8.54-8.50 (m, 1H, NH, 1H, HN-C-CH), 7.93 (d, J = 
8.75 Hz, 211 OC-CCH), 7.27-7.22 (m, 2H, AcO-C-CH), 7.07-6.96 (m, 1H, TBSO-C-
CH-CH, 1H,HN-C-CH-CH), 6.92-6.87 (m, 111, TBSO-C-CH), 2.35 (s, 3H, CH 3CO), 
1.03 (s, 9H, C(CH3)3), 0.30 (s, 6H, Si(CH 3) 2). 
"C NIMIR (62.5 MHz, CDC13): 168.88 (C=O), 164.05 (C=0), 153.28 (C-Ar), 144.27 
(C-Ar), 132.68 (C-Ar), 129.68 (CH-Ar), 128.33.(CH-Ar), 123.81 (CH-Ar), 121.90 
(CH-Ar), 121.83 (CH-Ar), 120.20 (CH-Ar), 117.41 (CH-Ar), 25.80 (C(CH 3)3), 21.15 
(CH3CO), 18.18 (C(CH3)3), -4.20 (Si(CH 3 )2). 
Mp: 108-110°C (methanol) 
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FTIR (neat): 3424 (m), 1757 (s), 1669 (s). 
HRMS (ES): caic. for C 21 1-127NO4 Si: 386.1782 [M+H] Found: 386.1783. 




The named compound was prepared in analogy to 4.57a. The residue obtained was 
purified by column chromatography (Hexane/EtOAc 7:3) to give 4.57b as a 
colourless sticky oil (7.93 g, 45% over two steps). 
HPLC (method B): tR = 8.59 mn. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDCI3): 7.87-7.82 (m, 11-1, N}1, 2H, OC-C-CH), 7.31 (t, J = 
2.25 Hz, 1H, HN-C-CH-C-OTBS), 7.23-7.11 (m, 411, Ar-H), 6.64 (ddd, J = 1.5 Hz, 
2.25 Hz, 7.5 Hz, TBSO-C-CH), 2.33 (s, 3H, CH3), 0.99 (s, 9H, C(CH3)3), 0.23 (s, 
61-1, Si(CH3)2). 
13 NMR (62.5 MHz, CDC13): 169.03 (C=O), 164.84 (C=O), 156.26 (C-Ar), 153.22 
(C-Ar), 138.91 (C-Ar), 132.63 (C-Ar), 129.65 (CH-Ar), 128.46 (CH-Ar), 121.91 
(CH-Ar), 116.30 (CH-Ar), 112.89 (CH-Ar), 112.06 (CH-Ar), 25.67 (C(CH3)3), 21.13 
(CH3CO), 18.19 (C(CH3)3), -4.41 (Si(CH3)2). 
FTIR (neat): 3306 (w), 1758 (s), 1650 (s). 
HRMS (ES): caic. for C 21 H27NO4 Si: 386.1782 [M+H] Found: 386.1785. 
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The named compound was prepared in analogy to 4.57a. The residue was 
crystallised from EtOAc / Hexane to give white crystals (8.64 g, 49% over two 
steps). 
HPLC (method B): tR = 8.58 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC13): 7.84 (d, J = 8.75 Hz, 2H, OC-C-CH), 7.81 (br s, 1H, 
NH), 7.46 (d, J = 8.75 Hz, 2H, I{N-C-CH), 7.17 (d, J = 8.5 Hz, 2H, AcO-C-CH), 
6.83 (d, J = 8.75 Hz, 2H, TBSO-C-CH), 2.33 (s, 3H, CH 3CO), 0.98 (s, 9H, C(CH 3 )3), 
0.19 (s, 6H, Si(CH3 )2). 
13C NMR (62.5 MHz, CDC13): 169.04 (C=0), 164.76 (C=O), 153.13 (C-Ar), 152.59 
(C-Ar), 132.68 (C-Ar), 131.44 (C-Ar), 128.43 (CH-Ar), 121.89 (CH-Ar), 121.83 
(CH-Ar), 120.41 (CH-Ar), 25.67 (C(CH3 )3), 21.13 (CH3CO), 18.20 (C(CH3 )3), -4.45 
(Si (CH3 )2). 
Mp:136-138°C (methanol) 
FTIR (neat): 3263 (w), 1756 (s), 1641 (s). 








To a solution of 4.57a (1.5 g, 3.89 mmol, 1 equiv.) in MeOH (50 mL) was added 
LiOH (171 mg, 4.08 mmol, 1.05 equiv.). The mixture was stirred for 5 mm. and 
concentrated in vacuo. The residue was taken up in water (100 mL), acidified with 
IN HO and extracted with DCM (3 x 50 mL). The organic extracts were combined 
and washed with brine (1 x 50 mL), dried with Na2SO4 and concentrated in vacuo. 
The oil obtained was purified by column chromatography (Hexane/EtOAc 6:4) to 
give the named compound as an off-white solid (1.07 g, 80%). 
HPLC (method B): tR = 8.95 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC1 3): 8.51 (br s, 1H, NH), 8.47-8.43 (m, 11-1, HN-C-CH), 
7.76 (d, J = 8.75 Hz, 21-1, OC-CCH), 7.67 (br s, 1H, OH), 7.02-6.86 (m, 5H, Ar-H), 
1.00 (s, 9H, C(C113)3), 0.28 (s, 61-1, Si(CH3)2). 
13 NIMR (62.5 MHz, CDC13): 165.75 (C=O), 159.94 (C-Ar), 144.49 (C-Ar), 
129.52 (C-Ar), 128.95 (CH-Ar), 126.45 (C-Ar), 123.98 (CH-Ar), 121.82 (CH-Ar), 
120.41 (CH-Ar), 117.54 (CH-Ar), 115.79 (CH-Ar), 25.77 (C(CH3)3), 18.16 
(C(CH3 ) 3), -4.24 (Si(CH3)2). 
Mp: 146-149°C (methanol) 
FTIR (neat): 3418 (m), 3297 (m), 1651 (s). 
HRMS (ES): caic. for C 19H25NO3 Si: 344.1676 [M+H] Found: 344.1680. 





The named compound was prepared in analogy to 4.58a. The residue was 
crystallised from EtOAc I Hexane to give white crystals (1.23 g, 92%). 
HPLC (method B): tR = 8.84 mm. 
Purity (ELSD): 99% 
'H NMR (250 MHz, d6-DMSO): 10.13 (br s, 1H, NH), 9.93 (s, 1H, OH), 7.83 (d, J 
= 8.5 Hz, 2H, OC-C-CH), 7.43-7.37 (m, 2H, HN-C-CH-CI-J), 7.17 (t, J = 8.25 Hz, 
1H, HN-C-CH-C-OTBS), 6.85 (d, J = 8.75 Hz, 2H, HO-C-CH), 6.54 (ddd, J = 1.0 
Hz, 2.25 Hz, 8.25 Hz, 1H, TBSO-C-CH-CH), 0.96 (s, 9H, C(CH3)3), 0.20 (s, 6H, 
Si(CH3)2). 
13 NMR (62.5 MHz, d6-DMSO): 165.01 (C=O), 160.46 (C-Ar), 155.08 (C-Ar), 
140.59 (C-Ar), 129.61 (CH-Ar), 129.19 (CH-Ar), 125.31 (C-Ar), 114.79 (CH-Ar), 
114.55 (CH-Ar), 113.11 (CH-Ar), 111.50 (CH-Ar), 25.49 (C(CH 3 )3), 17.85 
(C(CH3 )3), -4.58 (Si(CIH3)2). 
Mp: 109-112°C (methanol) 
FTIR (neat): 3271 (m), 1646 (s). 
HRMS (ES): caic. for C 19H25NO3Si: 344.1676 [M+H] Found: 344.1682. 
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The named compound was prepared in analogy to 4.58a. The residue was 
crystallised from EtOAc I Hexane to give white crystals (1.19 g, 91%). 
HPLC (method B): tR = 8.67 mm. 
Purity (ELSD): 100% 
1H NMR (250 MHz, CDC1 3): 10.07 (s, 1H, NH), 9.88 (s, 1H, OH), 7.83 (d, J = 8.75 
Hz, 211, OC-C-CH), 7.61 (d, J = 9.014z, 2H, HN-C-CH), 6.85 (d, J = 9 Hz, 211, HO-
C-CH), 6.82 (d, J = 9.25 Hz, 2H, TBSO-C-CH), 0.95 (s, 911, C(CH3 )3), 0.18 (s, 611, 
Si(CH3)2). 
13C N1VIR (62.5 MHz, CDC13): 164.64 (C=O), 160.28 (C-Ar), 150.78 (C-Ar), 
133.18 (C-Ar), 129.46 (CH-Ar), 125.44 (C-Ar), 121.77 (CH-Ar), 119.52 (CH-Ar), 
114.76 (CH-Ar), 25.52 (C(CH3)3), 17.87 (C(CH 3)3), -4.61 (Si(C'H3 )2). 
MP: 144-147°C (methanol) 
FTIR (neat): 3328 (m), 3108 (m), 1637 (s). 




Acetic acid 4-phenylcarbamoyl-phenyl ester (4.60) 
o 
ACO& H 
The named compound was prepared in analogy to 4.57a and obtained as a white 
solid (832 mg, 90%). 
HPLC (method B): tR = 7.06 mm. 
Purity (ELSD): 99% 
111 NMR (250 MHz, CDC13): 10.28 (s, 1H, NH), 8.00 (d, J = 8.75 Hz, 21-1, OC-C-
CH), 7.77 (d, J = 7.5 Hz, 2H, HN-C-CH), 7.39-7.28 (m, 2H, AcO-C-CH, 21-1, HN-C-
CH-CH), 7.10 (t, J= 7.25 Hz, 111, HN-C-CH-CH-CH), 2.31 (s, 3H, CH 3 ). 
13C NMR (62.5 MHz, CDCI3): 168.71 (C=O), 164.53 (C=O), 152.62 (C-Ar), 138.86 
(C-Ar), 132.25 (C-Ar), 128.92 (CH-Ar), 128.35 (CH-Ar), 123.42 (CH-Ar), 121.57 
(CH-Ar), 120.05 (CH-Ar), 20.63 (CH 3). 
Mp: 129-132°C (methanol) 
FTIR (neat): 3354 (m), 1755 (s), 1656 (s). 
HRMS (ES): calc. for C 151-1 13NO3 : 256.0968 [M+H] Found: 256.0969. 
4-Hydroxy-N-phenyl-benzamide 390 (4.61) 
o 
HO Q 
The named compound was prepared in analogy to 4.58a and obtained as a white 
solid (95%). 
NIVIR (250 MHz, CDC13): 10.11 (s, 11-1, NH), 9.99 (s, 1H, OH), 7.86 (d, J= 8.75 
Hz, 2H, OC-C-CH), 7.76 (d, J = 7.5 Hz, 2H, HN-C-CH), 7.33 (t, J = 7.5 Hz, 2H, 
HN-C-CH-CH), 7.06 (t, J = 7.5 Hz, 1H, HN-C-CHCHCH), 6.87 (d, J = 8.75 Hz, 2H, 
HO-C-CH). 




Synthesis of resin 4.89 
0 	 H 0 
HO)L Yf N 
HN—T—C—A—A—C—T—T—C—AThAC NH 
(Dde) 
Adipic acid monomethylester (52 mg, 0.3 mmol, 3 equiv.), HATU (122 mg, 0.3 
mmol, 3 equiv.) and DiPEA (53 jiL, 0.3 mmol, 3 equiv.) were premixed in DMA (1 
mL) and added to resin 4.44 (0.1 mmol, previously deprotected with 20% piperidine 
in DMF) and the mixture was shaken for 2h at room temperature. Completion of the 
reaction was confirmed by ninhydrin test. The resin was filtered, washed with DMF 
(3 x 5 mL), DCM (3 x 5 mL), MeOH (3 x 5 mL), DCM (3 x 5 mL) and MeOH (3 x 5 
mL). A 7:3 solution of 1 M aq LiOH in THE (5 mL) was added to the resin (pre-
swollen in THE) and the mixture was shaken for 3h at room temperature. The resin 
was filtered, washed with THF/H20 (1:1) (3 x 5 mL), THF/1M aq. KHSO 4 (3 x 5 
mL),7HF/H20 (1:1) (3 x 5 mL), MeOH (3 x 5 mL), DCM (3 x 5 mL) and MeOH (3 




Synthesis of resin 4.90 
HO 	N)L 
H N —T— C — A — A — C —T—T— C — A —T— A — C' NH 
(Dde) 
To resin 4.89 (0.025 mmol, 1 equiv.) pre-swollen in DMA was added a solution of 
DIC (32 pL, 0.2 mmol, 8 equiv.) and HOBt (31 mg, 0.2 mmol, 8 equiv.) in DMA 
(1.5 mL). The mixture was shaken at room temperature for 3h. A solution of 3-
aminopropanol (15 mg, 0.2 mmol, 8 equiv. in DMA (0.5 mL) was added and the 
mixture was shaken for a further 3 h. The resin was then filtered and washed with 
DMF (3 x 2 mL), DCM (3 x 2 mL), MeOH (3 x 2 mL), DCM (3 x 2 mL) and MeOH 
(3 x 2 mL). 
Synthesis of resin 4.91 
HO 	 N 
H N —T— C — A — A — C —T—T— C — A —T— A — C' NH 
(Dde) 
Resin 4.91 (0.025 mmol) was prepared in analogy with resin 4.90 using 5-




Synthesis of resin 4.92 
0 	 H 0 
HO0 N) yfNO 
H N—T— C—A—A— C—T—T— C—A—T—A—C NH 
(Dde) 
Resin 4.93 (0.025 mmol) was prepared in analogy with resin 4.90 using 2-(2-Amino-
ethoxy)-ethanol (21 mg, 0.2 mmol, 8 equiv.). 
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Synthesis of tagged spacer-fragment conjugates from Fragments F 2-F7 
Preparation of mother solutions 
The following solutions were prepared: 
Fragments: 
Fragment Ei (4.58a): 75 mg (0.218 mmol) in 900 j.tL anhydrous DCM 
(0.24 mmol /mL) 
Fragment E3 (4.58b): 75 mg (0.218 mmol) in 900 .tL anhydrous DCM 
(0.24 mmol /mL) 
Fragment F4 (4.58c): 75 mg (0.218 mmol) in 900 pL anhydrous DCM 
(0.24 mmol /mL) 
Fragment F5 (4.61): 47 mg (0.218 mmol) in 900 .tL anhydrous DCM 
(0.24 mmol /mL) 
Fragment E6 (4-hydroxvbenzotrifluoride): 35 mg (0.218 mmol) in 900 pL 
anhydrous DCM (0.24 mmol ImL) 
Fragment F (phenol): 21 mg (0.218 mmol) in 900 pL anhydrous DCM 
(0.24 mmol /mL) 
Mediating agents: 
triphenyiphosphine: 349 mg (1.33 mmol) in 5.4 mL anhydrous THF 
(0.24 mmol ImL) 
DIAD: 252 pL (1.33 mmol) in 5.4 mL anhydrous THF (0.24 mmol /mL) 
Procedure for the library synthesis 
Each of the resin 4.90, 4.91 and 4.92 were divided into six equal quantities. Each 
batch of resin was then swollen in 200 pL anhydrous DCM. 300 pL of a fragment 
solution, 300 .tL of DIAD solution and 300 pL of triphenylphosphine solution were 
then introduced as a 6x3 array and the mixtures were shaken at room temperature for 
16h. The resins were then filtered and washed with DCM (3 x 1 mL), MeOH (3 x 1 
mL), DCM (3 x 1 mL) and MeOH (3 x 1 mL). 
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Cleavage from the resin and precipitation 
Each tagged spacer-fragment conjugate was then cleaved from the resin with 
TFAJDCM/TIS (90:5:5) for 1.5 h at room temperature. The resin was then filtered 
and washed with DCM (2 x 1 mL). The collected filtrates were concentrated in 
vacuo. Cold Et20 was added to the residues resulting in precipitation of the PNAs. 
The solutions were then centrifugated for 5 mm. and the supernatants discarded. The 
compounds were then dried in vacuo. 
Synthesis of resin 4.95 
7 H2N NLy 
HN—T— C—A—A— C—T—T— C—A—T—A— NH 
(Ac/Dde) 
To resin 4.89 (0.017 mmol, 1 equiv.) pre-swollen in DMA was added a solution of 
DIC (16 tL, 0.1 mmol, 6 equiv.) and HOBt (16 mg, 0.1 mmol, 6 equiv.) in DMA 
(0.5 mL). The mixture was shaken at room temperature for 3h. A solution of mono-
fmoc 1,3-diaminopropane hydrochloride (33 mg, 0.1 mmol, 6 equiv.) and DIPEA (17 
j.iL, 0.1 mmol, 6 equiv.) in DMA (0.5 mL) was added and the mixture was shaken for 
a further 3 h. The resin was then filtered and washed with DIVIF (3 x 2 mL), DCM (3 
x 2 mL), MeOH (3 x 2 mL), DCM (3 x 2 mL) and MeOH (3 x 2 mL). The resin was 
then swollen in 0.5 mL DMF. A pre-mixed solution of acetic acid (6 tL, 0.1 mmol, 6 
equiv.), HATU (38 mg, 0.1 mmol, 6 equiv.) and DIPEA (17 .tL, 0.1 mmol, 6 equiv.) 
in DMA (0.5 mL) was added to the resin and the mixture was shaken at room 
temperature for 3 h. The resin was then filtered and washed with DIVIF (3 x 2 mL), 
DCM (3 x 2 mL), MeOH (3 x 2 mL), DCM (3 x 2 mL) and MeOH (3 x 2 mL). The 
resin was then shaken in 20% piperidine in DMIF (1 mL) for 25 mm. at room 
temperature, filtered and washed with DMF (3 x 2 mL), DCM (3 x 2 mL), MeOH (3 
x 2 mL), DCM (3 x 2 mL) and MeOH (3 x 2 mL). 
Chapter V 
Synthesis of resin 4.96 
0 	 H
0 
H2NN) Yf O 
H N—T— C—A—A— C—T—T— C—A—T—A— C NH 
(Ac/Dde) 
Resin 4.96 (0.017 mmol) was prepared in analogy with resin 4.95 using mono-fmoc 
1,5-diaminopentane hydrobromide (41 mg, 0.1 mmol, 6 equiv.). 
Synthesis of resin 4.97 
0 	 H
0 
N) T fO  
HN—T—C—A—A—C—T—T—C—ATAC NH 
(Ac/Dde) 
Resin 4.97 (0.017 mmol) was prepared in analogy with resin 4.95 using mono-fmoc 
2-(2-Amino-ethoxy)-ethylamine hydrochloride (36 mg, 0.1 mmol, 6 equiv.). 
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Coupling of fragment F1 and rhodamine to resins 4.95, 4.96 and 4.97 
Each resin was separated into two equal quantities (0.008 mmol). Then a pre-mixed 
solution of fragment F 1 4.50 (18 mg, 0.05 mmol, 6 equiv.) or rhodamine (20 mg, 
0.05 mmol, 6 equiv.), HATU (16 mg, 0.05 mmol, 6 equiv.) and DIPEA (9 tL, 0.05 
mmol, 6 equiv.) in DMA (0.5 mL) was added to the resins as a 3x2 array. The 
mixtures were shaken at room temperature for 3 h. The resins were filtered and 
washed with DMF (3 x 1 mL), DCM (3 x 1 mL), MeOH (3 x 1 mL), DCM (3 x 1 
mL) and MeOH (3 x 1 mL). The 3 spacer-fragment F 1 and 3 spacer-rhodamine 
conjugates were. released in solution in analogy with the other spacer-fragment 
conjugates. 
DNA microarray production 
3'amino modified DNA oligos were purchased from Sigma-Genosys, U. K. DNA 
printing was performed using a Robot Microarrayer (Genetix QMini, U.K.). 1 solid 
pin was used in order to print 3'amino modified DNA 18mers on aldehyde-coated 
glass slides (Genetix) and agarose-coated glass slides keeping humidity at 70%. The 
same pattern was reproduced twice: a 5x4 subarray for 3'-amino modified 5-
fluoresceine derivatised DNA oligo and eight 5x4 subarrays for 3-amino modified 
DNA oligo. Each DNA was printed 5 times on each spot. Then, the microarrays were 
kept overnight in a chamber containing a 3M NaCl solution. The chips were then 
washed successively with SDS (2 x 2 mm.), distilled water (2 x 2 mm), Reductive 
solution of NaBH4 (1 x 5 mm.), distilled water (1 x 1 mm.), and SDS (3 x 1 mm.) 
and distilled water (2 x 1 mm.). After spin-drying by centrifugation, the chips were 
stored in dark before hybridisation was carried out. 
Hybridisation onto DNA microarrays 
The PNA-tagged fragment-spacer conjugates were dissolved in DMSO at a 
concentration of 2 mM. Each solutions was then diluted with water to obtain 200tM 
solutions, which were then diluted with GenHYB buffer (Genetix) to afford stock 
solutions of single fragment at a concentration of 100 jiM. Stock ,solutions of 
mixtures of two fragments were prepared in a similar manor to obtain printing 
solutions with a concentration of 50 pM for each fragment. 
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Each stock solution was printed in a 3 x 1 subanay format with a repetition of 5 
printing onto the same spot. All the printing process was performed keeping 
humidity at 80%. 
After printing, the microarrays were kept for 24 h in a chamber containing a 3M 
NaCl solution. The chips were then washed successively with PBS buffer (2 x 15 
mm.) and distilled water (2 x 2 mm) and spin-dried by centrifugation. 
FKBP12 experiment 
RGS-His4 tagged FKBP12 was donated by Prof. Stuart Schreiber and Dr. Angela 
Koehler, Harvard University, U.S.A. 
300 j.xL PBST buffer (PBS buffer + 0.05 % Tween 20) containing 1 ig of RGS-His4-
FKBP12 was deposed on each microarray and incubated for 30 mm. at room 
temperature. The chips were then washed with PBST buffer (3 x 3 mm.) and 
incubated with 300 pL of a 1:1000 dilution of RGS-His4 mouse antibody (Qiagen) in 
PBST for a further 30 mm. at room temperature. The microarrays were then washed 
with PBST buffer (3 x 3 mm.) and incubated with 300 tL of a 1:1000 dilution of 
Alexa 488 anti-mouse (Molecular Probes) in PBS buffer containing 0.1 % of BSA 
(Sigma), for 30 mm. at room temperature. The chips were then washed with PBST 
buffer (3 x 5 mm.), PBS (1 x 2 mm.) and spin-dried by centrifugation. 
Scanning 
Microarrays were scanned with a CCD based fluorescence scanner (Bioanalyser 4F, 
LaVision Biotech, Germany) using FITC filters. Analysis of the microarray images 




Analysis of the aldehyde slides 
The following fluorescence intensities were measured (average over 3 spots): 
Composition of the spotted solution 
Slide 1 Slide 2 
Pattern 1 Pattern 2 Pattern 1 Pattern 2 
Fragment F2 —Spacer S' 1 414947 424352 606964 654781 
Fragment F3 —Spacer S' 1 421006 424055 589564 710556 
Fragment F4 — Spacer S' i 413838 407923 539736 571165 
Fragment F5 —Spacer S' 423804 424986 688889 588989 
Fragment F6 —Spacer S' i 421257 417096 572385 533254 
Fragment F7 —Spacer S' i 409736 410259 520926 573860 
Fragment F 1 — Spacer S" i 412382 406150 573514 535127 
Fragment F2 —Spacer S'2 402538 426871 683568 545325 
Fragment F3 —Spacer S' 2 397057 423771 597874 555504 
Fragment F4 — Spacer S' 2 421610 413513 545667 579793 
Fragment F5 - Spacer S'2 401742 418163 649002 621693 
Fragment F6 — Spacer S' 2 439746 451959 587641 575551 
Fragment F7 — Spacer S' 2 410109 410919 535710 636423 
Fragment F 1 — Spacer S" 2 397241 397377 534148 561620 
Fragment F2 —Spacer S' 3 393759 416593 660551 570570 
Fragment F3 —Spacer S' 3 417302 426579 566201 559208 
Fragment F4 —Spacer S' 3 - 410103 417208 580391 576277 
Fragment F5 — Spacer S' 3 401731 410811 624836 558516 
Fragment Fo — Spacer S' 3 443791 444107 634268 553399 
Fragment F7 —Spacer S' 3 398984 399276 534597 569902 
Fragment F 1 - Spacer S" 3 448709 446876 622037 579891 
FragmentsF 1 +F2 — Spacer S' i 419911 434264 525590 580263 
Fragments F 1 +F3 — Spacer S' i 404887 426177 568219 579161 
Fragments F 1 + F4 - Spacer S'i 398017 399486 508274 601762 
Fragments F 1 + F5 - Spacer S' 406382 426851 607740 562965 
Fragments F 1 + F6 - Spacer S' 403413 421285 572703 600877 
Fragments F 1 + F7 - Spacer S , 1 420870 414395 569779 601232 
Fragments F 1 + F2 - Spacer S' 2 423346 429048 587485 566325 
Fragments F 1 -i-F3 --- Spacer S' 2 412652 419167 583764 603304 
Fragments F 1 + F4 - Spacer S ' 2 438404 451788 894428 554787 
Fragments F 1 + F5 - Spacer S'2 393801 421515 586520 640702 
Fragments F 1 + F6 - Spacer S ' 2 406709 423718 630910 595974 
Fragments F 1 + F7 - Spacer S ' 2 402078 420098 549986 645742 
Fragments F 1 +F2 — Spacer S' 3 399503 424923 644137 614524 
Fragments F 1 + F3 - Spacer S' 3 400814 423174 542072 579257 
Fragments F 1 + F4 - Spacer S' 3 399299 410539 604025 564612 
Fragments F 1 +F5 — Spacer S' 3 417007 406077 558784 561635 
Fragments F 1 + F6 - Spacer S' 3 410422 417102 572282 584849 




Analysis of the agarose slides 
The following fluorescence intensities were measured (average over 3 spots): 
Composition of the spotted solution 
Slide 1 Slide 2 
Pattern 1 Pattern 2 Pattern 1 Pattern 2 
Fragment F2 —Spacer S' 1 916037 901373 939552 891684 
Fragment F3 - Spacer S' 873502 804969 925598 902744 
Fragment F4 —Spacer S'i 839867 805053 856282 961659 
Fragment F5 - Spacer S'l 837160 891007 874003 936411 
Fragment F6 —Spacer S' i 953537 820245 945578 927668 
Fragment F7 - Spacer S' 1 833571 807407 873696 1012043 
Fragment F 1 - Spacer S" 794145 888029 848689 855095 
Fragment F2 —Spacer S'2 838361 883476 908968 907774 
Fragment F 3 - Spacer S'2 839306 805679 909846 839113 
Fragment F4 —Spacer S' 2 826550 843758 876712 952712 
Fragment F5 —Spacer S'2 889920 897217 1006808 918578 
Fragment F6 - Spacer S'2 879052 841083 979612 904668 
Fragment F7 - Spacer S'2 832013 843461 846629 966186 
Fragment F 1 - Spacer S"2 845946 865014 812724 878019 
Fragment F2 —Spacer S' 3 845514 902088 855780 870427 
Fragment F3 — Spacer S' 3 860293 811411 888001 871720 
Fragment F4 — Spacer S'3 860983 842139 815289 921517 
Fragment F5 - Spacer S' 3 944433 863527 964462 867549 
Fragment F6 - Spacer S' 3 935931 856054 994746 931029 
Fragment F7 —Spacer S' 3 - 842919 850695 817190 872883 
Fragment F 1 - Spacer S" 3 926935 858386 1005291 930355 
Fragments F 1 +F2 — Spacer S' i 812554 912933 869561 926441 
Fragments F 1 + F3 - Spacer S' 962678 847309 957275 900371 
Fragments F i +F4 — Spacer S' i 839534 826999 837889 941759 
Fragments F 1 + F5 - Spacer S'i 825271 881309 827934 885839 
Fragments F 1 + F6 - Spacer S , 1 916552 837583 850719 899802 
Fragments F 1 +F7 — Spacer S' i 875666 880119 850314 931095 
Fragments F 1 + F2 - Spacer S'2 824531 860621 884522 883064 
Fragments F 1 + F3 - Spacer S'2 903368 848017 839676 902986 
Fragments F 1 + F4 - Spacer S'2 840014 847548 894377 986545 
Fragments F 1 + F5 - Spacer S'2 891391 840094 793937 936654 
Fragments F 1 + F6 - Spacer S'2 947485 853722 944708 923743 
Fragments F 1 + F7 - Spacer S'2 817352 818399 805349 944969 
Fragments F 1 + F2 - Spacer S' 3 937163 799670 927014 862498 
Fragments F 1 +F3 - Spacer S' 3 852179 861345 830661 1061510 
Fragments F 1 +F4 — Spacer S' 3 903359 813816 903627 981312 
Fragments F 1 +F5 — Spacer S'3 878866 819515 944470 882559 
Fragments F 1 + F6 - Spacer S' 3 945437 822420 944368 924053 
Fragments F 1 + F7 - Spacer S' 3 905201 839084 924204 931650 
209 
References 
Merrifield, R. B., J. Am. Chem. Soc. 1963, 85, 2149-2154. 
Gutte, B.; Merrifield, R. B., J. Biol. Chem. 1971,246, 1922-1941. 
Yu, Z.; Bradley, M., Curr. Opin. Chem. Biol. 2002, 6, 347-352. 
Czarnik, A. W., Biotechnol. Bioeng. (Comb. Chem.) 1998, 61, 77-79. 
Seneci, P., Solid-Phase Synthesis and Combinatorial Technologies. John Wiley & Sons, Inc.: 
New-York, 2000; p  620. 
Rend, M.; Ferreras, M.; Delaisse, J. M.; Foged, N. T.; Meldal, M., J. Pept. Sci. 1998, 4, 195-
210. 
Geysen, H. M.; Meleon, R. H.; Barteling, S. J., Proc. Nat!. Acad. Sci., USA 1984, 81, 3998-
4002. 
Smith, J. M.; Gard, J.; Cummings, W.; Kaniszai, A.; Krchnak, V., J. Comb. Chem. 1999, 1, 
368-370. 
9 	Atrash, B.; Kobylecki, R.; Cavell, D.; Reader, J.; Bradley, M., Angew. Chem.-Int. Edit. 2001, 
40, 938-941. 
Atrash, B.; Reader, J.; Bradley, M., Tetrahedron Lett. 2003, 44, 4779-4782. 
Frank, R., 2002, 267, 13-26. 
Eichler, J.; Bienert, M.; Stierandova, A.; Lebi, M., Pept. Res. 1991, 4, 296-307. 
Berg, R. H.; Almdal, K.; Pedersen, W. B.; Holm, A.; Tam, J. P.; Merrifield, R. B., J. Am. 
Chem. Soc. 1989, 111, 8024-8026. 
Fodor, S. P. A.; Read, J. L.; Pirrung, M. C.; Stryer, L.; Lu, A. T.; Solas, D., Science 1991, 251, 
767-773. 
Kirschning, A.; Monenschein, H.; Wittenberg, R., Angew. Chem.-Int. Edit. 2001, 40, 650-679. 
Cho, J. K.; White, P. D.; Kiute, W.; Dean, T. W.; Bradley, M., J. Comb. Chem. 2003, 5, 632-
638. 
Kaldor, S. W.; Siegel, M. C.; Fritz, J. E.; Dressman, B. A.; Hahn, P. J., Tetrahedron Lett. 
1996, 37, 7193-7196. 
Emerson, D. W.; Emerson, R. R.; Joshi, S. C.; Sorensen, E. M.; Turek, J. M., J. Org. Chem. 
1979,44,4634-4640. 
Raju, B.; Kassir, J. M.; Kogan, T. P., Bioorg. Med. Chem. Lett. 1998, 8, 3043-3048. 
Booth, R. J.; Hodges, J. C., J. Am. Chem. Soc. 1997, 119, 4882-4886. 
Mendonca, A. J.; Boguszewski, P. A.; Coffey, A. F.; Davies, J. W.; MacDonald, A. A.; 
Warner, F. P. In Solid-phase extraction of metals: facile removal of active metal species prior 
to compounds screening, 230th ACS National Meeting, Washington, 2005. 
Hu, Y.; Baudart, S.; Porco, J. A. J., J. Org. Chem. 1999, 64, 1049-105 1. 
Bhalay, G.; Dunstan, A.; Glen, A., Synlett 2000, 1846-1859. 
Sussman, S., Ind. Eng. Chem. 1946, 38, 1228-1230. 
Cainelli, G.; Contento, M.; Manescalchi, F.; Regnoli, R., J. Chem. Soc. Perkin Trans 1 1980, 
2516-2519. 
Leznoff, C. C., Chem. Soc. Rev. 1974, 3, 65-85. 
Sherrington, D. C.; Akelah, A., Chem. Rev. 1980, 81, 557. 
Hodges, J. C.; Richardson, G., J. Chem. Soc. Chem. Commun. 1975, 622-623. 
References 	 210 
Ley, S. V.; Baxendale, I. R.; Bream, R. N.; Jackson, P. S.; Leach, A. G.; Longbottom, D. A.; 
Nesi, M.; Scott, J. S.; Storer, R. I.; Taylor, S. J., J. Chem. Soc.-Perkin Trans. 1 2000, 3815-
4195. 
Hinzen, B.; Lenz, R.; Ley, S. V., Synthesis 1998, 977-979. 
Lecarpentier, P.; Crosignani, S.; Linclau, B., Mo!. Divers. 2005, 9, 341-35 1. 
Harris, J. M.; Liu, Y.; Chai, S.; Andrewas, M. D.; Vederas, J. C., J. Org. Chem. 1998, 63, 
2407-2409. 
Galaffu, N.; Sechi, G.; Bradley, M., Mol. Divers. 2005, 9, 263-275. 
Ley, S. V.; Bolli, M. H.; Hinzen, B.; Gervois, A. G.; Hall, B. J., J. Chem. Soc.-Perkin Trans. 1 
1998, 2239-2242. 
Drewry, D. H.; Coe, D. M.; Poom, S., Med. Res. Rev. 1999, 19, 97-148. 
Yoon, N. M.; Choi, J., Synlett 1993, 135-136. 
Yoon, N. M.; Choi, J.; Shon, Y. S., Synth. Commun. 1993, 23, 3047-3053. 
Bandgar, B. P.; Nikat, S. M.; Wadgaonkar, P. P., Synth. Commun. 1995, 25, 863-869. 
Habermann, J.; Ley, S. V.; Scott, J. S., J. Chem. Soc.-Perkin Trans. 11999, 1253-1256. 
Gerlach, M.; Joerdens, F.; Kuhn, H.; Neumann, W. P.; Peterseim, M., J. Org. Chem. 1991, 56, 
5971-5972. 
Neumann, W. P.; Peterseim, M., Syn!ett 1992, 801-802. 
Xu, W.; Mohan, R.; Morrissey, M. M., Tetrahedron Lett. 1997, 38, 7337-7340. 
Tomoi, M.; Kato, Y.; Kakiuchi, H., Makromo!. Chem. 1984,185,2117-2124. 
Shinkai, S.; Tsuji, H.; Hara, Y.; Manabe, 0., Bull. Chem. Soc. Jpn. 1981, 54, 631-632. 
Schwesinger, R.; Schlemper, H.; Hasenfratz, C.; Willaredt, J.; Dambacher, T., Liebigs Ann. 
Chem. 1996,1055-1082. 
Parlow, J. J.; Naing, W.; South, M. S.; Flynn, D. L., Tetrahedron Lett. 1997, 38, 7959. 
Ley, S. V.; Schucht, 0.; Thomas, A. W.; Murray, P. J., J. Chem. Soc.-Perkin Trans. 1 1999, 
1251-1253. 
Kulkarni, B. A.; Ganesan, A., Chem. Commun. 1998,785-786. 
Smith, R. A.; Bhargava, A.; Browe, C.; Chen, J.; Dumas, J.; Hatoum-Mokdad, H.; Romero, 
R., Bioorg. Med. Chem. Lett. 2001, 11, 2951-2954. 
Olah, G. A.; Husain, A.; Singh, B. P., Synthesis 1983, 11, 892-895. 
Liu, Y. S.; Zhao, C.; Bergbreiter, D. E.; Romo, D., J. Org.Chem. 1998, 63, 3471-3473. 
Cacchi, S.; Cagliotti, L., Synthesis 1979, 64-66. 
Bongini, A.; Cainelli, G.; Cotento, M.; Manescalchi, F., Synthesis 1980,143-146. 
Hodge, P.; Richardson, G., J. Chem. Soc. Chem. Commun. 1975, 622-623. 
Togo, H.; Nogami, G.; Yokoyama, M., Syn!ett 1998,534-536. 
Arnold, L. D.; Assil, H. I.; Vederas, J. C., J. Am. Chem. Soc. 1989, 111, 3973-3976. 
Tunoori, A. R., Tetrahedron Lett. 1998, 39, 8751-8754. 
Rebek, J.; Gavina, F., J. Am. Chem. Soc. 1974, 96, 7112. 
Bessodes, M.; Antonakis, K., Tetrahedron Lett. 1985, 26, 1305-1306. 
Parlow, J. J., Tetrahedron Lett. 1995, 36, 1395-1396. 
de Miguel, Y. R.; Brule, E.; Margue, R. G., J. Chem. Soc.-Perkin Trans. 12001, 3085-3094. 
McNamara, C. A.; Dixon, M. J.; Bradley, M., Chem. Rev. 2002, 102, 3275-3300. 
References 	 211 
Pittman, C. V.; Smith, L. R., J. Am. Chem. Soc. 1975, 97, 1749-1754. 
Akiyama, R.; Kobayashi, S., Angew. Chem.-Int. Edit. 2001, 40, 3469-347 1. 
SchUrer, S. C.; Gessler, S.; Buschmann, N.; Blechert, S., Angew. Chem.-Int. Edit. 2000, 39, 
3898-3901. 
Jorgensen, J. C.; Windridge, G. C.; Patton, W.; Lee, T. C., J. Med. Chem. 1969, 12, 733-737. 
Kier, L. B.; George, J. M., J. Med. Chem. 1972, 15, 384-386. 
Lindeberg, G.; Bodanszky, M.; Acosta, M.; Sawyer, W. H., J. Med. Chem. 1974,17,781-783. 
Hirata, Y., Curr. Opin. Nephrol. Hypertens. 1996, 5, 12-15. 
Lau, R. C. M.; Rinehar, K. L., J. Am. Chem. Soc. 1995,117,7606-7610. 
Merrifield, R. B.; Vizioli, L. D.; Boman, H. G., Biochemistry 1982, 21, 5020-503 1. 
Tyndall, J. D. A.; Pfeiffer, B.; Abbenante, G.; Fairlie, D. P., Chem. Rev. 2005, 105, 793-826. 
Sakai, R.; Rinehart, K. L.; Kishore, V.; Kundu, B.; Faircioth, G.; Gloer, J. B.; Carney, J. R.; 
Namikoshi, M.; Sun, M.; Hughes, R. G. J.; Garcia Cravalos, D.; de Queseda, T. G.; Wilson, 
G. R.; Heid, R. H., J. Med. Chem. 1996, 39, 2819-2834. 
Campbell, R. K.; White, J. R.; Levien, T.; Baker, D., Clin. Ther. 2001, 23, 1938-1957. 
Kaufman, M.; Jonat, W.; Blarney, R.; Cuzick, J.; Namer, M.; Fogelman, I.; de Haes, J. C.; 
Schumacher, M.; Sauerbrei, W., Eur. J. Cancer 2003, 39, 1711-1717. 
Schally, A. V., Peptides 1999,20,1247-1262. 
Sarges, R.; Witkop, B., J. Am. Chem. Soc. 1964, 86,1862-1863. 
Hausmann, W.; Weisiger, J. R.; Craig, L. C., J. Am. Chem. Soc. 1955, 77,721-722. 
Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D., Nat. Rev. 
Drug Discovery 2004, 3, 215-225. 
Celis, E., J. Clin. Invest. 2002, 110, 1765-1768. 
Rothbard, J., Nature 1987, 330, 106-107. 
Larche, M.; Wraith, D. C., Nat. Med. Supp. 2005, 11, S69-S76. 
Kast, W. M.; Melief, C. J., Immunol. Lett. 1991, 30, 229-232. 
Buteau, C.; Markovic, S. N.; Celis, E., Mayo Clin. Proc. 2002, 77, 339-349. 
Graul, A.; Castanet, J., Drugs Future 1997, 22, 956-968. 
Wu, M. T.; Douglas, A. W.; Ondeyka, D. L.; Payne, L. G.; Ikeler, T. J.; Joshua, H.; Patchett, 
A. A., J. Pham. Sci. 1985, 74, 352-354. 
Patchett, A. A., J. Med. Chem. 1993,36,2051-2058. 
de Gasparo, M.; Whitebread, S., Regul. Pept. 1995,59,303-311. 
Ananthanarayanan, V. S.; Tetreault, S.; Saint-Jean, A., J. Med. Chem. 1993, 36,1324-1332. 
Sanger, D. J.; Morel, B.; Perrault, G., Eur. J. Pharmacol. 1996, 313, 35-42. 
Clayden, J.; Greeves, N.; Warren, S.; Wothers, P., Organic Chemistry. Oxford University 
Press: Oxford, 2001; p  288. 
Han, S. Y.; Kim, Y. A., Tetrahedron 2004, 60,2447-2467. 
Humphrey, J. M.; Chamberlin, A. R., Chem. Rev. 1997, 97, 2243-2266. 
Katritzky, A. R.; Suzuki, K.; Singh, S. K., Arkivoc 2004, 12-35. 
Montalbetti, C. A. G. N.; Faique, V., Tetrahedron 2005, 61, 10827-10852. 
Najera, C., Synlett 2002, 1388-1403. 
References 	 212 
Bodanszky, M., mt. J. Pept. Protein Res. 1985, 25, 449-474. 
Bodanszky, M., Peptide Res. 1992, 5, 134-139. 
Williams, M. W.; Young, G. T., J. Chem. Soc. 1963, 881-889. 
Weinstein, B.; Pritchard, A. E., J. Chem. Soc.-Perkin Trans. 1 1972, 1015-1020. 
Bodanszky, A.; Conklin, L. E., Chem. Commun. 1967,773-774. 
Van der Auwera, C.; Van Danime, S.; Anteunis, M. J. 0., mt. J. Pept. Protein Res. 1987, 29, 
464-471. 
Anderson, G. W.; Callahan, F. M., J. Am. Chem. Soc. 1958, 80, 2902-2903. 
Izumiya, N.; Muraoka, M., J. Am. Chem. Soc. 1969, 91, 2391-2392. 
Sheehan, J. C.; Hess, G. P., J. Am. Chem. Soc. 1955, 77, 1067-1068. 
Sheehan, J. C.; Goodman, M.; Hess, G. P., J. Am. Chem. Soc. 1956, 78, 1367-1369. 
Koenig, W.; Geiger, R., Chem. Ber. 1970, 103, 788-798. 
Windridge, G. C.; Jorgensen, E. C., J. Am. Chem. Soc. 1971, 93, 6318-6319. 
Koenig, W.; Geiger, R., Chem. Ber. 1970, 103, 2024-2033. 
Williams, A.; Ibrahim, I. T., Chem. Rev. 1981, 81, 589-636. 
Carpino, L. A., J. Am. Chem. Soc. 1993,115,4397-4398. 
Carpino, L. A.; Imazumi, H.; Foxman, B. M.; Vela, M. J.; Henklein, P.; El-Faham, A.; Klose, 
J.; Bienert, M., Org. Lett. 2000, 2, 2253-2256. 
Van den Nest, W.; Yuval, S.; Albericio, F., J. Pept. Sci. 2001, 7,115-120. 
Nishiyama, Y.; Ishizuka, S.; Kurita, K., Tetrahedron Lett. 2001, 42, 8789-8791. 
Kurzer, F.; Douraghi-Zadeh, K., Chem. Rev. 1967, 67, 107-152. 
Mikolajcyk, M.; Kielbasinski, P., Tetrahedron 1981, 37, 233-284. 
Sheehan, J. C.; Hlavka, J. J., J. Org. Chem. 1955, 21, 439-441. 
Newman, M. S.; Boden, H., J. Org. Chem. 1961, 26,2525-2528. 
Carpino, L. A.; El-Faham, A., Tetrahedron 1999, 55, 6813-6830. 
Williams, A.; Ibrahim, I. T., J. Am. Chem. Soc. 1981, 103, 7090-7095. 
Bofill, J. M.; Albericio, F., Tetrahedron Lett. 1999,40, 2641-2644. 
Albericio, F.; Bofill, J. M.; El-Faham, A.; Kates, S. A., J. Org. Chem. 1998, 63, 9678-9683. 
Carpino, L. A.; Imazumi, H.; El-Faham, A.; Ferrer, F. J.; Zhang, C. W.; Lee, Y. S.; Foxman, 
B. M.; Henklein, P.; Hanay, C.; Mugge, C.; Wenschuh, H.; Klose, K.; Beyermann, M.; 
Bienert, M., Angew. Chem.-Int. Edit. 2002, 41, 442-445. 
Dourtoglou, V.; J.-C., Z.; Gross, B., Tetrahedron Lett. 1978, 15, 1269-1272. 
Knorr, R.; Trzeciak, A.; Bannwarth, W.; Gillessen, D., Tetrahedron Lett. 1989, 30, 1927-1930. 
Carpino, L. A.; Elfaham, A.; Albericio, F., Tetrahedron Lett. 1994, 35, 2279-2282.. 
Chen, S. Q.; Xu, J. C., Tetrahedron Lett. 1992, 33, 647-650. 
Ehrlich, A.; Rothemund, S.; Brudel, M.; Beyermann, M.; Carpino, L. A.; Bienert, M., 
Tetrahedron Lett. 1993, 34, 4781-4784. 
Henklein, P.; M., B.; M., B.; Knorr, R., New uronium salts as coupling reagents in peptide 
chemistry. In Pept. 1990, Proc. Eur. Pept. Symp., 21st, Giralt, E.; Andreu, D., 'Eds. ESCOM: 
Leiden, 1991; pp  67-68. 
Carpino, L. A.; Ferrer, F. J., Org. Lett. 2001, 3, 2793-2795. 
References 
	 213 
Marder, 0.; Shvo, Y.; Albericio, F. Gordon Research Conference, 2002. 
Marder, 0.; Albericio, F., Chim. Oggi-Chem. Today 2003, 21, 35-40. 
Parekh, T.; Bhattacharyya, S.; Gooding, 0.; Lindberg, T. J.; Labadie, J. W., In 225th ACS 
National Meeting, New Orleans, 2003. 
Sabatino, G.; Alcaro, M. C.; Pozo-Carrero, M. C.; Chelli, M.; Rovero, P.; Papini, A. M., 
Biopolymers 2003, 71, P004. 
Castro, B.; Dormoy, J. R.; Evin, G.; Selve, C., Tetrahedron Lett. 1975, 14, 1219-1222. 
Coste, J.; Campagne, J. M., Tetrahedron Lett. 1995, 36, 4253-4256. 
Coste, J.; Lenguyen, D.; Castro, B., Tetrahedron Lett. 1990, 31, 205-208. 
Frerot, E.; Coste, J.; Pantaloni, A.; Dufour, M. N.; Jouin, P., Tetrahedron 1991, 47, 259-270. 
Albericio, F.; Cases, M.; Alsina, J.; Triolo, S. A.; Carpino, L. A.; Kates, S. A., Tetrahedron 
Lett. 1997, 38, 4853-4856. 
Hoeg-Jensen, T.; Olsen, C. E.; Holm, A., J. Org. Chem. 1994, 59, 1257-1263. 
Li, P.; Xu, J. C., J. Pept. Res. 2001, 58, 129-139. 
Carpino, L. A.; Imazumi, H.; El-Faham, A. WO 02/094822, 2002. 
Li, P.; Xu, J. C., Tetrahedron Lett. 1999, 40, 3605-3608. 
Li, P.; Xu, J. C., Tetrahedron 2000, 56, 4437-4445. 
Li, P.;Xu,J. C., J. Pept. Res. 2000, 55, 110-119. 
Li, P.; Xu, J. C., Tetrahedron Lett. 2000,41, 721-724. 
Li, P.; Xu, J. C., J. Chem. Soc.-Perkin Trans. 22001, 113-120. 
Li, P.; Xu, J. C., J. Org. Chem. 2000, 65, 2951-2958. 
Carpino, L. A.; Xia, J. S.; Zhang, C. W.; El-Faham, A., J. Org. Chem. 2004, 69, 62-7 1. 
Kiose, J.; El-Faham, A.; Henklein, P.; Carpino, L. A.; Bienert, M., Tetrahedron Lett. 1999, 40, 
2045-2048. 
Itoh, M.; Nojima, H.; Notani, J.; Hagiwara, D.; Takai, K., Tetrahedron Lett. 1974, 35, 3089-
3092. 
Fischer, E.; Fourneau, E., Ber. Dtsch. Chem. Ges. 1901, 34, 2688-2877. 
Oku, A.; Yamaura, Y.; Harada, T., J. Org. Chem. 1986, 51, 3732-3734. 
Falb, E.; Yechezkel, T.; Salitra, Y.; Gilon, C., J. Pept. Res. 1999, 53, 507-517. 
Cotarca, L.; Delogu, P.; Nardelli, A.; Sunjic, V., Synthesis 1996, 553-576. 
Them, B.; Rudolph, J.; Jung, G., Tetrahedron Lett. 2002, 43, 5013-5016. 
Klausner, Y. S.; Bodanszky, M., Synthesis 1974,549-559. 
Carpino, L. A.; Sadataalaee, D.; Chao, H. G.; Deseims, R. H., J. Am. Chem. Soc. 1990, 112, 
9651-9652. 
Carpino, L. A.; Mansour, E.; Elfaham, A., J. Org. Chem. 1993, 58, 4162-4164. 
White, J. M.; Tunoori, A. R.; Turunen, B. J.; Georg, G. I., J. Org. Chem. 2004,69,2573-2576. 
Kaminski, Z. J., Biopolymers (Pept. Sci.) 2000, 55, 140-164. 
Kaminski, Z. J.; Kolesinska, B.; Malgorzata, M., Synth. Commun. 2004,34,3349-3358. 
Kunishima, M.; Kawachi, C.; Hioki, K.; Terao, K.; Tani, S., Tetrahedron 2001, 57, 1551- 
1558. 




Kaminski, Z. J.; Kolesinska, B.; Kolesinska, J.; Sabatino, 0.; Chelli, M.; Rovero, P.; 
Blaszcyk, M.; Glowka, M. L.; Papini, A. M., J. Am. Chem. Soc. 2005, 127, 16912-16920. 
Carpino, L. A.; Elfaham, A., J. Am. Chem. Soc. 1995, 117,5401-5402. 
El-Faham, A., Chem. Lett. 1998, 671-672. 
Coste, J.; Dufour, M. N.; Pantaloni, A.; Castro, B., Tetrahedron Lett. 1990, 31, 669-672. 
Coste, J.; Frerot, E.; Jouin, P.; Castro, B., Tetrahedron Lett. 1991, 32, 1967-1970. 
Coste, J.; Frerot, E.; Jouin, P., J. Org. Chem. 1994, 59, 2437-2446. 
Akaji, K.; Kuriyama, N.; Kiso, Y., Tetrahedron Lett. 1994, 35, 3315-3318. 
Castro, B.; Dormoy, J. R., Tetrahedron Lett. 1972,47,4747-4750. 
Van der Auwera, C.; Anteunis, M. J. 0., mt. J. Pept. Protein Res. 1987, 29,574-588. 
Tung R. D.; Rich, D. H., J. Am. Chem. Soc. 1985, 107, 4342-4343. 
175, 	Colucci, W. J.; Tung, R. D.; Petri, J. A.; Rich, D. H., J. Org. Chem. 1990, 55, 2895-2903. 
Przybylski, J.; Wasilewski, K. PL19920296449, 1993. 
Li, P.; Xu, J. C., Tetrahedron Lett. 1999, 40, 8301-8304. 
Wischnat, R.; Rudolph, J.; Hanke, R.; Kaese, R.; May, A.; Theisc, H.; Zuther, U., Tetrahedron 
Lett. 2003,44, 4393-4394. 
Li, P.; Xu, J. C., Tetrahedron 2000, 56, 8119-8131. 
Mukaiyama, T., Angew. Chem.-Int. Edit. 1979, 18, 707-72 1. 
Belleau, B.; Martel, R.; Lacasse, G.; Menard, M.; Weinberg, N. L.; Perron, Y. G., J. Am. 
Chem. Soc. 1968, 90, 823-824. 
Belleau, B.; Malek, G., J. Am. Chem. Soc. 1968, 90, 1651-1652. 
Hernandez, B. A.; Chang, V.; Villanueva, I.; Heagy, M. D., J. Org. Chem. 1999, 64, 6905-
6906. 
Vaino, A. R.; Depew, W. T.; Szarek, W. A., Chem. Commun. 1997, 1871-1872. 
Thomas, J. B.; Fall, M. J.; Cooper, J. B.; Burgess, J. P.; Carroll, F. I., Tetrahedron Lett. 1997, 
38, 5099-5102. 
Hyun, M. H.; Kang, M. H.; Han, S. C., Tetrahedron Lett. 1999, 40, 3435-3438. 
Kiso, Y.; Yajima, H., Chem. Commun. 1972,942-943. 
Pudhom, K.; Vilaivan, T., Synth. Commun. 2001, 31, 61-70. 
Chen, S. Q.; Xu, J. C., Tetrahedron Lett. 1991, 32, 6711-6714. 
Ye, Y. H.; Li, H.; Jiang, X., Biopolymers (Pept. Sci.) 2004, 80, 172-178. 
Li, H.; Jiang, X.; Yun-hua, Y.; Fan, C.; Romoff, T.; Goodman, M., Org. Lett. 1999, 1, 91-93. 
Carpi no, L. A.; Xia, J. S.; El-faham, A., .1. Org. Chem. 2004, 69, 54-6 1. 
Kiso, Y.; Miyazaki, T.; Satomi, M.; Hiraiwa, H.; Akita, T., J. Chem. Soc.-Chem. Commun. 
1980,1029-1030. 
Ogura, H.; Nagai, S.; Takeda, K., Tetrahedron Lett. 1980, 21, 1467-1468. 
Jackson, A. 0.; Kenner, G. W.; Moore, G. A.; Ramage, R.; Thorpe, W. D., Tetrahedron Lett. 
1976,40,3627-3630. 
Galpin, I. J.; Mohammed, A. K.; Patel, A., Tetrahedron 1988, 44, 1685-1690. 
Shiori, T.; Ninomiya, K.; Yamada, S.-i., J. Am. Chem. Soc. 1972, 94, 6203-6205. 
Yamada, S.-i.; Ikota, N.; Shiori, T.; Tachibana, S., J. Am. Chem. Soc. 1975, 97, 7174-7175. 
References 	 215 
Shiori, T.; Yokoyama, Y.; Kasai, Y.; Yamada, S.-i., Tetrahedron 1976, 32, 2211-2217. 
Yasuhara, T.; Nagaoka, Y.; Tomioka, K., J. Chem. Soc.-Perkin Trans. 12000, 2901-2902. 
Ueda, M.; Oikawa, H., J. Org. Chem. 1985, 50, 760-763. 
Kim, S.; Kim, S. S., J. Chem. Soc.-Chem. Commun. 1986,719-720. 
Gomez, L.; Gellibert, F.; Wagner, A.; Mioskowski, C., Tetrahedron Lett. 2000, 41, 6049-
6052. 
Gomez, L.; Ngouela, S.; Gellibert, F.; Wagner, A.; Mioskowski, C., Tetrahedron Lett. 2002, 
43, 7597-7599. 
Bailen, M. A.; Chinchilla, R.; Dodsworth, D. J.; Najera, C., J. Org. Chem. 1999, 64, 8936-
8939. 
Bailen, M. A.; Chinchilla, R.; Dodsworth, D. J.; Najera, C., Tetrahedron Lett. 2000, 41, 9809-
9813. 
Albericio, F.; Baden, M. A.; Chinchilla, R.; Dodsworth, D. J.; Najera, C., Tetrahedron 2001, 
57, 9607-9613. 
Cabaret, D.; Wakselman, M., Tetrahedron Lett. 1994, 35, 9561-9564. 
Saha, A. K.; Schultz, P.; Rapoport, H., J. Am. Chem. Soc. 1989, 111, 4856-4859. 
Yang, T.; Lin, C.; Fu, H.; Jiang, Y.; Zhao, Y. F., Bioorganic Chem. 2005, 33, 386-392. 
Tozawa, T.; Yamane, Y.; Mukaiyama, T., Chem. Lett. 2005, 34, 1334-1335. 
Vaughan Jr., J. R.; Osato, R. L., J. Am. Chem. Soc. 1951, 5553-5555. 
Vaughan Jr., J. R., J. Am. Chem. Soc. 1951, 3547-3547. 
Vaughan Jr., J. R.; Osato, R. L., J. Am. Chem. Soc. 1952, 74, 676-678. 
Anderson, G. W.; Zimmerman, J. E.; Callahan, F. M., J. Am. Chem. Soc. 1967, 89, 5012-5017. 
Anderson, G. W.; Zimmerman, J. E.; Callahan, F. M., J. Am. Chem. Soc. 1963, 85, 3039-3040. 
Albertson, N. F., Org. Reac. 1962, 12, 157-355. 
Kovacs, J.; Kapoor, A., J. Am. Chem. Soc. 1965, 87, 118-119. 
Jakobsen, M. H.; Buchardt, 0.; Engdahl, T.; Holm, A., Tetrahedron Lett. 1991, 32, 6199-
6202. 
Barton, D. H. R.; Ferreira, J. A., Tetrahedron 1996, 52, 9367-9386. 
Zhang, M.; Vedantham, P.; Flynn, D. L.; Hanson, P. R., J. Org. Chem. 2004, 69, 8340-8344. 
Weinshenker, N. M.; Shen, C. M., Tetrahedron Lett. 1972, 13, 3281-3284. 
Desai, M. C.; Stramiello, L. M. S., Tetrahedron Lett. 1993, 34, 7685-7688. 
Adamczyk, M.; Fishpaugh, J. R.; Mattingly, P. G., Tetrahedron Lett. 1995, 36, 8345-8346. 
Sturino, C. F.; Labelle, M., Tetrahedron Lett. 1998, 39, 5891-5894. 
Lannuzel, M.; Lamothe, M.; Perez, M., Tetrahedron Lett. 2001, 42, 6703-6705. 
Wolman, Y.; Kivity, S.; Frankel, M., Chem. Commun. 1967,629-630. 
Pop, I. E.; Deprez, B. P.; Tartar, A. L., J. Org. Chem. 1997, 62, 2594-2603. 
Dendrinos, K.; Jeong, J.; Huang, W.; Kalivretenos, A. G., Chem. Commun. 1998,499-500. 
Dendrinos, K. G.; Kalivretenos, A. 0., Tetrahedron Lett. 1998, 39, 1321-1324. 
Chinchilla, R.; Dodsworth, D. J.; Najera, C.; Soriano, J. M., Tetrahedron Lett. 2000, 41, 2463-
2466. 
Filip, S. V.; Lejeune, V.; Vors, J. P.; Martinez, J.; Cavelier, F., Eur. J. Org. Chem. 2004, 
1936-1939. 
References 	 216 
Masala, S.; Taddei, M., Org. Lett. 1999, 1, 1355-1357. 
Chinchilla, R.; Dodsworth, D. J.; Najera, C.; Soriano, J. M.; Yus, M., Arkivoc 2003, 41-47. 
Chinchilla, R.; Dodsworth, D. J.; Najera, C.; Soriano, J. M., Tetrahedron Lett. 2003, 44, 463-
466. 
Convers, E.; Tye, H.; Whittaker, M., Tetrahedron Litt. 2004, 45, 3401-3404. 
Crosignani, S.; Gonzalez, J.; Swinnen, D., Org. Lett. 2004,6,4579-4582. 
Crosignani, S.; Swinnen, D., J. Comb. Chem. 2005, 7,688-696. 
Wischnat, R.; Rudolph, J. WO 031002546, 2003. 
Mickle, T.; Bera, B.; Linn, D.; Miller, C.; Guenther, S.; Hirscheiman, W.; Bera, S., In 230th 
ACS National Meeting, Washington D.C., USA, 2005. 
Cremin, D. J.; Hegarty, A. F.; Begley, M. J., J. Chem. Soc.-Perkin Trans. 2 1980,412-420. 
Pitts, M. R.; Harrison, J. R.; Moody, C. J., J. Chem. Soc. Perkin Trans. 12001, 955-977. 
Perranti, A.; Garuti, L.; Giovanninetti, 0.; Gaggi, R.; Roncada, P.; Nardi, P., ii Farmaco Ed. 
Sc. 1987,42, 237-249. 
Agfa-Gevaert-AG Patent FR2298541, 1976. 
Alexandratos, S. D.; Zhu, X., Macromolecules 2003, 36, 3436-3439. 
Delgado, M.; Janda, K. D., Curr. Org. Chem. 2002, 6, 1031-1043. 
Crosignani, S.; White, P. D.; Linclau, B., J. Org. Chem. 2004, 69, 5897-5905. 
Boissonnas, R. A.; Guttmann, S.; Jaquenoud, P. A.; Wailer, J. P., Helv. Chim. Acta 1955, 38, 
1491-1501. 
Erlanson, D. A.; McDowell, R. S.; O'Brien, 1., J. Med. Chem. 2004, 47, 3463-3482. 
Jencks, W. P., Proc. Natl. Acad. Sci. U. S. A. 1981, 78,4046-4050. 
Zartker, E. R.; Chapiro, M. J., Curr. Opin. Chem. Biol. 2005, 9, 366-370. 
Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R., Nat. Rev. Drug Discovery 2004, 3, 660-
672. 
Murray, C. W.; Verdonk, M. L., J. Comput. -A ided Mol. Des. 2002, 16,741-753. 
Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Adv. Drug Delivery Rev. 1997, 
23,3-25. 
Veber, D. F.; Johson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D., J. Med. 
Chem. 2002,45,2615-2623. 
Hann, M. M.; Leach, A. R.; Harper, G., J. Chem. Inf. Comput. Sci. 2001, 41, 856-864. 
Congreve, M.; Carr, R.; Murray, C. W.; Jhoti, H., Drug Discov. Today 2003, 8, 876-877. 
Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M., J. Chem. Inf. Comput. Sci. 1998, 38, 
511-522. 
Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W., Science 1996, 274, 1531-1534. 
Jacoby, E.; Davies, J.; Blommers, M. J., Curr. Top. Med. Chem. 2003,3,11-23. 
Maly, D. J.; Choong, I. C.; Ellman, J. A., Proc. Natl. Acad. Sci. U. S. A. 2000,97,2419-2424. 
Freundlieb, S.; Garner, J., New Drugs 2001, 3, 54-60. 
Hauske, J. R.; Dorff, P.; Julin, S.; DiBrino, J.; Spencer, R.; Williams, R., J. Med. Chem. 1992, 
35, 4284-4296. 
Wang, G. T.; Lane, B.; Fesik, S. W.; Petros, A.; Luly, J.; Kraft, G. A., Bioorg. Med. Chem. 
Lett. 1994, 4, 1161-1166. 
References 	 217 
Jahnke, W.; Perez, L. B.; Paris, 0.; Strauss, A.; Fendrich, G.; Nalin, C. M., J. Am. Chem. Soc. 
2000, 122, 7394-7395. 	 - 
Swayze, E. E.; Jefferson, E. A.; Sannes-Lowery, K. A.; Blyn; L. B.; Risen, L. M.; Arakawa, 
S.; Osgood, S. A.; Hofstadler, S. A.; Griffey, R. H., J. Med. Chem. 2002,45,3816-3819. 
Hofstadler, S. A.; Griffey, R. H., Chem. Rev. 2001, 101, 377-390. 
He, Y.; Yang, Y. H.; Wu, B.; Robinson, D.; Sprankle, K.; Kung, P.-P.; Lowery, K.; Mohan, 
V.; Hofstadler, S. A.; Swayze, E. E.; Griffey, R. H., Bioorg. Med. Chem. Lett. 2004, 14, 695-
699. 
Gilbert, A. M.; Kirisits, M.; Toy, P.; Nunn, D. S.; Failli, A.; Dushin, E. G.; Novikova, E.; 
Petersen, P. J.; Joseph-McCarthy, D.; McFadyen, I.; Fritz, C. C., Bioorg. Med. Chem. Lett. 
2004, 14, 37-41. 
Ockey, D. A.; Gadek, T. R., Bioorg. Med. Chem. Lett. 2004, 14, 389-391. 
Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; 
Wells, J. A., Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 9367-9372. 
Erlanson, D. A.; Wells, J. A.; Braisted, A. C., Annu. Rev. Biophys. Biomolec. Struct. 2004, 33, 
199-223. 
Nienaber, V. L.; Richardson, P. L.; Klighofer, V.; Bouska, J. J.; Giranda, V. L.; Greer, J., Nat. 
Biotechnol. 2000,18,1165-1108. 
Congreve, M. S.; Davis, D. J.; Devine, L.; Granata, C.; O'Reilly, M.; Wyatt, P. G.; Jhoti, H., 
Angew. Chem.-Int. Edit. 2003,42,4479-4482. 
Lesuisse, D.; Lange, G.; Deprez, P.; Benard, D.; Schoot, B.; Delettre, G.; Marquette, J.-P.; 
Broto, P.; Jean-Baptiste, V.; Bichet, P.; Sarubbi, B.; Mandine, E., J. Med. Chem. 2002, 45, 
2379-2387. 
Lange, G.; Lesuisse, D.; Deprez, P.; Schoot, B.; Loenze, P.; Benard, D.; Marquette, J.-P.; 
Broto, P.; Sarubbi, E.; Mandine, E., J. Med. Chem. 2003,46,5184-5195. 
Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H., J. 
Med. Chem. 2005,48,403-413. 
Gill, A.; Cleasby, A.; Jhoti, H., Chem. Bio. Chem. 2005,6,506-512. 
Yeo, D. S. Y.; Panicker, R. C.; Tan, L.-P.; Yao, S. Q., Comb. Chem. High Throughput Screen. 
2004, 7,213-221. 
Schena, M.; Shalon, D.; Davis, R. W.; OBrown, P., Science 1995,270,467-470. 
MacBeath, G.; Schreiber, S. L., Science 2000, 289, 1760-1763. 
Fang, Y.; Frutos, A. G.; Lahiri, J., J. Am. Chem. Soc. 2002, 124, 2394-2395. 
Panicker, R. C.; Huang, X.; Yao, S. Q., Comb. Chem. High Throughput Screen. 2004, 7,547- 
556. 
Mm, D.-H.; Mrksich, M., Curr. Opin. Chem. Biol. 2004,8,554-558. 
Kononen, J.; Bubendorf, L.; Kallionimeni, A.; Bärlund, M.; Schram], P.; Leighton, S.; 
Torhorst, J.; Mihatsch, M. J.; Sauter, G.; Kallionimeni, 0.-P., Nat. Med. 1998, 4, 844-847. 
Ziauddin, J.; Sabatini, D. M., Nature 2001,411, 107-110. 
MacBeath, G.; Koehler, A. N.; Schreiber, S. L., J. Am. Chem. Soc. 1999, 121, 7967-7968. 
Breinbauer, R.; Kohn, M.; Peters, C., Small Molecule Arrays. In Highlights in Bioorganic 
Chemistry: Methods and Applications, Schmuck, C.; Wennemers, H., 'Eds.' Wiley-VCH: 
Weinheim, 2004; pp  485-500. 
Uttamchandani, M.; Walsh, D. P.; Yao, S. Q.; Chang, Y. T., Curr. Opin. Chem. Biol. 2005, 9, 
4-13. 
Walsh, D. P.; Chang, Y. T., Comb. Chem. High Throughput Screen. 2004, 7, 557-564. 
References 	 218 
Hergenrother, P. J.; Depew, K. M.; Schreiber, S. L., J. Am. Chem. Soc. 2000, 122, 7849-7850. 
Kuruvilla, F. 0.; Shamji, A. F.; Sternson, S. M.; Hergenrother, P. J.; Schreiber, S. L., Nature 
2002,416, 653-657. 
Blackwell, H. E.; Perez, L. B.; Stavenger, R. A.; Tallarico, J. A.; Eatough, E. C.; Foley, M. A.; 
Schreiber, S. L., Chem. Biol. 2001, 8, 1167-1182. 
Sternson, S. M.; Louca, J. B.; Wong, J. C.; Schreiber, S. L., J. Am. Chem. Soc. 2001, 123, 
1740-1747. 
Clemons, P. A.; Koehler, A. N.; Wagner, B. K.; Sprigings, T. G.; Spring, D. R.; King, R. W.; 
Schreiber, S. L.; Foley, M. A., Chem. Biol. 2001, 8, 1183-1195. 
Koehler, A. N.; Shamji, A. F.; Schreiber, S. L., J. Am. Chem. Soc. 2003, 125, 8420-842 1. 
Barnes-Seeman, D.; Park, S. B.; Koehler, A. N.; Schreiber, 5: L., Angew. Chem.-Int. Edit. 
2003, 42, 2376-2379. 
Kwon, 0.; Bum Park, S.; Schreiber, S. L., J. Am. Chem. Soc. 2002, 124, 13402-13404. 
Tallarico, J. A.; Depew, K. M.; Pelish, H. E.; Westwood, N. J.; Lindsley, C. W.; Shair, M. D.; 
Schreiber, S. L.; Foley, M. A., J. Comb. Chem. 2001, 3, 312-318. 
Kohn, M.; Wacker, R.; Peters, C.; Schroder, H.; Soulere, L.; Breinbauer, R.; Niemeyer, C. M.; 
Waldmann, H., Angew. Chem.-Int. Edit. 2003, 42, 5830-5834. 
Uttamchandani, M.; Walsh, D. P.; Khersonsky, S. M.; Huang, X.; Yao, S. Q.; Chang, Y. T., J. 
Comb. Chem. 2004,6,862-868. 
Lee, M. R.; Shin, I., Angew. Chem.-Int. Edit. 2005,44,2881-2884. 
Winssinger, N.; Harris, J. L.; Backes, B. J.; Schultz, P. G., Angew. Chem.-Int. Edit. 2001, 40, 
3152-3155.  
Lovrinovic, M.; Niemeyer, C. M., Angew. Chem. -Int. Edit. 2005, 44, 3179-3183. 
Winssinger, N.; Damoiseaux, R.; Tully, D. C.; Geierstanger, B. H.; Burdick, K.; Harris, J. L., 
Chem. Biol. 2004, 11, 1351-1360. 
Winssinger, N.; Ficarro, S.; Schultz, P. G.; Harris, J. L., Proc. Nat!. Acad. Sci. U. S. A. 2002, 
99,11139-11144. 
Harris, J.; Mason, D. E.; Li, J.; Burdick, K. W.; Backes, B. J.; Chen, T.; Shipway, A.; Van 
Heeke, G.; Gough, L.; Ghaemmaghami, A.; Shakib, F.; Debaene, F.; Winssinger, N., Chem. 
Biol. 2004, 11, 1361-1372. 
Harris, J. L.; Winssinger, N., Chem. Eur. 12065, 11, 6792-6801. 
Diaz-Mochon, J. J.; Bialy, L.; Keinicke, L.; Bradley, M., Chem. Commun. 2005, 11, 1384-
1386. 
Dillmore, W. S.; Yousaf, M. N.; Mrksich, M., Langmuir 2004, 20, 7223-723 1. 
Kanoh, N.; Kiumashiro, S.; Simizu, S.; Kondoh, Y.; Hatakeyama, S.; Tashiro, H.; Osada, H., 
Angew. Chem.-Int. Edit. 2003,42, 5584-5587. 
Fodor, S. P. A.; Rava, R. P.; Huang, X. C.; Pease, A. C.; Holmes, C. P.; Adams, C. L., Science 
1991,251, 767-773. 
Frank, R., Tetrahedron 1992, 48, 9217-9232. 
Frank, R., J. immunol. Methods 2002, 267, 13-26. 
Scharn, D.; Wenshuh, H.; Reineke, U.; Schneider-Mergener, J.; Germeroth, L., J. Comb. 
Chem. 2000, 2, 361-369. 
Gosalia, D. N.; Diamond, S. L., Proc. Nat!. Acad. Sci. U. S. A. 2003, 100, 8721-8726. 
Hackler Jr., L.; Dorman, G.; Kele, Z.; Urge, L.; Darvas, F.; Puskas, L. G., Mo!. Div. 2003, 7, 
25-36. 
Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, 0., Science 1991, 254, 1497-1500. 
References 
	 219 
Eghoim, M.; Buchardt, 0.; Christensen, L.; Behrens, C.; Freier, S. M.; Driver, D. A.; Berg, R. 
H.; Kim, S. K.; Norden, B.; Nielsen, P. E., Nature 1993, 365, 566-568. 
Hyrup, B.; Nielsen, P. E., Bioorg. Med. Chem. 1996, 4, 5-23. 
Uhlmann, E.; Peyman, A.; Breipohl, G.; Will, D. W., Angew. Chem.-Int. Edit. 1998, 37, 2797- 
2823. 
Dueholm, K. L.; Egholm, M.; Behrens, C.; Christensen, L.; Hansen, H. F.; Vulpius, T.; 
Petersen, K. H.; Berg, R. H.; Nielsen, P. E.; Buchardt, 0., J. Org. Chem. 1994, 59, 5767-5773. 
Christensen, L.; Fitzpatrick, R.; Gildea, B.; Petersen, K. H.; Hansen, H. F.; Koch, T.; Eghoim, 
M.; Buchardt, 0.; Nielsen, P. E.; Coull, J.; Berg, R. H., J. Peptide Science 1995, 3, 175-183. 
Thomson, S. A.; Josey, J. A.; Cadilla, R.; Gaul, M. D.; Hassman, C. F.; Luzzio, M. J.; Pipe, A. 
J.; Reed, K. L.; Ricca, D. J.; Wiethe, R. W.; Noble, S. A., Tetrahedron 1995, 51, 6179-6194. 
Diaz-Mochon, J. J.; Bialy, L.; Bradley, M., Org. Lett. 2004, 6, 1127-1129. 
Bialy, L.; Diaz-Mochon, J. J.; Specker, E.; Keinicke, L.; Bradley, M., Tetrahedron 2005, 61, 
8295-8305. 
Chhabra, S. R.; Parekh, H.; Khan, A. N.; Bycroft, B. W.; Kellan, B., Tetrahedron Lett. 2001, 
41, 2189-2192. 
Smith III, A. B.; Condon, S. M.; McCauley, J. A., Acc. Chem. Res. 1998, 31, 35-46. 
Sehgal, S. N.; Molnar-Kimber, K.; Ocain, T. D.; Weichman, B. M., Med. Res. Rev. 1994, 14, 
1-22. 
Belshaw, P. J.; Meyer, S. D.; Johnson, D. D.; Romo, D.; Ikeda, Y.; Andrus, M.; Alberg, D. G.; 
Schultz, L. W.; Clardy, J.; Schreiber, S. L., Synlett 1994, 381-392. 
Taylor, M. J.; Hoffman, T. Z.; Yli-Kauhaluoma, J. T.; Lerner, R. A.; Janda, K. D., J. Am. 
Chem. Soc. 1998, 120, 12783-12790. 
Swenton, J. S.; Bonke, B. R.; Chen, C.-P.; Chou, C.-T., J. Org. Chem. 1988, 54, 51-58. 
Varasi, M.; Walker, K. A. M.; Maddox, M. L., J. Org. Chem. 1987, 52, 4235-423 8. 
Crich, D.; Dyker, H.; Harris, R. J., J. Org. Chem. 1989, 54, 257-259. 
Pautard-Cooper, A.; Evans, S. A., J. Org. Chem. 1989, 54, 2485-2488. 
Hughes, D. L.; Reamer, R. A.; Bergan, J. J.; Grabowski, E. J. J., J. Am. Chem. Soc. 1988, 110, 
6487-6491. 
Dembinski, R., Eur. J. Org. Chem. 2004, 2763-2772. 
Camp, D.; Jenkins, I. D., Aust. J. Chem. 1992, 45, 47-55. 
Mitsunobu, 0., In Comprehensive Organic Synthesis, Trost, B. M.; Fleming, I., 'Eds.' 
Pergamon Press: 1991; 'Vol.' 6, pp  65. 
Tsunoda, T.; Yamamiya, Y.; Ito, S., Tetrahedron Lett. 1993,34, 1639-1642. 
Kiankarimi, M.; Lowe, R.; McCarthy, J. R.; Whitten, J. P., Tetrahedron Lett. 1999, 40, 4497-
4500. 
Barrett, A. G.; Roberts, R. S.; Schroeder, J., Org. Lett. 2000,2, 2999-3001. 
Tsunoda, T.; Yamamiya, Y.; Kawamura, Y.; Ito, S., Tetrahedron Lett. 1995, 36, 2529-2530. 
Tsunoda, T.; Ozaki, F.; Shirakata, N.; Tamaoka, Y.; Yamamoto, H.; Ito, S., Tetrahedron Lett. 
1996, 37, 2463-2466. 
Arnold, L. D.; Assil, H. I.; Vederas, J. C., J. Am. Chem. Soc. 1989, 111, 3973-3976. 
Von Itzstein, M.; Mocerino, M., Synth. Commun. 1990, 20, 2049-2059. 
Valentine, D. H. J.; Hillhouse, J. H., Synthesis 2003, 3, 317-334. 
References 
	 220 
O'Neil, I. A.; Thompson, S.; Murray, C. L.; Barret Kalindjian, S., Tetrahedron Lett. 1998, 39, 
7787-7790. 
Camp, D.; Jenkins, I. D., Aust. J. Chem. 1988, 41, 1835-1839. 
Grynkiewicz, G.; Jurczak, J.; Zamojski, A., Tetrahedron 1975, 31, 1411-1414. 
Tunoori, A. R.; Dutta, D.; Georg, G. I., Tetrahedron Lett. 1998, 39, 8751-8754. 
Amos, R. A.; Emblidge, R. W.; Havens, N., J. Org. Chem. 1983, 48, 3598-3600. 
Pelletier, J. C.; Kincaid, S., Tetrahedron Lett. 2000, 41, 797-800. 
Gentles, R. G.; Wodka, D.; Park, D. C.; Vasudevan, A., J. Comb. Chem. 2002, 4, 442-456. 
Starkey, G. W.; Parlow, J. J.; Flynn, D. L., Bioorg. Med. Chem. Lett. 1998, 8, 2385-2390. 
Yoakim, C.; Guse, I.; O'Meara, J. A.; Thavonekham, B., Synlett 2003, 4, 473-476. 
Jackson, T.; Routledge, A., Tetrahedron Lett. 2003, 44, 1305-1307. 
Lan, P.; Porco Jr., J. A.; South, M. S.; Pariow, J. J., J. Comb. Chem. 2003, 5, 660-669. 
Rano, T. A.; Chapman, K. T., Tetrahedron Lett. 1995, 36, 3789-3792. 
Roussel, P.; Bradley, M., Tetrahedron Lett. 1997, 38, 4861-4864. 
Roussel, P.; Bradley, M.; Kane, P.; Bailey, C.; Arnold, R.; Cross, A., Tetrahedron 1999, 55, 
6219-6230. 
Mourtas, S.; Gatos, D.; Karavolsos, M.; Katakalou, C.; Barbs, K., Tetrahedron Lett. 2002, 43, 
3419-3421. 
Afanassiec, V.; Haneman, V.; Woeif, S., Nucleic Acids Research 2000, 28, e66. 
Leonard, J.; B., L.; Procter, 0., Advanced practical organic chemistry. Stanley Thornes: 
Cheltenham, 1998; p 298. 
Perreux, L.; Loupy, A.; Volatron, F., Tetrahedron 2002, 58, 2155-2162. 
Heyde, C.; Zug, I.; Hartmann, H., Eur.J. Orj Chem. 2000, 3273-3278. 
Yin, J.; Buchwald, S. L., Org. Lett. 2000, 2, 1101-1104. 
Park, S.-D.; Oh, J.-H.; Lim, D., Tetrahedron Lett. 2002, 43, 6309-6311. 
Tillack, A.; Rudloff, I.; Beller, M., Eur.J. Org. Chem. 2001, 523-528. 
Dondoni, A.; Perrone, D.; Semola, T., Synthesis 1995, 2, 181-186. 
Boissonnas, R. A.; Guttmann, S.; Jaquenoud, P. A.; Wailer, J. P., Helv. Chim. Acta 1955, 38, 
1491-1501. 
Albericio, F.; Bailen, M. A.; Chinchilla, R.; Dodsworth, D. J.; Najera, C., Tetrahedron 2001, 
57, 9607-9613. 
Zhang, R.; Madalengoita, J. S., Tetrahedron Lett. 1996, 37, 6235-6239. 
Obrecht, D.; Heimgartner, H., Helv. Chim. Acta 1987, 70, 102-115. 
Wintner, E. A.; Conn, M. M.; Rebek Jr., J., J. Am. Chem. Soc. 1994, 116, 8877-8884. 
Wipf, P.; Heimgartner, H., Helv. Chirn. Acta 1987, 70, 354-368. 
Ogawa, T.; Hikasa, T.; Ikegami, T.; Ono, N.; Suzuki, H., J. Chem. Soc. -Perkin Trans 1 1994, 
3473-3478. 
Koh, H. J.; Kim, T. H.; Lee, B.-S'; Lee, I., J. Chem. Res. 1996, 11, 2741-2751. 
Frkanec, L.; Visnjevac, A.; Kojic-Prodic, B.; Zinic, M., Chem. Eur. 1 2000,6,442-453. 
Abraham, D. J.; Gazze, D. M.; Kennedy, P. E.; Mokotoff, M., J. Med. Chem. 1984, 12, 1549- 
1559. 
Yoshikawa, K.; Achiwa, K., Chem. Pharm. Bull. 1995,43, 2048-2053. 
References 
	 221 
Bialy, L.; Diaz-Mochon, J. J.; Specker, E.; Keinicke, L.; Bradley, M., Tetrahedron 2005, 61, 
8295-8305. 
Chhabra, S. R.; Parekh, H.; Khan, A. N.; Bycroft, B. W.; Kellan, B., Tetrahedron Lett. 2001, 
41, 2189-2192. 
Duehoim, K. L.; Eghoim, M.; Behrens, C.; Christensen, L.; Hansen, H. F.; Vulpius, T.; 
Petersen, K. H.; Berg, R. H.; Nielsen, P. E.; Buchardt, 0., J. Org. Chem. 1994, 59,5767-5773. 
Breipohi, G.; Knolle, J.; Langner, D.; O'Malley, G.; Uhlmann, E., Bioorg. Med. Chem. Lett. 
1996,6, 665-670. 
Chhabra, S. R.; Hothi, B.; Evans, D. J.; White, P. D.; Bycroft, B. W.; Chan, W. C., 
Tetrahedron Lett. 1998, 39, 1603-1606. 
Ishii, H.; Kawanabe, E.; Harada, K.-I.; Deushi, T.; Ueda, E., Chem. Pharm. Bull. 1983, 31, 
3039-3055. 
Booth, H.; Dixon, J. M.; Khedhair, K. A., Tetrahedron 1992, 48, 6161-6174. 
Swenton, J. S.; Bonke, B. R.; Chen, C.-P.; Chou, C.-T., J. Org. Chem. 1988, 54, 51-58. 
Yuzuri, T.; Suezawa, H.; Hirota, M., Bull. Chem. Soc. Jpn. 1994, 67, 1664-1673. 
